PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1656856-1	1991	Erythromycin and some other macrolide antibiotics can first induce a cytochrome P-450 isozyme similar to the one induced in rats by pregnenolone-16 alpha-carbonitrile and then inhibit it by forming a stable cytochrome P-450-metabolite complex.	Erythromycin	0-12	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	69-85
1926941-1	1991	In low dosages erythromycin imitates the effect of motilin on the gastrointestinal motility.	Erythromycin	15-27	motilin	Homo sapiens	51-58
1926941-2	1991	In vitro experiments show that erythromycin is a motilin agonist: it displaces motilin which is bound to its receptor; it directly acts on smooth musculature and it possesses the same animal and tissue specificity.	Erythromycin	31-43	motilin	Homo sapiens	49-56
1926941-2	1991	In vitro experiments show that erythromycin is a motilin agonist: it displaces motilin which is bound to its receptor; it directly acts on smooth musculature and it possesses the same animal and tissue specificity.	Erythromycin	31-43	motilin	Homo sapiens	79-86
1656856-1	1991	Erythromycin and some other macrolide antibiotics can first induce a cytochrome P-450 isozyme similar to the one induced in rats by pregnenolone-16 alpha-carbonitrile and then inhibit it by forming a stable cytochrome P-450-metabolite complex.	Erythromycin	0-12	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	207-223
1656856-4	1991	Approximately 40% of cytochrome P-450 was complexed with erythromycin metabolite.	Erythromycin	57-69	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	21-37
1919096-10	1991	In five DPB-patients treated with low-dose long-term erythromycin chemotherapy, elastase activity in BALF decreased significantly.	Erythromycin	53-65	elastase, neutrophil expressed	Homo sapiens	80-88
1710636-9	1991	The cytochrome P-450 dependent activity in microsomes from the epidermis of control and erythromycin-treated rats and in microsomes from psoriatic tissue was at the detection limits of the assay system.	Erythromycin	88-100	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	4-20
2269307-13	1990	Microsomal suspensions containing P450 NF25 were also able to catalyze several oxidation reactions that were expected from the activities of the protein isolated from human liver, including nifedipine 1,4-oxidation, quinidine 3-hydroxylation and N-oxygenation, and N-demethylation of the macrolide antibiotics erythromycin and troleandomycin.	Erythromycin	310-322	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-43
2002453-6	1991	Erythromycin A (2), which presents a less rigid macrocycle with two free hydroxyl groups (6-OH and 11-OH), forms a dimer detected by FAB mass spectroscopy.	Erythromycin	0-14	FA complementation group B	Homo sapiens	133-136
1991439-6	1991	CONCLUSIONS: These data demonstrate that motilin and related compounds such as erythromycin derivatives could be useful for the treatment of disturbed gastric emptying in diabetic subjects.	Erythromycin	79-91	motilin	Homo sapiens	41-48
1909052-0	1991	Erythromycin and phenoxymethylpenicillin (penicillin V) in the treatment of respiratory tract infections as related to microbiological findings and serum C-reactive protein.	Erythromycin	0-12	C-reactive protein	Homo sapiens	154-172
2041262-3	1991	Furthermore, the relationship between the post-therapeutic change of NE in sputum and clinical effect of erythromycin (EM) was investigated in the same cases.	Erythromycin	105-117	elastase, neutrophil expressed	Homo sapiens	69-71
2379773-5	1990	The correlation between the maximum contractile response toward motilin and erythromycin was almost perfect (r2 = 0.82).	Erythromycin	76-88	promotilin	Oryctolagus cuniculus	64-71
2381873-0	1990	The erythromycin derivative EM-523 is a potent motilin agonist in man and in rabbit.	Erythromycin	4-16	motilin	Homo sapiens	47-54
2375764-0	1990	In vivo effects of erythromycin, oleandomycin and erythralosamine derivatives on hepatic cytochrome P-450.	Erythromycin	19-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	89-105
2375764-1	1990	Rats have been treated with several derivatives of the erythromycin, erythralosamine or oleandomycin series, in order to compare their ability to induce cytochrome P-450 and to form stable 456 nm-absorbing cytochrome P-450 metabolite complexes.	Erythromycin	55-67	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	153-169
2375764-1	1990	Rats have been treated with several derivatives of the erythromycin, erythralosamine or oleandomycin series, in order to compare their ability to induce cytochrome P-450 and to form stable 456 nm-absorbing cytochrome P-450 metabolite complexes.	Erythromycin	55-67	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	206-222
2381873-1	1990	Erythromycin may stimulate gastrointestinal motor activity via its effect upon motilin receptors.	Erythromycin	0-12	motilin	Homo sapiens	79-86
2324013-4	1990	Methylation of the hydroxyl groups of erythromycin A analogue proceeded stepwise by the two main pathways beginning at the C-6 and C-11 positions, individually.	Erythromycin	38-52	complement C6	Homo sapiens	123-126
2344166-10	1990	Nonspecific inhibition of cytochrome P-450 was ruled out since erythromycin N demethylation (cytochrome P-450 mediated) was unaffected in the presence of enoxacin.	Erythromycin	63-75	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	93-109
2324013-4	1990	Methylation of the hydroxyl groups of erythromycin A analogue proceeded stepwise by the two main pathways beginning at the C-6 and C-11 positions, individually.	Erythromycin	38-52	aldo-keto reductase family 1 member C4	Homo sapiens	131-135
2106291-11	1990	The catalytic turnover of microsomal cytochrome P450p was estimated from the increase in testosterone oxidation and the apparent increase in cytochrome P450 concentration following treatment of liver microsomes from troleandomycin- or erythromycin-induced rats with potassium ferricyanide (which dissociates the cytochrome P450p-inducer complex).	Erythromycin	235-247	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	37-53
2106291-11	1990	The catalytic turnover of microsomal cytochrome P450p was estimated from the increase in testosterone oxidation and the apparent increase in cytochrome P450 concentration following treatment of liver microsomes from troleandomycin- or erythromycin-induced rats with potassium ferricyanide (which dissociates the cytochrome P450p-inducer complex).	Erythromycin	235-247	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	37-52
2106291-11	1990	The catalytic turnover of microsomal cytochrome P450p was estimated from the increase in testosterone oxidation and the apparent increase in cytochrome P450 concentration following treatment of liver microsomes from troleandomycin- or erythromycin-induced rats with potassium ferricyanide (which dissociates the cytochrome P450p-inducer complex).	Erythromycin	235-247	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	312-328
2107034-3	1990	Previous studies have shown that treatment of rats by the macrolide antibiotics of the oleandomycin and erythromycin series lead to the induction of an hepatic cytochrome P-450 which is implicated into their own metabolism.	Erythromycin	104-116	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	160-176
2154437-4	1990	Rate constants and the time for 10% decay (T1/10) were determined for both azithromycin and erythromycin A at pH2 using various levels of acetonitrile cosolvent and constant ionic strength.	Erythromycin	92-106	CD5 molecule	Homo sapiens	43-48
34626662-6	2022	Erythromycin and clarithromycin can be considered ubiquitous with mean concentrations of 2.5 +- 2.3 ngL-1 and 5.7 +- 4.6 ngL-1 respectively, and the presence of sulfamethoxazole and trimethoprim was also noticeable with maximum concentrations of 78.3 ngL-1 for sulfamethoxazole.	Erythromycin	0-12	leucine rich repeat containing 4C	Homo sapiens	100-113
33803007-0	2021	Effects of Erythromycin on Osteoclasts and Bone Resorption via DEL-1 Induction in Mice.	Erythromycin	11-23	EGF-like repeats and discoidin I-like domains 3	Mus musculus	63-68
33803007-5	2021	Therefore, in the present study, we investigated whether the osteoclastogenesis inhibitory effects of erythromycin (ERM) are mediated through upregulation of DEL-1 expression.	Erythromycin	102-114	EGF-like repeats and discoidin I-like domains 3	Mus musculus	158-163
34674222-0	2022	Effects of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib: a randomized cross-over trial in patients with breast cancer.	Erythromycin	41-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
34674222-3	2022	This study aimed to investigate the effects of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib.	Erythromycin	77-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
34674222-10	2022	To conclude, concomitant intake of palbociclib with the moderate CYP3A4 inhibitor erythromycin resulted in an increase in AUC0-24h and Cmax of both 43%.	Erythromycin	82-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
34626662-6	2022	Erythromycin and clarithromycin can be considered ubiquitous with mean concentrations of 2.5 +- 2.3 ngL-1 and 5.7 +- 4.6 ngL-1 respectively, and the presence of sulfamethoxazole and trimethoprim was also noticeable with maximum concentrations of 78.3 ngL-1 for sulfamethoxazole.	Erythromycin	0-12	leucine rich repeat containing 4C	Homo sapiens	121-126
34626662-6	2022	Erythromycin and clarithromycin can be considered ubiquitous with mean concentrations of 2.5 +- 2.3 ngL-1 and 5.7 +- 4.6 ngL-1 respectively, and the presence of sulfamethoxazole and trimethoprim was also noticeable with maximum concentrations of 78.3 ngL-1 for sulfamethoxazole.	Erythromycin	0-12	leucine rich repeat containing 4C	Homo sapiens	251-256
34977827-10	2022	Also, isolate PS2 showed resistance to erythromycin, ciprofloxacin, methicillin, novobiocin and penicillin.	Erythromycin	39-51	taste 2 receptor member 64 pseudogene	Homo sapiens	14-17
34718190-1	2021	The objective of this study was to analyze erythromycin and clindamycin resistance patterns among different MRSA lineages in China.	Erythromycin	43-55	solute carrier family 9 member A6	Homo sapiens	108-112
34520335-9	2021	ST8/USA300 isolates were highly susceptible to non-beta-lactams antibiotics, except fluoroquinolone and erythromycin.	Erythromycin	104-116	Oncogene OVC (ovarian adenocarcinoma oncogene)	Homo sapiens	0-3
34718190-8	2021	Summarily, high erythromycin and clindamycin resistance rates were observed in MRSA isolates.	Erythromycin	16-28	solute carrier family 9 member A6	Homo sapiens	79-83
34718190-11	2021	Erythromycin and clindamycin resistance genes transfer between MRSA isolates in healthcare settings remains a problem, and infection control procedures should be applied.	Erythromycin	0-12	solute carrier family 9 member A6	Homo sapiens	63-67
34741083-8	2021	Dex 1 mg/kg, EM 7.5 or 75 mg/kg treatments significantly inhibited serum IgE and IgG2a in CRS mice.	Erythromycin	13-15	immunoglobulin heavy variable V1-9	Mus musculus	81-86
34827354-8	2021	Fourteen S. aureus were susceptible to all antimicrobials tested and the remaining showed resistance to penicillin, erythromycin and/or tetracycline encoded by the blaZ, ermT, msr(A/B), tetL, and vgaA genes.	Erythromycin	116-128	ABC transporter permease protein	Staphylococcus aureus	176-183
34783193-4	2022	Subsequently, the finerenone model was validated regarding the contribution of CYP3A4 metabolism to total clearance by comparing to observed data from dedicated clinical interaction studies with erythromycin (simulated geometric mean ratios of the area under the plasma concentration-time curve (AUCR) of 3.46 and geometric mean peak plasma concentration ratios (Cmax R) of 2.00 versus observed of 3.48 and 1.88, respectively) and verapamil (simulated AUCR of 2.91 and Cmax R of 1.86 versus observed of 2.70 and 2.22, respectively).	Erythromycin	195-207	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
34741083-10	2021	MUC5AC expressions were significantly reduced in the 7.5 or 75 mg/kg EM-treated mice compared with untreated mice.	Erythromycin	69-71	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	0-6
34574752-8	2021	The mecA gene was surprisingly found in methicillin-susceptible S. aureus (MSSA), which also carried the ermA gene from those erythromycin-susceptible strains.	Erythromycin	126-138	rRNA methylase Erm(A)	Staphylococcus aureus	105-109
34656079-4	2021	ErmX was present in the genome sequence and this isolate owned the resistance to erythromycin and clindamycin.	Erythromycin	81-93	Erm(X)	Corynebacterium diphtheriae	0-4
34162143-0	2021	Erythromycin inhibits cigarette smoke-induced inflammation through regulating the PPARgamma/NF-kappaB signaling pathway in macrophages.	Erythromycin	0-12	peroxisome proliferator activated receptor gamma	Homo sapiens	82-91
34162143-0	2021	Erythromycin inhibits cigarette smoke-induced inflammation through regulating the PPARgamma/NF-kappaB signaling pathway in macrophages.	Erythromycin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	92-101
34162143-10	2021	In conclusion, the present study suggested that EM may reduce the damage of PPARgamma by inhibiting oxidative stress and reducing the expression of ROS and finally relieving cigarette smoke-induced inflammation through the PPARgamma/NF-kappaB signaling pathway in macrophages.	Erythromycin	48-50	peroxisome proliferator activated receptor gamma	Homo sapiens	76-85
34162143-10	2021	In conclusion, the present study suggested that EM may reduce the damage of PPARgamma by inhibiting oxidative stress and reducing the expression of ROS and finally relieving cigarette smoke-induced inflammation through the PPARgamma/NF-kappaB signaling pathway in macrophages.	Erythromycin	48-50	peroxisome proliferator activated receptor gamma	Homo sapiens	223-232
34162143-10	2021	In conclusion, the present study suggested that EM may reduce the damage of PPARgamma by inhibiting oxidative stress and reducing the expression of ROS and finally relieving cigarette smoke-induced inflammation through the PPARgamma/NF-kappaB signaling pathway in macrophages.	Erythromycin	48-50	nuclear factor kappa B subunit 1	Homo sapiens	233-242
35150012-1	2022	BACKGROUND: Erythromycin, a macrolide antibiotic with motilin agonist properties, shortens gastric emptying (GE) time in healthy cats.	Erythromycin	12-24	motilin	Felis catus	54-61
34168479-2	2021	The aim of the study is to compare the antibacterial susceptibility of C. acnes to clindamycin and erythromycin in AV patients compared with healthy patients in the control group (CG).	Erythromycin	99-111	cathepsin G	Homo sapiens	180-182
35561342-4	2022	In WELCOME, we develop an MphR-based Escherichia coli whole-cell biosensor sensitive to erythromycin and co-cultivate it with Saccharopolyspora erythraea in droplets for high-throughput screening.	Erythromycin	88-100	erythromycin resistance repressor protein	Escherichia coli	26-30
35389533-7	2022	In inhibitor experiments, quinidine and erythromycin inhibited ITZ hydroxylation in CYP2D15 and CYP3A12, respectively, in an isoform-specific manner.	Erythromycin	40-52	cytochrome P450 2D15	Canis lupus familiaris	84-91
35389533-7	2022	In inhibitor experiments, quinidine and erythromycin inhibited ITZ hydroxylation in CYP2D15 and CYP3A12, respectively, in an isoform-specific manner.	Erythromycin	40-52	cytochrome P450 3A12	Canis lupus familiaris	96-103
35288286-6	2022	The hsa mutant of NDU1118 was generated by insertion of the erythromycin resistance gene.	Erythromycin	60-72	albumin	Homo sapiens	4-7
35175912-10	2022	The MYCO WELL D-ONE kit overestimated tetracycline and erythromycin resistance in Ureaplasma spp.	Erythromycin	55-67	histocompatibility minor 13	Homo sapiens	93-96
35007529-0	2022	Crystal structure and functional analysis of mycobacterial erythromycin resistance methyltransferase Erm38 reveals its RNA binding site.	Erythromycin	59-71	23S rRNA (adenine(2058)-N(6))-methyltransferase Erm(38)	Mycolicibacterium smegmatis	101-106
2480236-8	1989	Additionally, physical evidence was obtained demonstrating that during induction, the stalled ribosome protects codons 9 and 10 of the leader peptide from modification by dimethyl sulfate, in agreement with genetic data obtained previously that identified the integrity of codons 5-9 as critical for induction of ermC by erythromycin.	Erythromycin	321-333	ErmC	Staphylococcus aureus	313-317
2802615-1	1989	Adult human liver contains a form of cytochrome P450, termed HLp, that resembles the glucocorticoid-inducible cytochrome P450p in rat liver in its structure, function, and regulation and catalyzes the oxidation of such clinically important substrates as cyclosporin, nifedipine, erythromycin, and midazolam.	Erythromycin	279-291	HLP	Homo sapiens	61-64
2592348-0	1989	Erythromycin-induced ribosome stall in the ermA leader: a barricade to 5"-to-3" nucleolytic cleavage of the ermA transcript.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	43-47
2592348-0	1989	Erythromycin-induced ribosome stall in the ermA leader: a barricade to 5"-to-3" nucleolytic cleavage of the ermA transcript.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	108-112
2592348-1	1989	The Staphylococcus aureus ermA gene, whose product confers resistance to the macrolide-lincosamide-streptogramin B family of antibiotics, is induced at the level of translation by nanomolar concentrations of erythromycin.	Erythromycin	208-220	rRNA methylase Erm(A)	Staphylococcus aureus	26-30
2592348-2	1989	Erythromycin also specifically stabilizes ermA transcripts, and the induced stabilization requires in-phase translation of at least one of two small leader peptides in the 5" leader region of the transcript.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	42-46
2592348-3	1989	Erythromycin-induced mRNA stabilization was tested in three constructions in which the ermA transcript was elongated by making insertions at the ermA transcription start.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	87-91
2592348-3	1989	Erythromycin-induced mRNA stabilization was tested in three constructions in which the ermA transcript was elongated by making insertions at the ermA transcription start.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	145-149
2592348-5	1989	In the presence of erythromycin, specific mRNA decay intermediates in both the extended ermA genes and the wild-type ermA gene were detected by both Northern blotting and S1 nuclease mapping.	Erythromycin	19-31	rRNA methylase Erm(A)	Staphylococcus aureus	88-92
2592348-5	1989	In the presence of erythromycin, specific mRNA decay intermediates in both the extended ermA genes and the wild-type ermA gene were detected by both Northern blotting and S1 nuclease mapping.	Erythromycin	19-31	rRNA methylase Erm(A)	Staphylococcus aureus	117-121
2592348-6	1989	The 5" ends of the intermediates map to the sequences that encode each of the two ermA leader peptides, suggesting that the intermediates are produced by stalled erythromycin-bound ribosomes acting as barricades to degradation by 5"-to-3" RNases.	Erythromycin	162-174	rRNA methylase Erm(A)	Staphylococcus aureus	82-86
2592348-7	1989	In addition, whereas erythromycin was found previously to stabilize ermA transcripts only physically, an ermC-cat-86 hybrid transcript was stabilized both physically and functionally by erythromycin.	Erythromycin	21-33	rRNA methylase Erm(A)	Staphylococcus aureus	68-72
2810120-0	1989	An erythromycin derivative, EM-523, induces motilin-like gastrointestinal motility in dogs.	Erythromycin	3-15	motilin	Canis lupus familiaris	44-51
2515189-6	1989	Supporting these results, a marked decrease (more than 75%) in the content of P-450-male, a major constitutive form of cytochrome P-450 in male rats, was noted with oleandomycin, troleandomycin, erythromycin and erythromycin estolate, while the decrease was rather small with rokitamycin and leucomycin.	Erythromycin	195-207	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	119-135
2697468-0	1989	A single nucleotide substitution at the rib2 locus of the yeast mitochondrial gene for 21S rRNA confers resistance to erythromycin and cold-sensitive ribosome assembly.	Erythromycin	118-130	bifunctional DRAP deaminase/tRNA pseudouridine synthase RIB2	Saccharomyces cerevisiae S288C	40-44
2515189-3	1989	Cytochrome P-450-metabolite complex was detected with oleandomycin, troleandomycin, erythromycin and erythromycin estolate, whereas no such effect was observed with rokitamycin, leucomycin and josamycin.	Erythromycin	84-96	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
2515189-4	1989	The content of uncomplexed cytochrome P-450 in liver microsomes remained unchanged with rokitamycin, leucomycin and josamycin, decreased with troleandomycin and oleandomycin, and increased with erythromycin and erythromycin estolate, indicating that oleandomycin, troleandomycin, erythromycin and erythromycin estolate also affect the amounts of other forms of cytochrome P-450.	Erythromycin	194-206	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	27-43
2782416-0	1989	Erythromycin is a motilin receptor agonist.	Erythromycin	0-12	motilin	Homo sapiens	18-25
2515189-4	1989	The content of uncomplexed cytochrome P-450 in liver microsomes remained unchanged with rokitamycin, leucomycin and josamycin, decreased with troleandomycin and oleandomycin, and increased with erythromycin and erythromycin estolate, indicating that oleandomycin, troleandomycin, erythromycin and erythromycin estolate also affect the amounts of other forms of cytochrome P-450.	Erythromycin	211-223	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	27-43
2676971-6	1989	The Agrobacterium recA gene was disrupted by insertion of a cassette encoding resistance to erythromycin, and the mutated gene was marker exchanged into the chromosome of strain NT-1.	Erythromycin	92-104	recombinase RecA	Agrobacterium fabrum str. C58	18-22
2925281-0	1989	Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: reversal of drug resistance by erythromycin.	Erythromycin	134-146	tumor necrosis factor	Mus musculus	27-49
2684005-6	1989	New macrolide derivatives also show promise to expand the antimicrobial spectrum of erythromycin to include Mycobacterium and Borrelia spp.	Erythromycin	84-96	histocompatibility minor 13	Homo sapiens	135-138
2478074-0	1989	Purification and characterization of macrolide 2"-phosphotransferase from a strain of Escherichia coli that is highly resistant to erythromycin.	Erythromycin	131-143	macrolide 2-phosphotransferase	Escherichia coli	37-68
2478074-1	1989	Macrolide 2"-phosphotransferase [MPH(2")] was purified 90-fold from an erythromycin-resistant strain of Escherichia coli, and its enzymatic properties were investigated.	Erythromycin	71-83	macrolide 2-phosphotransferase	Escherichia coli	0-31
2767221-3	1989	In particular, a strain (CT28) isolated from a patient with nongonococcal urethritis long treated with erythromycin revealed a MIC greater than 100 micrograms/ml for this antibiotic.	Erythromycin	103-115	leucine zipper protein 4	Homo sapiens	25-29
2767221-6	1989	Strain CT28 was resistant to josamycin, erythromycin, roxithromycin, lincomycin and clindamycin but sensitive to minocycline.	Erythromycin	40-52	leucine zipper protein 4	Homo sapiens	7-11
2513373-0	1989	Enhanced secretion of Escherichia coli beta-lactamase by a spontaneous erythromycin-resistant mutant of Bacillus subtilis.	Erythromycin	71-83	beta-lactamase	Escherichia coli	39-53
2513373-8	1989	The amount of beta-lactamase in the culture supernatants of ME162 increased significantly when the cells were cultured with erythromycin, suggesting that proteolysis of the beta-lactamase in the supernatants of ME162 was greatly reduced as compared to that in the supernatants of the wild-type strain.	Erythromycin	124-136	beta-lactamase	Escherichia coli	14-28
2513373-8	1989	The amount of beta-lactamase in the culture supernatants of ME162 increased significantly when the cells were cultured with erythromycin, suggesting that proteolysis of the beta-lactamase in the supernatants of ME162 was greatly reduced as compared to that in the supernatants of the wild-type strain.	Erythromycin	124-136	beta-lactamase	Escherichia coli	173-187
2463370-0	1988	Erythromycin-induced stabilization of ermA messenger RNA in Staphylococcus aureus and Bacillus subtilis.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	38-42
2913056-3	1989	To develop a practical method to estimate the amounts of HLp in patients [14C]N-methyl erythromycin was injected into rats that had been pretreated with dexamethasone or with inducers of other forms of cytochrome P-450.	Erythromycin	87-99	HLP	Homo sapiens	57-60
2463370-1	1988	Erythromycin-induced stabilization of ermA mRNA was studied in Staphylococcus aureus, its original host background, and in Bacillus subtilis, subcloned on plasmid vectors.	Erythromycin	0-12	rRNA methylase Erm(A)	Staphylococcus aureus	38-42
2463370-2	1988	By RNA blot analysis it was shown that 40 nM-erythromycin specifically increased the chemical half-life of ermA mRNA from 2.5 to 17.5 minutes whereas the half-life of cat-86 mRNA was not increased by erythromycin.	Erythromycin	45-57	rRNA methylase Erm(A)	Staphylococcus aureus	107-111
2463370-3	1988	While expression of ermA has been shown to be induced by erythromycin at the level of translation, our studies with three ermA constitutive mutants demonstrated that mRNA stabilization in growing cells occurred independently of induced gene expression, suggesting that the stabilized mRNA was not functional for protein synthesis.	Erythromycin	57-69	rRNA methylase Erm(A)	Staphylococcus aureus	20-24
3395131-4	1988	In addition, anti-P-450 HFLa IgG inhibited erythromycin N-demethylase in liver microsomes from erythromycin- or oleandomycin-pretreated rats.	Erythromycin	43-55	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	18-28
2847507-6	1988	Further, erythromycin A and azithromycin at concentrations of 10(-7) M, 10(-6) M and 10(-5) M significantly (p less than 0.01) reduced excocytosis of both lysosomal enzymes, beta-Gluc and beta-Glm from human PMNL initiated by BSA/anti-BSA in a dose-related fashion.	Erythromycin	9-23	glucuronidase, beta	Rattus norvegicus	174-183
3395131-4	1988	In addition, anti-P-450 HFLa IgG inhibited erythromycin N-demethylase in liver microsomes from erythromycin- or oleandomycin-pretreated rats.	Erythromycin	95-107	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	18-28
3259880-2	1988	This study was undertaken into liver microsomal fractions prepared from untreated rabbits or animals treated with drugs known to specifically induce various cytochrome P-450 isozymes such as form LM2 by phenobarbital, LM4 and LM6 by 3-methylcholanthrene and beta-naphthoflavone, LM3a by ethyl alcohol and acetone, and LM3c by macrolide antibiotics (rifampicin, erythromycin and triacetyloleandomycin).	Erythromycin	361-373	cytochrome P-450	Oryctolagus cuniculus	157-173
3395477-2	1988	Incubation in erythromycin - even in high dilutions - caused a significant increase in the percentage of PMNs bearing receptors for the Fc portion of IgG (Fc gamma R) and for C3b (C3bR) as measured by rosette formation with EA (erythrocyte-antibody) and EAC (erythrocyte-antibody-complement) indicator cells.	Erythromycin	14-26	complement C3	Homo sapiens	175-178
3395477-2	1988	Incubation in erythromycin - even in high dilutions - caused a significant increase in the percentage of PMNs bearing receptors for the Fc portion of IgG (Fc gamma R) and for C3b (C3bR) as measured by rosette formation with EA (erythrocyte-antibody) and EAC (erythrocyte-antibody-complement) indicator cells.	Erythromycin	14-26	complement C3b/C4b receptor 1 (Knops blood group)	Homo sapiens	180-184
3275651-5	1988	It has been found that protein L22 is the protein mainly, and under some conditions exclusively, labeled by the erythromycin derivatives.	Erythromycin	112-124	ribosomal protein L22	Homo sapiens	31-34
3275651-6	1988	These results were confirmed using ribosomes from erythromycin-resistant mutants having a protein L22 with modified electrophoretical mobility.	Erythromycin	50-62	ribosomal protein L22	Homo sapiens	98-101
3275651-8	1988	Competition experiments with erythromycin indicate that labeling in protein L22, and probably in L15, is specific, while the specificity of labeling in proteins L2 and L4 is questionable.	Erythromycin	29-41	ribosomal protein L22	Homo sapiens	76-79
3120728-3	1987	Like PCN, treatment of rats with dexamethasone, spironolactone, troleandomycin or erythromycin estolate markedly induced both UDP-GT-dt1 and cytochrome P-450p (measured as erythromycin demethylase and testosterone 2 beta-, 6 beta-, 15 beta-, and 18-hydroxylase activities).	Erythromycin	82-94	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	141-158
3816008-6	1987	Erythromycin has known effects on hepatic enzyme function, with altered cytochrome P-450 function.	Erythromycin	0-12	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
2962674-3	1987	The quantification limit for 2"-ethylsuccinate ester was 50 ng ml-1 and for erythromycin 100 ng ml-1.	Erythromycin	76-88	interleukin 17F	Homo sapiens	96-100
3606934-5	1987	The unbound fraction (fu) of erythromycin was significantly higher in cirrhotic patients (58.3 +/- 17.7%) than in normal subjects (30.5 +/- 2.8%, P less than 0.01), and a negative correlation was found between fu values and serum AAG (r = -0.867, P less than 0.01).	Erythromycin	29-41	N-methylpurine DNA glycosylase	Homo sapiens	230-233
3606934-9	1987	It is concluded that in cirrhotic patients, low serum AAG levels and reduced liver metabolic capacity may lead to marked changes in pharmacokinetics of erythromycin, and that similar results might be expected for drugs which exhibit the same serum binding and pharmacokinetic behaviour as erythromycin.	Erythromycin	152-164	N-methylpurine DNA glycosylase	Homo sapiens	54-57
3606934-9	1987	It is concluded that in cirrhotic patients, low serum AAG levels and reduced liver metabolic capacity may lead to marked changes in pharmacokinetics of erythromycin, and that similar results might be expected for drugs which exhibit the same serum binding and pharmacokinetic behaviour as erythromycin.	Erythromycin	289-301	N-methylpurine DNA glycosylase	Homo sapiens	54-57
2955899-2	1987	Twenty patients received 250 mg of tetracycline BID and 20 received 250 mg of erythromycin BID for four months.	Erythromycin	78-90	BH3 interacting domain death agonist	Homo sapiens	91-94
3976891-2	1985	It was found that the 14-membered macrolides erythromycin and oleandomycin are active in inducing IMC in the stomach in association with the endogenous release of motilin.	Erythromycin	45-57	motilin	Canis lupus familiaris	163-170
3943442-7	1986	It is concluded that erythromycin at a dose of 1-3 mg/kg/hr for 15 min during the interdigestive state, similar to motilin, has a significant influence upon the initiation of MMC in the human gastrointestinal tract, but further investigations are required to confirm whether endogenous motilin is involved or not.	Erythromycin	21-33	motilin	Homo sapiens	286-293
3490132-1	1986	Macrolide antibiotics like Erythromycin and Tri-acetyl oleandomycin (TAO) are metabolized to nitrosoderivatives which cause inactivation of Cytochrome P-450 by forming stable complex with the Iron of the hemoporphyrin.	Erythromycin	27-39	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	140-156
3490132-2	1986	Several derivatives of erythromycin having lost their cladinose moiety are stronger inducer of liver cytochrome P-450 itself.	Erythromycin	23-35	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	101-117
3898085-4	1985	We purified HLp to homogeneity and found that it was immunochemically related to P-450p and to its homologue in the rabbit (LM3c), actively demethylated erythromycin in a reconstituted system, exhibited electrophoretic mobility identical to that of P-450p, and shared 57% homology in its NH2-terminal amino acid sequence with that of a pregnenolone-16 alpha-carbonitrile-inducible rat cytochrome P-450.	Erythromycin	153-165	HLP	Homo sapiens	12-15
3877043-2	1985	In rats and in humans, troleandomycin, erythromycin and erythromycin derivatives induce microsomal enzymes; the induced isozymes of cytochrome P-450 have a high activity for these macrolides but a poor activity with several other substrates.	Erythromycin	39-51	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3877043-2	1985	In rats and in humans, troleandomycin, erythromycin and erythromycin derivatives induce microsomal enzymes; the induced isozymes of cytochrome P-450 have a high activity for these macrolides but a poor activity with several other substrates.	Erythromycin	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	132-148
3873941-0	1985	Some erythromycin derivatives are strong inducers in rats of a cytochrome P-450 very similar to that induced by 16 alpha-pregnenolone carbonitrile.	Erythromycin	5-17	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	63-79
3873941-1	1985	Erythromycin derivatives having lost the cladinose moiety, erythralosamine and its mono- and diacetate, are strong inducers of liver cytochrome P-450, better than troleandomycin, in rats.	Erythromycin	0-12	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	133-149
3994346-7	1985	The concentration of erythromycin by a variety of human cell types probably accounts, in part, for the effectiveness of the antibiotic against intracellular parasites such as Legionella and Chlamydia spp.	Erythromycin	21-33	histocompatibility minor 13	Homo sapiens	200-203
3084433-2	1986	The three erythromycins induced the synthesis of microsomal enzymes, but the products of their metabolism inactivated cytochrome P-450 in the order base less than or equal to stearate less than estolate.	Erythromycin	10-23	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	118-134
3976891-6	1985	The mechanisms by which erythromycin and oleandomycin stimulate endogenous motilin release are not known.	Erythromycin	24-36	motilin	Canis lupus familiaris	75-82
6387646-0	1984	Erythromycin-resistant group A beta-hemolytic streptococci: prevalence at four medical centers.	Erythromycin	0-12	amyloid beta precursor protein	Homo sapiens	29-35
6507625-0	1984	Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog.	Erythromycin	0-12	motilin	Canis lupus familiaris	30-37
6095195-0	1984	Erythromycin and spiramycin resistance mutations of yeast mitochondria: nature of the rib2 locus in the large ribosomal RNA gene.	Erythromycin	0-12	bifunctional DRAP deaminase/tRNA pseudouridine synthase RIB2	Saccharomyces cerevisiae S288C	86-90
6095195-1	1984	Two linked genetic loci, rib 2 and rib 3, of yeast mitochondrial genome are the sites of mutations that confer resistance to erythromycin and/or spiramycin.	Erythromycin	125-137	bifunctional DRAP deaminase/tRNA pseudouridine synthase RIB2	Saccharomyces cerevisiae S288C	25-30
6095195-1	1984	Two linked genetic loci, rib 2 and rib 3, of yeast mitochondrial genome are the sites of mutations that confer resistance to erythromycin and/or spiramycin.	Erythromycin	125-137	3,4-dihydroxy-2-butanone-4-phosphate synthase RIB3	Saccharomyces cerevisiae S288C	35-40
6660855-3	1983	Subinhibitory concentrations of lincosamines, erythromycin, and chloramphenicol decreased fibronectin binding to Staphylococcus aureus, whereas beta-lactam antibiotics enhanced this interaction.	Erythromycin	46-58	fibronectin 1	Homo sapiens	90-101
6091534-1	1984	The association and conformational structure of the molecule of erythromycin in solutions of CCl4, C2Cl4 and CHCl3 were studied by the IR spectra in the region of v OH and vC = O.	Erythromycin	64-76	C-C motif chemokine ligand 4	Homo sapiens	93-97
6422856-0	1984	Malonyl-CoA decarboxylase from Streptomyces erythreus: purification, properties, and possible role in the production of erythromycin.	Erythromycin	120-132	malonyl-CoA decarboxylase	Homo sapiens	0-25
6422856-1	1984	Malonyl-CoA decarboxylase was purified (800-fold) from an erythromycin-producing strain of Streptomyces erythreus using DEAE-cellulose, Sephadex G-100, SP-Sephadex, and gel filtration with Sephadex G-75.	Erythromycin	58-70	malonyl-CoA decarboxylase	Homo sapiens	0-25
6143534-0	1984	Source of methylmalonyl-coenzyme A for erythromycin synthesis: methylmalonyl-coenzyme A mutase from Streptomyces erythreus.	Erythromycin	39-51	methylmalonyl-CoA mutase	Homo sapiens	63-94
6603844-2	1983	Previous studies have shown that the macrolide antibiotics, troleandomycin and erythromycin, are able to induce their own transformation into a metabolite forming an inactivated complex with rat liver cytochrome P-450.	Erythromycin	79-91	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	201-217
7322948-0	1981	Quantitative structure-activity relationships in erythromycin group with MTD technique.	Erythromycin	49-61	metallothionein 1E	Homo sapiens	73-76
6348483-1	1983	The accumulation of respiratory deficient (RD) mutants in Saccharomyces cerevisiae depended upon the mutagens used and upon the presence of the nuclear gene previously identified as MMC1 (one) which we showed to control the spontaneous and the erythromycin-induced RD mutability.	Erythromycin	244-256	Mps2p	Saccharomyces cerevisiae S288C	182-186
7096266-1	1982	Bacteroides fragilis TMP10, which is clindamycin-erythromycin resistant (Clnr) and tetracycline resistant (Tetr), contains several plasmids and is capable of transferring drug resistance markers to suitable recipients.	Erythromycin	49-61	oligodendrocytic myelin paranodal and inner loop protein	Homo sapiens	21-26
6838653-1	1983	In rats, erythromycin has been shown to induce microsomal enzymes and to promote its own transformation into a metabolite which forms an inactive complex with reduced cytochrome P-450.	Erythromycin	9-21	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	167-183
6838653-3	1983	In the treated patients, NADPH-cytochrome c reductase activity was increased; the total cytochrome P-450 concn was also increased but part of the total cytochrome P-450 was complexed by an erythromycin metabolite.	Erythromycin	189-201	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	152-168
6757890-0	1982	Erythromycin resistance in group A beta-hemolytic streptococci.	Erythromycin	0-12	amyloid beta precursor protein	Homo sapiens	33-39
7103442-8	1982	Ethambutol (C/E = 5), clindamycin (C/E = 11), and two erythromycin preparations (C/E = 10 to 13) were markedly concentrated within PMN.	Erythromycin	54-66	BCL10 immune signaling adaptor	Homo sapiens	81-89
7025754-0	1981	Susceptibility of group A beta-hemolytic Streptococcus isolates to penicillin and erythromycin.	Erythromycin	82-94	amyloid beta precursor protein	Homo sapiens	24-30
6975423-6	1981	Nine beta-lactamase producing strains had MICs to erythromycin of 2.0 mg/L or less.	Erythromycin	50-62	beta-lactamase TEM-1	Haemophilus influenzae	5-19
7025754-1	1981	We have reevaluated the antibiotic susceptibilities of group A beta-hemolytic streptococci in view of recent reports of a high prevalence of erythromycin resistance in Japan and of an increase in penicillin treatment failures in the United States.	Erythromycin	141-153	amyloid beta precursor protein	Homo sapiens	61-67
14453579-2	1962	The biogenesis of erythronolide, the C-21 branched chain lactone in erythromycin.	Erythromycin	68-80	TBL1X/Y related 1	Homo sapiens	37-41
7252850-0	1981	Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450.	Erythromycin	18-30	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	116-132
7252850-1	1981	Erythromycin, 0.3 mM, elicited a small reverse type I binding spectrum with, and was slowly demethylated by, cytochrome P-450 from control rats.	Erythromycin	0-12	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	109-125
7252850-11	1981	It is concluded that erythromycin induces its own transformation into a metabolite which forms a inactive 456-nm absorbing complex with the iron (II) of cytochrome P-450.	Erythromycin	21-33	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	153-169
6970806-6	1980	showed no significant toxicity at concentrations higher than 10(-4)M. It was noted that the inhibition of CFU-C proliferation either by mitomycin C (an inhibitor of DNA synthesis) or by erythromycin(an inhibitor of protein synthesis) occurred in a manner competitive to the added CSF activity.	Erythromycin	186-198	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	280-283
7410293-0	1980	Activity of ampicillin and erythromycin against Haemophilus spp.	Erythromycin	27-39	histocompatibility minor 13	Homo sapiens	60-63
291565-4	1979	Resistance to erythromycin has been mapped on the chromosomes of two S. coelicolor A3(2) derivatives in different sites: between markers adeC (v 10) and ArgA1 in the strain A617, between pheA1 and SCP1 in the strain S18.	Erythromycin	14-26	synaptonemal complex protein 1	Homo sapiens	197-201
438530-1	1979	A clindamycin- and erythromycin-resistant strain of Bacteroides fragilis, TMP10, that had been isolated from a blood culture transferred its drug resistance in a Millipore mating procedure to another strain of B. fragilis, TM2000, and to a strain of Bacteroides thetaiotaomicron.	Erythromycin	19-31	oligodendrocytic myelin paranodal and inner loop protein	Homo sapiens	74-79
572556-3	1979	Erythromycin base and estolate enhanced bile flow recovery after TCDC and potentiated the increase of plasma 5"-nucleotidase, as did CPZ.	Erythromycin	0-17	5' nucleotidase, ecto	Rattus norvegicus	109-124
792404-2	1976	The in vitro assay measured total erythromycin activity against a group A beta hemolytic streptococcus.	Erythromycin	34-46	amyloid beta precursor protein	Homo sapiens	72-78
4966066-0	1968	Group A beta-hemolytic streptococci resistant to erythromycin and lincomycin.	Erythromycin	49-61	amyloid beta precursor protein	Homo sapiens	6-12
7021320-2	1981	The genetic element IMP1 is not allelic to any of the known GAL genes; IMP1 strains can grow on  and ferment galactose in respiratory-deficient (RD) condition or in the presence of the mitochondrial inhibitors ethidium bromide and erythromycin; whereas, imp1 strains can grow on and ferment galactose only in respiratory-sufficient (RS) condition.	Erythromycin	231-243	endopeptidase catalytic subunit IMP1	Saccharomyces cerevisiae S288C	20-24
7021320-2	1981	The genetic element IMP1 is not allelic to any of the known GAL genes; IMP1 strains can grow on  and ferment galactose in respiratory-deficient (RD) condition or in the presence of the mitochondrial inhibitors ethidium bromide and erythromycin; whereas, imp1 strains can grow on and ferment galactose only in respiratory-sufficient (RS) condition.	Erythromycin	231-243	endopeptidase catalytic subunit IMP1	Saccharomyces cerevisiae S288C	71-75
29219-3	1978	Multiply resistant Type 19A strains, resistant to beta-lactam antibiotics, erythromycin, clindamycin, tetracycline and chloramphenicol, were isolated from 128 carriers, and were responsible for bacteremia in four patients.	Erythromycin	75-87	SLAM family member 7	Homo sapiens	24-27
352690-7	1978	The incorporation of radioactive leucine into the apoprotein of cytochrome b isolated by immunoprecipitation followed by gel electrophoresis was insensitive to cycloheximide (an inhibitor of cytoplasmic protein synthesis) and sensitive to acriflavin, erythromycin, and chloramphenicol (inhibitors of mitochondrial protein synthesis).	Erythromycin	251-263	cytochrome b	Saccharomyces cerevisiae S288C	64-76
4598840-0	1972	Resistance of group A beta-hemolytic streptococci to lincomycin and erythromycin.	Erythromycin	68-80	amyloid beta precursor protein	Homo sapiens	20-26
33747180-12	2021	In contrast, the IL-8 mRNA expression levels were decreased and increased in the erythromycin and vorinostat groups, respectively.	Erythromycin	81-93	interleukin-8	Oryctolagus cuniculus	17-21
13185438-0	1954	Erythromycin as an aid in the management of aleukemic myeloblastic leukemias.	Erythromycin	0-12	activation induced cytidine deaminase	Homo sapiens	19-22
33570481-6	2021	The ability of compounds to inhibit activity of the ABCG2 transporter and the CYP3A4 enzyme were assessed using human ABCG2 vesicles and demethylation of erythromycin by rat liver microsomes, respectively.	Erythromycin	154-166	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	52-57
33570481-6	2021	The ability of compounds to inhibit activity of the ABCG2 transporter and the CYP3A4 enzyme were assessed using human ABCG2 vesicles and demethylation of erythromycin by rat liver microsomes, respectively.	Erythromycin	154-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84
33555859-3	2021	We demonstrate that trapping erythromycin within Escherichia coli through phosphorylation increases the sensitivity of its biosensor (MphR) by approximately 10-fold.	Erythromycin	29-41	erythromycin resistance repressor protein	Escherichia coli	134-138
33877033-2	2022	Erythromycin is associated with adverse reactions, including corrected QT interval prolongation and cytochrome P450 3A4 isoenzyme inhibition.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-119
33635515-7	2021	The tested substances demonstrated effectiveness at decreasing the MIC of erythromycin, tetracycline and ethidium bromide, potentially by inhibiting the MsrA macrolide and the TetK tetracycline efflux pumps present in the tested S. aureus strains.	Erythromycin	74-86	ABC transporter permease protein	Staphylococcus aureus	153-157
33550966-2	2021	The present work is an effort for a computational target to block the spike proteins (S) and ACE2 receptor proteins with Macrolide antibiotics like Azithromycin, (AZM), Clarithromycin (CLAM) and Erythromycin (ERY) along with RNA-dependent RNA polymerase (RdRp).	Erythromycin	195-207	angiotensin converting enzyme 2	Homo sapiens	93-97
33550966-2	2021	The present work is an effort for a computational target to block the spike proteins (S) and ACE2 receptor proteins with Macrolide antibiotics like Azithromycin, (AZM), Clarithromycin (CLAM) and Erythromycin (ERY) along with RNA-dependent RNA polymerase (RdRp).	Erythromycin	209-212	angiotensin converting enzyme 2	Homo sapiens	93-97
33550966-6	2021	Interaction of CLAM and ERY presented low binding energy (-6.8 and -6.6) with the ACE2 receptor.	Erythromycin	24-27	angiotensin converting enzyme 2	Homo sapiens	82-86
32967779-2	2020	Typical CYP3A4-substrates including erythromycin, cyclosporin A (ca.1200 Da), ivermectin B1a and taxanes were applied successfully and regioselective metabolisms of these ligands were reconstituted faithfully on Template.	Erythromycin	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14
32967779-5	2020	The observed differences were associated with different inhibitory/inactivation potentials of troleandomycin, erythromycin, clarithromycin and azithromycin, suggesting CYP3A4 Template also as a tool for drug-interaction mechanisms.	Erythromycin	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-174
32559772-3	2020	The aim of this study was to compare the effects of erythromycin, clarithromycin and azithromycin on cell viability and expression of ERG1 gene in H9c2 cells.	Erythromycin	52-64	potassium voltage-gated channel subfamily H member 2	Rattus norvegicus	134-138
32771913-3	2020	Based on the special photodynamic properties triggered by commonly available light emitting diode (LED) lamps, a kind of graphene quantum dots (GQDs) based composite system (termed GQDs@hMSN(EM)) was prepared through loading both GQDs and erythromycin (EM) into the hollow mesoporous silica nanoparticle (hMSN), aiming to achieve joint antimicrobial effect.	Erythromycin	239-251	moesin	Homo sapiens	186-190
32603314-0	2020	Erythromycin inhibits neutrophilic inflammation and mucosal disease by upregulating DEL-1.	Erythromycin	0-12	EGF-like repeats and discoidin I-like domains 3	Mus musculus	84-89
32603314-2	2020	In this study, using two distinct mouse models of mucosal inflammatory disease (LPS-induced acute lung injury and ligature-induced periodontitis), we demonstrated that the anti-inflammatory action of erythromycin (ERM) is mediated through upregulation of the secreted homeostatic protein DEL-1.	Erythromycin	200-212	EGF-like repeats and discoidin I-like domains 3	Mus musculus	288-293
32503882-2	2020	Erythromycin (ERY), a moderate, mechanism-based inhibitor of CYP3A, was evaluated as a tool in the HepatoPac model to assess contribution of CYP3A to the clearance of drug candidates.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-66
32503882-3	2020	ERY inhibited CYP3A activity by 58 and 80% for 3 and 10 muM, respectively, for up to 72 h. At 30 microM, ERY inhibited MDZ hydroxylation by >85% for the entire 144 h duration of the incubation.	Erythromycin	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-19
32503882-9	2020	SIGNIFICANCE STATEMENT: This work describes the use of erythromycin as a selective CYP3A inhibitor in a long-term hepatocyte model.	Erythromycin	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-88
32559772-0	2020	Comparative Study of the Effect of Macrolide Antibiotics Erythromycin, Clarithromycin, and Azithromycin on the ERG1 Gene Expression in H9c2 Cardiomyoblast Cells.	Erythromycin	57-69	potassium voltage-gated channel subfamily H member 2	Rattus norvegicus	111-115
33174961-9	2020	Among erythromycin-resistant MRSA, 53.4%, 45.3%, 37.9%, 13.0%, and 6.8% carried ermA, msrA, msrB, ermC, and ermB genes, respectively.	Erythromycin	6-18	ABC transporter permease protein	Staphylococcus aureus	86-90
33174961-9	2020	Among erythromycin-resistant MRSA, 53.4%, 45.3%, 37.9%, 13.0%, and 6.8% carried ermA, msrA, msrB, ermC, and ermB genes, respectively.	Erythromycin	6-18	ErmC	Staphylococcus aureus	98-102
32777256-9	2020	Therefore, erythromycin could enhance muscle glycogen and endurance via up-regulating the level of ORM and activating CCR5-AMPK pathway, indicating it might act as a potential drug to treat muscle fatigue.	Erythromycin	11-23	chemokine (C-C motif) receptor 5	Mus musculus	118-122
31857248-5	2020	TP1 exhibited resistance to aminoglycosides (gentamicin and amikacin), macrolides (erythromycin), lincosamides (clindamycin), sulfonamides (sulfamonomethoxine), tetracyclines (tetracycline and doxycycline) and chloramphenicols (chloramphenicol and florfenicol).	Erythromycin	83-95	transition protein 1	Bos taurus	0-3
32712589-5	2020	The kinetic parameters (k cat) of the N-demethylation reaction of erythromycin, the antibiotic of the macrolide group, used as a marker substrate for the comparative analysis of the catalytic activity of cytochrome P450 3A4, both in the presence of alpha-lipoic acid and in the cytochrome P450 3A4-erythromycin complex, amounted to comparable values of 3.5 +- 0.9 and 3.4 +- 0.9 min-1, respectively.	Erythromycin	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	204-223
32712589-5	2020	The kinetic parameters (k cat) of the N-demethylation reaction of erythromycin, the antibiotic of the macrolide group, used as a marker substrate for the comparative analysis of the catalytic activity of cytochrome P450 3A4, both in the presence of alpha-lipoic acid and in the cytochrome P450 3A4-erythromycin complex, amounted to comparable values of 3.5 +- 0.9 and 3.4 +- 0.9 min-1, respectively.	Erythromycin	66-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	278-297
32712589-5	2020	The kinetic parameters (k cat) of the N-demethylation reaction of erythromycin, the antibiotic of the macrolide group, used as a marker substrate for the comparative analysis of the catalytic activity of cytochrome P450 3A4, both in the presence of alpha-lipoic acid and in the cytochrome P450 3A4-erythromycin complex, amounted to comparable values of 3.5 +- 0.9 and 3.4 +- 0.9 min-1, respectively.	Erythromycin	298-310	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	204-223
32116227-8	2020	Electrocatalytic properties of cytochrome P450 3A4, immobilized on modified screen-printed graphite electrodes, has been investigated using erythromycin (macrolide antibiotics).	Erythromycin	140-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-50
31770582-9	2020	Erythromycin had no effects on the phosphorylated and total protein expression levels of P38MAPK and ERK; however, it induced inhibition of the phosphorylated and total protein expression levels of JNK.	Erythromycin	0-12	mitogen-activated protein kinase 8	Homo sapiens	198-201
31770582-11	2020	JNK inhibition by erythromycin restores corticosteroid sensitivity via the inhibition of c-Jun expression.	Erythromycin	18-30	mitogen-activated protein kinase 8	Homo sapiens	0-3
31770582-11	2020	JNK inhibition by erythromycin restores corticosteroid sensitivity via the inhibition of c-Jun expression.	Erythromycin	18-30	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	89-94
32174014-3	2020	Here we reported 16 pediatric patients with PL and systematically reviewed published literatures on erythromycin treatment response in pediatric PL patients, to observed the different treatment response to erythromycin in the PLC and the PLEVA groups.	Erythromycin	206-218	heparan sulfate proteoglycan 2	Homo sapiens	226-229
32147975-1	2020	The macrolide antibiotic erythromycin has been associated with QT interval prolongation and inhibition of the hERG-encoded channels responsible for the rapid delayed rectifier K+ current I(Kr ).	Erythromycin	25-37	ETS transcription factor ERG	Homo sapiens	110-114
32147975-2	2020	It has been suggested that low concentrations of erythromycin may have a protective effect against hERG block and associated drug-induced arrhythmia by reducing the affinity of the pore-binding site for high potency hERG inhibitors.	Erythromycin	49-61	ETS transcription factor ERG	Homo sapiens	99-103
31286572-1	2020	Potential drug-drug interactions of the antitumor drug abiraterone and the macrolide antibiotic erythromycin were studied at the stage of cytochrome P450 3A4 (CYP3A4) biotransformation.	Erythromycin	96-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-157
31286572-5	2020	An electrochemical enzymatic system based on CYP3A4 immobilized on a screen-printed electrode was used to show that abiraterone acts as a competitive inhibitor toward erythromycin N-demethylase activity of CYP3A4 (apparent Ki  = 8.1 +- 1.2 muM), while erythromycin and its products of enzymatic metabolism do not affect abiraterone N-oxidation by CYP3A4.	Erythromycin	167-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
31286572-5	2020	An electrochemical enzymatic system based on CYP3A4 immobilized on a screen-printed electrode was used to show that abiraterone acts as a competitive inhibitor toward erythromycin N-demethylase activity of CYP3A4 (apparent Ki  = 8.1 +- 1.2 muM), while erythromycin and its products of enzymatic metabolism do not affect abiraterone N-oxidation by CYP3A4.	Erythromycin	167-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	206-212
31286572-5	2020	An electrochemical enzymatic system based on CYP3A4 immobilized on a screen-printed electrode was used to show that abiraterone acts as a competitive inhibitor toward erythromycin N-demethylase activity of CYP3A4 (apparent Ki  = 8.1 +- 1.2 muM), while erythromycin and its products of enzymatic metabolism do not affect abiraterone N-oxidation by CYP3A4.	Erythromycin	167-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	206-212
32411785-0	2020	Erythromycin Suppresses the Cigarette Smoke Extract-Exposed Dendritic Cell-Mediated Polarization of CD4+ T Cells into Th17 Cells.	Erythromycin	0-12	CD4 antigen	Mus musculus	100-103
32411785-4	2020	Accordingly, in this study, we evaluated the effects of erythromycin (EM) on CSE-exposed DCs polarizing naive CD4+ T cells into Th17 cells.	Erythromycin	56-68	CD4 antigen	Mus musculus	110-113
32411785-4	2020	Accordingly, in this study, we evaluated the effects of erythromycin (EM) on CSE-exposed DCs polarizing naive CD4+ T cells into Th17 cells.	Erythromycin	70-72	CD4 antigen	Mus musculus	110-113
32689927-14	2020	Such as, we found that Erythromycin (ERY) can establish an interaction relationship with HTH-type transcriptional repressor, which is fitted well with silico DBP-drug prediction.	Erythromycin	23-35	zinc finger protein 763	Homo sapiens	158-161
32689927-14	2020	Such as, we found that Erythromycin (ERY) can establish an interaction relationship with HTH-type transcriptional repressor, which is fitted well with silico DBP-drug prediction.	Erythromycin	37-40	zinc finger protein 763	Homo sapiens	158-161
31770582-0	2020	Erythromycin reverses cigarette smoke extract-induced corticosteroid insensitivity by inhibition of the JNK/c-Jun pathway.	Erythromycin	0-12	mitogen-activated protein kinase 8	Homo sapiens	104-107
31770582-0	2020	Erythromycin reverses cigarette smoke extract-induced corticosteroid insensitivity by inhibition of the JNK/c-Jun pathway.	Erythromycin	0-12	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
32111258-10	2020	Strains resistant to erythromycin carried the ermC, ermA, and msrA genes; the same ermC and ermA genes were detected in strains resistant to clindamycin.	Erythromycin	21-33	ABC transporter permease protein	Staphylococcus aureus	62-66
31286572-6	2020	In conclusion, the inhibition properties of abiraterone toward CYP3A4-dependent N-demethylation of erythromycin and the biologically inert behavior of erythromycin toward abiraterone hydroxylation were demonstrated.	Erythromycin	99-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
31165980-1	2019	Erythromycin is an antibiotic that prolongs the QT-interval and causes Torsade de Pointes (TdP) by blocking the rapid delayed rectifying potassium current (IKr) without affecting either the slow delayed rectifying potassium current (IKs) or inward rectifying potassium current (IK1).	Erythromycin	0-12	IKAROS family zinc finger 1	Homo sapiens	278-281
31819402-0	2019	Erythromycin Prevents Elastin Peptide-Induced Emphysema and Modulates CD4+T Cell Responses in Mice.	Erythromycin	0-12	elastin	Mus musculus	22-29
31819402-0	2019	Erythromycin Prevents Elastin Peptide-Induced Emphysema and Modulates CD4+T Cell Responses in Mice.	Erythromycin	0-12	CD4 antigen	Mus musculus	70-73
31819402-12	2019	Erythromycin reduced IFN-gamma, IL-17, IL-6 inflammatory cytokines, MLI, and the inflammation score in the lungs of EP-exposed mice.	Erythromycin	0-12	interferon gamma	Mus musculus	21-30
31819402-12	2019	Erythromycin reduced IFN-gamma, IL-17, IL-6 inflammatory cytokines, MLI, and the inflammation score in the lungs of EP-exposed mice.	Erythromycin	0-12	interleukin 17A	Mus musculus	32-37
31819402-12	2019	Erythromycin reduced IFN-gamma, IL-17, IL-6 inflammatory cytokines, MLI, and the inflammation score in the lungs of EP-exposed mice.	Erythromycin	0-12	interleukin 6	Mus musculus	39-43
31819402-13	2019	In vitro, erythromycin also limited Th17 and Th1 cell differentiation and downregulated transcript levels of Ifngamma and IL17a in the EP-stimulated CD4+T cells.	Erythromycin	10-22	interferon gamma	Mus musculus	109-117
31819402-13	2019	In vitro, erythromycin also limited Th17 and Th1 cell differentiation and downregulated transcript levels of Ifngamma and IL17a in the EP-stimulated CD4+T cells.	Erythromycin	10-22	interleukin 17A	Mus musculus	122-127
31819402-13	2019	In vitro, erythromycin also limited Th17 and Th1 cell differentiation and downregulated transcript levels of Ifngamma and IL17a in the EP-stimulated CD4+T cells.	Erythromycin	10-22	CD4 antigen	Mus musculus	149-152
31819402-15	2019	Prophylactic use of erythromycin effectively ameliorated emphysema and modulated CD4+T cells responses in EP-induced lung inflammation in mice.	Erythromycin	20-32	CD4 antigen	Mus musculus	81-84
31342602-5	2019	Furthermore, a significantly lower TNF-alpha response (P < 0 05) was observed in U937 cells challenged with GBS when erythromycin and nisin were used in combination.	Erythromycin	117-129	tumor necrosis factor	Homo sapiens	35-44
31399494-1	2019	Erythromycin is a substrate of cytochrome P4503A4 (CYP3A4) and multiple drug transporters.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	31-49
31781630-4	2019	Using real-time PCR, we show that the relative expression level of T2R7 mRNA in 5, 1, 0.1, and 10-3 mM of camphor and erythromycin solutions and 5 mM of chlorpheniramine maleate solutions was significantly higher than that in 50 mM KCL solutions.	Erythromycin	118-130	taste 2 receptor member 7	Homo sapiens	67-71
31180127-6	2019	The ermB gene was detected in 66 (95.7%) erythromycin-resistant E. faecalis isolates, which was higher than that of 32 (71.7%) erythromycin-resistant E. faecium isolates.	Erythromycin	41-53	erythromycin resistance protein	Enterococcus faecalis	4-8
31180127-6	2019	The ermB gene was detected in 66 (95.7%) erythromycin-resistant E. faecalis isolates, which was higher than that of 32 (71.7%) erythromycin-resistant E. faecium isolates.	Erythromycin	127-139	erythromycin resistance protein	Enterococcus faecalis	4-8
31399494-1	2019	Erythromycin is a substrate of cytochrome P4503A4 (CYP3A4) and multiple drug transporters.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
31485578-0	2019	Combination Treatment of Erythromycin and Furamidine Provides Additive and Synergistic Rescue of Mis-Splicing in Myotonic Dystrophy Type 1 Models.	Erythromycin	25-37	sialic acid binding Ig-like lectin E	Mus musculus	97-100
31515489-8	2019	In vivo, erythromycin decreased NETs in the airway and ameliorated emphysema with Th1 and Th17 cell down-regulation and CD40+ and CD86+ mDCs suppression in mice chronically exposed to cigarette smoke.	Erythromycin	9-21	negative elongation factor complex member C/D, Th1l	Mus musculus	82-85
31485578-8	2019	In a DM1 mouse model, a combination of erythromycin and the prodrug of furamidine (pafuramidine), administered orally, displayed both additive and synergistic mis-splicing rescue.	Erythromycin	39-51	sialic acid binding Ig-like lectin E	Mus musculus	159-162
30862504-0	2019	Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity.	Erythromycin	0-12	growth hormone secretagogue receptor	Mus musculus	30-46
30876886-5	2019	Caspase-3 activity was increased with all these tested hepatotoxic drugs and except with erythromycin, was further augmented in presence of cytokines mainly when these were co-added as a mixture.	Erythromycin	89-101	caspase 3	Homo sapiens	0-9
30862504-3	2019	We report that in human primary articular chondrocytes, erythromycin, a well-known macrolide antibiotic, had the ability to inhibit pro-inflammatory cytokine Interleukin 1beta (IL-1beta)-induced catabolic gene expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activation.	Erythromycin	56-68	interleukin 1 beta	Homo sapiens	158-175
30862504-3	2019	We report that in human primary articular chondrocytes, erythromycin, a well-known macrolide antibiotic, had the ability to inhibit pro-inflammatory cytokine Interleukin 1beta (IL-1beta)-induced catabolic gene expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activation.	Erythromycin	56-68	interleukin 1 alpha	Homo sapiens	177-185
30862504-3	2019	We report that in human primary articular chondrocytes, erythromycin, a well-known macrolide antibiotic, had the ability to inhibit pro-inflammatory cytokine Interleukin 1beta (IL-1beta)-induced catabolic gene expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activation.	Erythromycin	56-68	nuclear factor kappa B subunit 1	Homo sapiens	289-298
30862504-7	2019	The association of erythromycin with chondrocytes was diminished in ghrelin receptor null chondrocytes, and administration of the ghrelin ligand prevented the association of erythromycin with chondrocytes.	Erythromycin	19-31	growth hormone secretagogue receptor	Mus musculus	68-84
30862504-8	2019	Importantly, the anti-inflammatory activity of erythromycin was diminished in ghrelin receptor null chondrocytes.	Erythromycin	47-59	growth hormone secretagogue receptor	Mus musculus	78-94
31133071-6	2019	In our results, the high level of resistance to gentamicin, erythromycin and vancomycin in enterococci isolates were mainly related to the presence of aac (6")-Ie aph (2""), ermB and vanA genes, respectively.	Erythromycin	60-72	erythromycin resistance protein	Enterococcus faecalis	174-178
31269587-14	2019	Except between the erythromycin group and the normal control group, the protein expression of mTOR in other groups was statistically significant different (all P&lt;0.05).	Erythromycin	19-31	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	94-98
31269587-15	2019	Conclusion: Penicillin,erythromycin and budesonide can alleviate inflammation by increasing SIRT-1, alleviate tracheal scar hyperplasia induced by TGF-beta/mTOR pathway, and reduce the degree of tracheal stenosis in rabbits.	Erythromycin	23-35	NAD-dependent protein deacetylase sirtuin-1	Oryctolagus cuniculus	92-98
31269587-15	2019	Conclusion: Penicillin,erythromycin and budesonide can alleviate inflammation by increasing SIRT-1, alleviate tracheal scar hyperplasia induced by TGF-beta/mTOR pathway, and reduce the degree of tracheal stenosis in rabbits.	Erythromycin	23-35	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	156-160
30934667-7	2019	The level of acyl-ghrelin was significantly attenuated by EM administration.	Erythromycin	58-60	ghrelin	Mus musculus	18-25
30987227-11	2019	When MA5 was screened for antibiotic resistance, broad resistance against penicillin, streptomycin, tetracycline, ampicillin, rifampicin, and erythromycin was found; this correlated with the presence of multiple gene determinants for antibiotic resistance within the whole genome sequence of MA5.	Erythromycin	142-154	PNMA family member 3	Homo sapiens	5-8
30987227-11	2019	When MA5 was screened for antibiotic resistance, broad resistance against penicillin, streptomycin, tetracycline, ampicillin, rifampicin, and erythromycin was found; this correlated with the presence of multiple gene determinants for antibiotic resistance within the whole genome sequence of MA5.	Erythromycin	142-154	PNMA family member 3	Homo sapiens	292-295
30731142-2	2019	Erythromycin is a ligand of TAS2R10, but its relaxant profile is unknown.	Erythromycin	0-12	taste receptor, type 2, member 110	Mus musculus	28-35
30789939-3	2019	Motilin receptors (MTLRs) are G protein-coupled receptors that may represent a clinically useful pharmacological target as they can be activated by erythromycin.	Erythromycin	148-160	motilin	Rattus norvegicus	0-7
31242482-0	2019	Erythromycin Regulates Cigarette Smoke-Induced Proinflammatory Mediator Release Through Sirtuin 1-Nuclear Factor kappaB Axis in Macrophages and Mice Lungs.	Erythromycin	0-12	sirtuin 1	Mus musculus	88-97
30308294-4	2019	As a result, tetracycline and erythromycin promoted the growth and digestive activity of lipase, pepsin, and trypsin, but norfloxacin did not show significant prompting effect on digestive activity and even retarded the weight gain of the sea cucumbers.	Erythromycin	30-42	lipase	Cucumis sativus	89-95
31242482-3	2019	OBJECTIVES: The present study was designed to examine the effects of erythromycin (EM) on the SIRT1-NF-kappaB axis and NF-kappaB-dependent proinflammatory cytokines.	Erythromycin	69-81	sirtuin 1	Mus musculus	94-99
31242482-3	2019	OBJECTIVES: The present study was designed to examine the effects of erythromycin (EM) on the SIRT1-NF-kappaB axis and NF-kappaB-dependent proinflammatory cytokines.	Erythromycin	69-81	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	100-109
31242482-3	2019	OBJECTIVES: The present study was designed to examine the effects of erythromycin (EM) on the SIRT1-NF-kappaB axis and NF-kappaB-dependent proinflammatory cytokines.	Erythromycin	83-85	sirtuin 1	Mus musculus	94-99
31242482-3	2019	OBJECTIVES: The present study was designed to examine the effects of erythromycin (EM) on the SIRT1-NF-kappaB axis and NF-kappaB-dependent proinflammatory cytokines.	Erythromycin	83-85	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	100-109
30262964-4	2018	Erythromycin/clindamycin-resistant staphylococci carried lnuA/lnuB genes frequently alone or combined with msrA gene.	Erythromycin	0-12	ABC transporter permease protein	Staphylococcus aureus	107-111
30414267-11	2018	Erythromycin treatment significantly decreased cell proliferation and the expression of p-MEK1 and p-ERK1, and increased apoptosis in nasal polyp-derived cells compared with control cells.	Erythromycin	0-12	mitogen-activated protein kinase kinase 1	Homo sapiens	90-94
30414267-11	2018	Erythromycin treatment significantly decreased cell proliferation and the expression of p-MEK1 and p-ERK1, and increased apoptosis in nasal polyp-derived cells compared with control cells.	Erythromycin	0-12	mitogen-activated protein kinase 3	Homo sapiens	101-105
30414267-12	2018	Selumetinib treatment had a synergistic effect with erythromycin to reduce the expression of p-MEK1 and p-ERK1, reduce cell proliferation, and increase cell apoptosis.	Erythromycin	52-64	mitogen-activated protein kinase kinase 1	Homo sapiens	95-99
30414267-12	2018	Selumetinib treatment had a synergistic effect with erythromycin to reduce the expression of p-MEK1 and p-ERK1, reduce cell proliferation, and increase cell apoptosis.	Erythromycin	52-64	mitogen-activated protein kinase 3	Homo sapiens	106-110
30414267-13	2018	CONCLUSIONS In cultured cells derived from nasal polyps, erythromycin treatment reduced cell proliferation and increased apoptosis by inhibiting the activation of the ERK/MAPK signaling pathway.	Erythromycin	57-69	mitogen-activated protein kinase 1	Homo sapiens	167-170
29625331-6	2018	Results demonstrated that irg-1 gene could be induced in the presence of P. aeruginosa strain PA14 in a dose-dependent manner, and the survival of infected worm could be rescued under gentamicin or erythromycin treatments.	Erythromycin	198-210	NADAR domain-containing protein	Caenorhabditis elegans	26-31
29524153-7	2018	Erythromycin-resistant staphylococci harbored the ermC gene and/or the efflux gene msrA.	Erythromycin	0-12	ABC transporter permease protein	Staphylococcus aureus	83-87
29463692-7	2018	Azithromycin and erythromycin showed the greatest effect in subjects with COPD, with evidence suggesting improvement in exacerbation-related outcomes and health status, as measured by the St George Respiratory Questionnaire.	Erythromycin	17-29	COPD	Homo sapiens	74-78
29849580-5	2018	Meta-analysis showed that erythromycin significantly increases the rate of successful postpyloric feeding tube placement (RR 1.45, 95% CI (1.12, 1.86)) and did not increase the risk of adverse effects (RR 2.15, 95% CI (0.20, 22.82)).	Erythromycin	26-38	ribonucleotide reductase catalytic subunit M1	Homo sapiens	122-126
29098603-6	2018	RESULTS: Model predictions indicated that co-administration of GXR with the moderate CYP3A4 inhibitors erythromycin 500 mg three times a day or fluconazole 200 mg daily (q.d.)	Erythromycin	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
29255993-7	2018	The second most frequent contraindicated drug-drug interaction involved CYP3A4 interaction between atorvastatin or simvastatin with either posaconazole or erythromycin.	Erythromycin	155-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
28783915-4	2017	Erythromycin, cyprofloxacin and iopromide also increased rapidly up to tens of ngL-1 within a few days.	Erythromycin	0-12	leucine rich repeat containing 4C	Homo sapiens	79-84
29515175-10	2018	Groups treated with amoxicillin, amoxicillin/clavulanate, erythromycin and acetaminophen showed significantly lower amounts of immunoreactive COX2 at the enamel organ maturation stage of the mouse incisors.	Erythromycin	58-70	prostaglandin-endoperoxide synthase 2	Mus musculus	142-146
29323165-6	2018	The activities of erythromycin N-demethylase, aminopyrine N-demethylase and NAD (P)H quinone oxidoreductase in female rats can be induced post-dose, but these activities were inhibited in male rats.	Erythromycin	18-30	crystallin zeta	Rattus norvegicus	85-107
29564245-8	2018	The majority of the erythromycin-resistant isolates harbored the msrA gene (four iMLSB) with the remaining iMLSB isolate harboring the ermC gene.	Erythromycin	20-32	ABC transporter permease protein	Staphylococcus aureus	65-69
29379095-0	2018	The motilin agonist erythromycin increases hunger by modulating homeostatic and hedonic brain circuits in healthy women: a randomized, placebo-controlled study.	Erythromycin	20-32	motilin	Homo sapiens	4-11
29379095-1	2018	The motilin agonist, erythromycin, induces gastric phase III of the migrating motor complex, which in turn generates hunger peaks.	Erythromycin	21-33	motilin	Homo sapiens	4-11
29379095-10	2018	The motilin agonist erythromycin increases hunger by modulating neurocircuitry related to homeostatic and hedonic control of appetite and feeding.	Erythromycin	20-32	motilin	Homo sapiens	4-11
29138350-8	2018	This inference is supported by the finding that loss of RH50 renders chloroplast protein synthesis sensitive to erythromycin and exposure to cold.	Erythromycin	112-124	Rh associated glycoprotein	Homo sapiens	56-60
28584401-4	2017	We first confirmed that erythromycin suppresses the transcriptional activity of nuclear factor-kappaB and activator protein-1 and the expression of its downstream targets, interleukin-6 and cyclooxygenase-2 in human colon cancer cells.	Erythromycin	24-36	interleukin 6	Homo sapiens	172-185
28884090-8	2017	Two days after treatment completion, erythromycin monotherapy did not suppress bacterial growth and had no effect in bone infection, although it reduced serum pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6.	Erythromycin	37-49	tumor necrosis factor	Rattus norvegicus	186-219
28884090-8	2017	Two days after treatment completion, erythromycin monotherapy did not suppress bacterial growth and had no effect in bone infection, although it reduced serum pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6.	Erythromycin	37-49	interleukin 6	Rattus norvegicus	224-242
28884090-10	2017	Erythromycin and curcumin combined treatment markedly suppressed bacterial growth, substantially alleviated bone infection and reduced TNF-alpha and IL-6.	Erythromycin	0-12	tumor necrosis factor	Rattus norvegicus	135-144
28884090-10	2017	Erythromycin and curcumin combined treatment markedly suppressed bacterial growth, substantially alleviated bone infection and reduced TNF-alpha and IL-6.	Erythromycin	0-12	interleukin 6	Rattus norvegicus	149-153
28678842-3	2017	Our current analysis of mutations leading to erythromycin resistance indicates that only some of them arise in mitochondrial DNA and that the GC AT transition is a hallmark of the mitochondrial mutagenesis in rad27 null background.	Erythromycin	45-57	multifunctional nuclease RAD27	Saccharomyces cerevisiae S288C	209-214
28425104-0	2017	Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.	Erythromycin	75-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
28425104-1	2017	This study aimed to characterize the inactivation kinetics of cytochrome P450 3A4 (CYP3A4) by erythromycin, which involves mechanism-based inhibition (MBI), in detail.	Erythromycin	94-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-81
28425104-1	2017	This study aimed to characterize the inactivation kinetics of cytochrome P450 3A4 (CYP3A4) by erythromycin, which involves mechanism-based inhibition (MBI), in detail.	Erythromycin	94-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
28425104-9	2017	In conclusion, the relatively long-term evaluation of the kinetics of CYP3A4 inactivation revealed that the enzyme was not fully inactivated by erythromycin.	Erythromycin	144-156	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
29296270-7	2017	The most common erythromycin resistance genes, in S. aureus isolates were ermC (35.2%), followed by ermA (20.4%) and msrA (17.3%).	Erythromycin	16-28	ABC transporter permease protein	Staphylococcus aureus	117-121
27858342-6	2017	RESULTS: The statin models reasonably predicted the observed exposure change due to Organic Anion Transporting Polypeptide (OATP) 1B1 polymorphism or clinical DDIs with itraconazole, erythromycin, and gemfibrozil, while under-predicted the observed DDIs caused by rifampin and cyclosporine.	Erythromycin	183-195	solute carrier organic anion transporter family member 1B1	Homo sapiens	84-133
28584401-4	2017	We first confirmed that erythromycin suppresses the transcriptional activity of nuclear factor-kappaB and activator protein-1 and the expression of its downstream targets, interleukin-6 and cyclooxygenase-2 in human colon cancer cells.	Erythromycin	24-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	190-206
28584401-7	2017	Moreover, erythromycin reduced the levels of interleukin-6 and cyclooxygenase-2 mRNA expression in intestinal polyps.	Erythromycin	10-22	interleukin 6	Mus musculus	45-58
28584401-7	2017	Moreover, erythromycin reduced the levels of interleukin-6 and cyclooxygenase-2 mRNA expression in intestinal polyps.	Erythromycin	10-22	prostaglandin-endoperoxide synthase 2	Mus musculus	63-79
28189992-9	2017	In in vitro assessment of CYP3A activity model the erythromycin-N-demethylation (EMD) levels in quercetin treated group were significantly reduced (p&lt;0.05).	Erythromycin	51-63	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	26-31
27825873-0	2017	Highly sensitive and selective erythromycin nanosensor employing fiber optic SPR/ERY imprinted nanostructure: Application in milk and honey.	Erythromycin	31-43	sepiapterin reductase	Homo sapiens	77-80
28219384-7	2017	RESULTS: Clarithromycin and erythromycin, but not josamycin, inhibited IL-13-stimulated periostin production.	Erythromycin	28-40	interleukin 13	Homo sapiens	71-76
27702915-7	2017	Phenotypic resistance to erythromycin was encoded in 98.4% strains by the ermB gene.	Erythromycin	25-37	erythromycin resistance protein	Enterococcus faecalis	74-78
27515985-0	2017	The ORACLE Children Study: educational outcomes at 11 years of age following antenatal prescription of erythromycin or co-amoxiclav.	Erythromycin	103-115	LIM domain binding 3	Homo sapiens	4-10
27515985-2	2017	METHODS: From the National Pupil Database, we used Key Stage 2 scores, national test scores in school year 6 at 11 years of age, to explore the hypothesis that erythromycin and co-amoxiclav were associated with poorer educational outcomes within the ORACLE Children Study.	Erythromycin	160-172	LIM domain binding 3	Homo sapiens	250-256
28221736-8	2017	CYP3A4-activity was mesured using the Erythromycin Breath Test (ERMBT).	Erythromycin	38-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
28219384-7	2017	RESULTS: Clarithromycin and erythromycin, but not josamycin, inhibited IL-13-stimulated periostin production.	Erythromycin	28-40	periostin	Homo sapiens	88-97
27688845-7	2016	In our in vitro studies, primary bovine articular chondrocytes were treated with erythromycin in the presence of pro-inflammatory cytokine IL-1beta or lipopolysaccharide (LPS), and cartilage gene expression analysis was performed.	Erythromycin	81-93	interleukin 1 beta	Bos taurus	139-147
28184339-9	2017	The statistical analysis showed that the esp infective gene has significant associations with ciprofloxacin, erythromycin and tetracycline in E. faecium and with chloramphenicol in E. faecalis strains; the hyl with teicoplanin and vancomycin in E. faecium strains; and also asa1 with vancomycin in E. faecium and with ampicillin and chloramphenicol in E. faecalis strains.	Erythromycin	109-121	aggregation substance	Enterococcus faecalis	274-278
27503388-1	2016	Due to a long history of improper and excessive use, Penicillin G (Pen G) and erythromycin (Ery) are regularly detected in environmental samples and pose a great threat to human health.	Erythromycin	92-95	proprotein convertase subtilisin/kexin type 1 inhibitor	Mus musculus	53-56
27790208-10	2016	However, the decreases in resistant isolates among serotypes 14 and 19A led to an overall decrease in penicillin non-susceptibility (from 17 to 13%, p = 0.174) and erythromycin resistance (from 19 to 13%, p = 0.034).	Erythromycin	164-176	SLAM family member 7	Homo sapiens	68-71
27688845-11	2016	Furthermore, erythromycin prevented LPS-induced NF-kappaB activation, a key mediator of TLR4-mediated cartilage destruction process.	Erythromycin	13-25	toll-like receptor 4	Mus musculus	36-39
27688845-11	2016	Furthermore, erythromycin prevented LPS-induced NF-kappaB activation, a key mediator of TLR4-mediated cartilage destruction process.	Erythromycin	13-25	toll-like receptor 4	Mus musculus	88-92
27688845-12	2016	CONCLUSIONS: Erythromycin has the ability to inhibit catabolic gene expression mediated by IL-1beta and TLR4 in chondrocytes in vitro and maintains cartilage matrix levels in experimental inflammatory joint destruction in vivo, suggesting that it possesses a chondroprotective activity.	Erythromycin	13-25	interleukin 1 beta	Mus musculus	91-99
27688845-12	2016	CONCLUSIONS: Erythromycin has the ability to inhibit catabolic gene expression mediated by IL-1beta and TLR4 in chondrocytes in vitro and maintains cartilage matrix levels in experimental inflammatory joint destruction in vivo, suggesting that it possesses a chondroprotective activity.	Erythromycin	13-25	toll-like receptor 4	Mus musculus	104-108
27688845-7	2016	In our in vitro studies, primary bovine articular chondrocytes were treated with erythromycin in the presence of pro-inflammatory cytokine IL-1beta or lipopolysaccharide (LPS), and cartilage gene expression analysis was performed.	Erythromycin	81-93	toll-like receptor 4	Mus musculus	171-174
27688845-10	2016	In addition, erythromycin inhibited IL-1beta and LPS-induced expression of MMPs and iNOS, as well as the positive regulatory loop between IL-1beta and Toll-like receptor 4 (TLR4) in articular chondrocytes.	Erythromycin	13-25	interleukin 1 beta	Mus musculus	36-44
27688845-10	2016	In addition, erythromycin inhibited IL-1beta and LPS-induced expression of MMPs and iNOS, as well as the positive regulatory loop between IL-1beta and Toll-like receptor 4 (TLR4) in articular chondrocytes.	Erythromycin	13-25	toll-like receptor 4	Mus musculus	49-52
27688845-10	2016	In addition, erythromycin inhibited IL-1beta and LPS-induced expression of MMPs and iNOS, as well as the positive regulatory loop between IL-1beta and Toll-like receptor 4 (TLR4) in articular chondrocytes.	Erythromycin	13-25	nitric oxide synthase 2, inducible	Mus musculus	84-88
27688845-10	2016	In addition, erythromycin inhibited IL-1beta and LPS-induced expression of MMPs and iNOS, as well as the positive regulatory loop between IL-1beta and Toll-like receptor 4 (TLR4) in articular chondrocytes.	Erythromycin	13-25	interleukin 1 beta	Mus musculus	138-146
27688845-10	2016	In addition, erythromycin inhibited IL-1beta and LPS-induced expression of MMPs and iNOS, as well as the positive regulatory loop between IL-1beta and Toll-like receptor 4 (TLR4) in articular chondrocytes.	Erythromycin	13-25	toll-like receptor 4	Mus musculus	151-171
27688845-10	2016	In addition, erythromycin inhibited IL-1beta and LPS-induced expression of MMPs and iNOS, as well as the positive regulatory loop between IL-1beta and Toll-like receptor 4 (TLR4) in articular chondrocytes.	Erythromycin	13-25	toll-like receptor 4	Mus musculus	173-177
25986945-9	2016	Hunger scores during phase III were significantly lower in obese patients, but could be restored to control levels through the administration of a low dose of the motilin agonist, erythromycin.	Erythromycin	180-192	motilin	Homo sapiens	163-170
27942364-7	2016	The detection of ermA, ermB, ermC and msrA genes by PCR was performed for isolates that had positive D-test results and that were resistant to erythromycin.	Erythromycin	143-155	ABC transporter permease protein	Staphylococcus aureus	38-42
26797959-7	2016	TMP and ERY were the other PCs present at higher concentrations in STP outlets (1 mug/L and 0-0.13 mug/L, respectively).	Erythromycin	8-11	thyroid hormone receptor interactor 10	Homo sapiens	67-70
27928482-7	2016	Out of all the erythromycin resistant isolates, 57.8% harbored both ermA and ermC genes which possessed constitutive resistance.	Erythromycin	15-27	rRNA methylase Erm(A)	Staphylococcus aureus	68-72
27928482-9	2016	msrA gene was detected in 3.5% of the erythromycin resistant S. aureus isolates with constitutive resistance.	Erythromycin	38-50	ABC transporter permease protein	Staphylococcus aureus	0-4
27195143-5	2016	The polymerase chain reaction (PCR) assay was applied to determine the major erythromycin-resistant genes (ermA, ermB, ermC and msrA).	Erythromycin	77-89	ErmC	Staphylococcus aureus	119-123
27086674-1	2016	It has recently been reported that ribosomes from erythromycin-resistant Escherichia coli strains, when isolated in S30 extracts and incubated with chemically mis-acylated tRNA, can incorporate certain beta-amino acids into full length DHFR in vitro.	Erythromycin	50-62	dihydrofolate reductase	Escherichia coli	236-240
25976554-8	2016	The frequency of ermA and ermC genes among erythromycin-resistant MRSA isolates was 21.6% and 66.7%, respectively.	Erythromycin	43-55	ErmC	Staphylococcus aureus	26-30
26817505-0	2016	The motilin receptor agonist erythromycin stimulates hunger and food intake through a cholinergic pathway.	Erythromycin	29-41	motilin	Homo sapiens	4-11
26817505-4	2016	OBJECTIVES: We sought to 1) investigate the occurrence of hunger peaks and their relation to phase III contractions, 2) evaluate whether this relation was cholinergically driven, and 3) assess the ability of the motilin receptor agonist erythromycin to induce food intake.	Erythromycin	237-249	motilin	Homo sapiens	212-219
26817505-13	2016	Moreover, erythromycin stimulated food intake, suggesting a physiologic role of motilin as an orexigenic signal from the gastrointestinal tract.	Erythromycin	10-22	motilin	Homo sapiens	80-87
27195143-5	2016	The polymerase chain reaction (PCR) assay was applied to determine the major erythromycin-resistant genes (ermA, ermB, ermC and msrA).	Erythromycin	77-89	ABC transporter permease protein	Staphylococcus aureus	128-132
27195143-11	2016	In addition, out of 39 erythromycin-susceptible isolates, 3 (7.7%) isolates were positive for ermB or ermC genes.	Erythromycin	23-35	ErmC	Staphylococcus aureus	102-106
25539673-6	2016	The motilin agonist erythromycin, but not the cholinesterase inhibitor neostigmine, induced a premature gastric phase III, which coincided with an increase in hunger scores from 29.2+-7 to 61.7+-8.	Erythromycin	20-32	motilin	Homo sapiens	4-11
26353895-3	2016	It is susceptible to metabolic drug-drug interactions with drugs that are moderate or strong CYP3A inhibitors (e.g. ritonavir and erythromycin) or CYP3A inducers (e.g. rifampin and efavirenz); coadministration of these drugs may increase or decrease plasma concentrations of simeprevir, respectively, and should be avoided.	Erythromycin	130-142	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-98
26808288-6	2016	MRSA isolates included spa types t008, t034, and t5706 and were resistant to methicillin, tetracycline, clindamycin, and erythromycin.	Erythromycin	121-133	pulmonary surfactant-associated protein A	Sus scrofa	23-26
27127346-1	2016	OBJECTIVE: To study the effects of low-dose and long-term treatment with erythromycin on IL-17 and IL-23, in peripheral blood and induced sputum, in patients with stable chronic obstructive pulmonary disease (COPD).	Erythromycin	73-85	interleukin 23 subunit alpha	Homo sapiens	99-104
25957293-0	2015	Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-delta/Akt pathway and increasing GR expression.	Erythromycin	15-27	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	116-126
26636619-2	2015	Covalently linking unacylated tridecaptin A1 (H-TriA1) to rifampicin, vancomycin, and erythromycin enhanced their activity in vitro but not by the same magnitude as coadministration of the peptide and these antibiotics.	Erythromycin	86-98	T cell receptor induced activation 1	Mus musculus	48-53
26636619-3	2015	The antimicrobial activities of the conjugates were retained in vivo, with the H-TriA1-erythromycin conjugate proving a more effective treatment of Klebseilla pneumoniae infections in mice than erythromycin alone or in combination with H-TriA1.	Erythromycin	87-99	T cell receptor induced activation 1	Mus musculus	81-86
26636619-3	2015	The antimicrobial activities of the conjugates were retained in vivo, with the H-TriA1-erythromycin conjugate proving a more effective treatment of Klebseilla pneumoniae infections in mice than erythromycin alone or in combination with H-TriA1.	Erythromycin	87-99	T cell receptor induced activation 1	Mus musculus	238-243
26885197-11	2015	We conclude that erythromycin can enhance the anti-inflammatory activity of budesonide in COPD model rats, possibly through inhibiting the PI3K/AKT pathway and enhancing the activity of HDAC2.	Erythromycin	17-29	AKT serine/threonine kinase 1	Rattus norvegicus	144-147
26885197-11	2015	We conclude that erythromycin can enhance the anti-inflammatory activity of budesonide in COPD model rats, possibly through inhibiting the PI3K/AKT pathway and enhancing the activity of HDAC2.	Erythromycin	17-29	histone deacetylase 2	Rattus norvegicus	186-191
26783549-8	2016	RESULTS: Of the 20 FDA-approved small molecules tested, erythromycin showed the highest affinity to CUG (exp) and a capacity to inhibit its binding to MBNL1.	Erythromycin	56-68	muscleblind like splicing regulator 1	Homo sapiens	151-156
26783549-9	2016	Erythromycin decreased foci formation and rescued missplicing in DM1 cell models.	Erythromycin	0-12	DM1 protein kinase	Homo sapiens	65-68
26783549-10	2016	Both systemic and oral administration of erythromycin in the DM1 model mice showed splicing reversal and improvement of myotonia with no toxicity.	Erythromycin	41-53	DM1 protein kinase	Homo sapiens	61-64
26783549-11	2016	Long-term oral administration of erythromycin at the dose used in humans also improved the splicing abnormality in the DM1 model mice.	Erythromycin	33-45	DM1 protein kinase	Homo sapiens	119-122
26783549-12	2016	INTERPRETATION: Oral erythromycin treatment, which has been widely used in humans with excellent tolerability, may be a promising therapy for DM1.	Erythromycin	21-33	DM1 protein kinase	Homo sapiens	142-145
26223917-5	2015	The enzymatic activity of CYP3A4 was measured using erythromycin and testosterone as probe substrates.	Erythromycin	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
27127346-0	2016	Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease.	Erythromycin	49-61	interleukin 37	Homo sapiens	84-98
27127346-1	2016	OBJECTIVE: To study the effects of low-dose and long-term treatment with erythromycin on IL-17 and IL-23, in peripheral blood and induced sputum, in patients with stable chronic obstructive pulmonary disease (COPD).	Erythromycin	73-85	interleukin 17A	Homo sapiens	89-94
26142839-5	2015	The major effects were observed in the O-deethylation of ethoxyresorufin and O-demethylation of methoxyresorufin (reflecting CYP1A1/2 activities), in the O-depenthylation of pentoxyresorufin and 16beta-hydroxylation of testosterone (reflecting CYP2B1/2 activities), and in the N-demethylation of erythromycin and 6beta-hydroxylation of testosterone (reflecting CYP3A1/2 activities).	Erythromycin	296-308	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	125-131
25769240-9	2015	EM900, CAM, or erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis factor-alpha from NCI-H292 cells.	Erythromycin	15-27	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	52-58
25769240-9	2015	EM900, CAM, or erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis factor-alpha from NCI-H292 cells.	Erythromycin	15-27	tumor necrosis factor	Homo sapiens	80-107
25957293-0	2015	Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-delta/Akt pathway and increasing GR expression.	Erythromycin	15-27	AKT serine/threonine kinase 1	Homo sapiens	127-130
25957293-10	2015	Our results demonstrate that the combination therapy of EM and Dex can restore corticosteroid sensitivity through inhibition of the PI3K-delta/Akt pathway and enhancing GRalpha expression.	Erythromycin	56-58	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	132-142
25957293-10	2015	Our results demonstrate that the combination therapy of EM and Dex can restore corticosteroid sensitivity through inhibition of the PI3K-delta/Akt pathway and enhancing GRalpha expression.	Erythromycin	56-58	AKT serine/threonine kinase 1	Homo sapiens	143-146
25888804-5	2015	[14]-Erythromycin uptake remained unaltered in the presence of valine-valine-prednisolone (VVP) indicating lower affinity toward P-gp.	Erythromycin	5-17	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	129-133
25761690-5	2015	Taurine protected cytochrome P450 3A4 due to stabilizing it during electrolysis at controlled voltage in the presence of erythromycin as a substrate.	Erythromycin	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-37
25424246-5	2015	When using HL60, losartan and the CYP3A4-selective inhibitors, erythromycin and ketoconazole, caused a greater inhibition of the paclitaxel metabolism than quercetin, a CYP2C8-selective inhibitor.	Erythromycin	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
25424246-5	2015	When using HL60, losartan and the CYP3A4-selective inhibitors, erythromycin and ketoconazole, caused a greater inhibition of the paclitaxel metabolism than quercetin, a CYP2C8-selective inhibitor.	Erythromycin	63-75	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	169-175
25425539-9	2015	For the primary outcomes, the concentrations of ECP changed from 176.4 microl/l +- 79.0 to 226.1 microl/l +- 200.6 in the erythromycin group and from 186.9 microl/l +- 36.0 to 192.9 microl/l +- 189.2 in the placebo group; no statistical differences were found.	Erythromycin	122-134	ribonuclease A family member 3	Homo sapiens	48-51
26168679-4	2015	The highest levels of the MRSA resistance were stated against ciprofloxacin--92%(MIC50 32 mcg/ml), gentamicin--85% (MIC50 128 mcg/ml), erythromycin--54% (MIC50 32-mcg/ml) and clindainycin - 45% (MIC50 0.03 mcg/ml), as well as against rifampicin--38% (MIC50 0.06 mcg/ml).	Erythromycin	135-147	solute carrier family 9 member A6	Homo sapiens	26-30
25744828-0	2015	[Erythromycin inhibits elastin peptides-induced differentiation of CD4+T cells into Th17 cells].	Erythromycin	1-13	elastin	Mus musculus	23-30
25744828-1	2015	OBJECTIVE: To investigate the effect of erythromycin on differentiation into T helper 17 (Th17) cells from CD4+T cells exposed to elastin peptides.	Erythromycin	40-52	elastin	Mus musculus	130-137
25744828-11	2015	CONCLUSION: Erythromycin can suppress the differentiation into Th17 cells from CD4+T cells exposed to elastin peptides.	Erythromycin	12-24	elastin	Mus musculus	102-109
24964176-1	2014	Two previously conducted rivaroxaban studies showed that, separately, renal impairment (RI) and concomitant administration of erythromycin (P-glycoprotein and moderate cytochrome P450 3A4 [CYP3A4] inhibitor) can result in increases in rivaroxaban exposure.	Erythromycin	126-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	189-195
25139487-3	2014	In this study, the systemic availability of topical erythromycin, hence the influence on the activity of CYP3A, is evaluated in comparison to orally administered erythromycin.	Erythromycin	52-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-110
25139487-9	2014	The relationship between erythromycin exposure and CYP3A activity (Hill equation) revealed a 50% reduction of CYP3A activity by an erythromycin AUC  of 2106 h ng ml(-1).	Erythromycin	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-56
25139487-9	2014	The relationship between erythromycin exposure and CYP3A activity (Hill equation) revealed a 50% reduction of CYP3A activity by an erythromycin AUC  of 2106 h ng ml(-1).	Erythromycin	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-115
25139487-9	2014	The relationship between erythromycin exposure and CYP3A activity (Hill equation) revealed a 50% reduction of CYP3A activity by an erythromycin AUC  of 2106 h ng ml(-1).	Erythromycin	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-56
25139487-9	2014	The relationship between erythromycin exposure and CYP3A activity (Hill equation) revealed a 50% reduction of CYP3A activity by an erythromycin AUC  of 2106 h ng ml(-1).	Erythromycin	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-115
25826929-7	2014	Moreover, the concentration of ERY-ARGs exhibited significant positive correlation with the concentration of erythromycin and triclosan (P &lt; 0.05), respectively, elucidating that erythromycin played an important role in the occurrence and spread of ERY-ARGs, while triclosan may confer cross-selection for ERY-ARGs.	Erythromycin	109-121	serpin family A member 2 (gene/pseudogene)	Homo sapiens	35-39
25826929-7	2014	Moreover, the concentration of ERY-ARGs exhibited significant positive correlation with the concentration of erythromycin and triclosan (P &lt; 0.05), respectively, elucidating that erythromycin played an important role in the occurrence and spread of ERY-ARGs, while triclosan may confer cross-selection for ERY-ARGs.	Erythromycin	182-194	serpin family A member 2 (gene/pseudogene)	Homo sapiens	35-39
25826929-7	2014	Moreover, the concentration of ERY-ARGs exhibited significant positive correlation with the concentration of erythromycin and triclosan (P &lt; 0.05), respectively, elucidating that erythromycin played an important role in the occurrence and spread of ERY-ARGs, while triclosan may confer cross-selection for ERY-ARGs.	Erythromycin	182-194	serpin family A member 2 (gene/pseudogene)	Homo sapiens	256-260
25826929-7	2014	Moreover, the concentration of ERY-ARGs exhibited significant positive correlation with the concentration of erythromycin and triclosan (P &lt; 0.05), respectively, elucidating that erythromycin played an important role in the occurrence and spread of ERY-ARGs, while triclosan may confer cross-selection for ERY-ARGs.	Erythromycin	182-194	serpin family A member 2 (gene/pseudogene)	Homo sapiens	256-260
25327846-5	2015	AREAS COVERED: Modifications at C-10 of erythromycin were seldom reported.	Erythromycin	40-52	homeobox C10	Homo sapiens	32-36
25826929-2	2014	Quantitative PCR (qPCR) was used to determine the distribution and removal of seven erythromycin resistance genes (ERY-ARGs).	Erythromycin	84-96	serpin family A member 2 (gene/pseudogene)	Homo sapiens	119-123
25444568-8	2014	MRSA-CC1 strains showed higher percentages of erythromycin/clindamycin resistance (95%/89%) than MRSA-CC398 strains (58%/63%), and this resistance was usually mediated by erm(C) gene.	Erythromycin	46-58	C-C motif chemokine ligand 14	Homo sapiens	5-8
25359648-7	2014	However, patients taking anticoagulants or cytochrome P450 3A4 substrates (such as clarithromycin, erythromycin, ketoconazole, itraconazole, midazolam and triazolam) in addition to specific vitamin or mineral supplements (vitamins D, E, K, calcium, fluoride, iron, magnesium, selenium or zinc) may face additional challenges.	Erythromycin	99-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-62
24878007-8	2014	Erythromycin may up-regulate the activity of gamma-GCS, increasing the expression of GSH, inhibiting the levels of oxidant-mediated IL-1 beta and alleviating hyperoxia-induced lung injury via an antioxidant effect.	Erythromycin	0-12	interleukin 1 beta	Rattus norvegicus	132-141
25223381-9	2014	Of 225 erythromycin resistant isolates 48 had ermA, 20 had ermC, and 128 had ermA-C. PCR was negative for 15 strains.	Erythromycin	7-19	ErmC	Staphylococcus aureus	59-63
24981100-6	2014	CONCLUSIONS: Compared to females, males have lower levels of cytochrome P450 3A4 (CYP3A4), for which erythromycin is both a substrate and inhibitor.	Erythromycin	101-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-80
24981100-6	2014	CONCLUSIONS: Compared to females, males have lower levels of cytochrome P450 3A4 (CYP3A4), for which erythromycin is both a substrate and inhibitor.	Erythromycin	101-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
24981100-7	2014	Use of CYP3A4-inhibiting drugs such as erythromycin in men may thus result in even lower levels of CYP3A4 and, consequently, higher levels of CYP3A4-metabolized substances.	Erythromycin	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	7-13
24981100-7	2014	Use of CYP3A4-inhibiting drugs such as erythromycin in men may thus result in even lower levels of CYP3A4 and, consequently, higher levels of CYP3A4-metabolized substances.	Erythromycin	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
24981100-7	2014	Use of CYP3A4-inhibiting drugs such as erythromycin in men may thus result in even lower levels of CYP3A4 and, consequently, higher levels of CYP3A4-metabolized substances.	Erythromycin	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
24440401-3	2014	[14C]-erythromycin was selected as a model substrate to study interaction of quinidine and Ile-quinidine with P-gp.	Erythromycin	6-18	PGP	Canis lupus familiaris	110-114
24628435-7	2014	The concomitant incubation of hepatocytes with butyrate and erythromycin led to an increased CYP2H1 expression and a less pronounced inhibition of CYP3A37.	Erythromycin	60-72	cytochrome P450 2H1	Gallus gallus	93-99
24628435-7	2014	The concomitant incubation of hepatocytes with butyrate and erythromycin led to an increased CYP2H1 expression and a less pronounced inhibition of CYP3A37.	Erythromycin	60-72	cytochrome P450 family 3 subfamily A member 5	Gallus gallus	147-154
24588627-6	2014	In contrast, agents blocking ATRA degradation such as erythromycin and tetracyclines may improve acne by increasing FoxO1 expression with consecutive inhibition of mTORC1 signalling.	Erythromycin	54-66	forkhead box O1	Homo sapiens	116-121
24588627-6	2014	In contrast, agents blocking ATRA degradation such as erythromycin and tetracyclines may improve acne by increasing FoxO1 expression with consecutive inhibition of mTORC1 signalling.	Erythromycin	54-66	CREB regulated transcription coactivator 1	Mus musculus	164-170
24277204-0	2014	Erythromycin pretreatment induces tolerance against focal cerebral ischemia through up-regulation of nNOS but not down-regulation of HIF-1alpha in rats.	Erythromycin	0-12	nitric oxide synthase 1	Rattus norvegicus	101-105
24277204-1	2014	The purpose of this study was to determine whether the antibiotic erythromycin induces tolerance against focal cerebral ischemia, and the possible underlying mechanism including the involvement of neuronal nitric oxide synthase (nNOS) and hypoxia-inducible factor-1alpha (HIF-1alpha).	Erythromycin	66-78	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	272-282
24277204-4	2014	Moreover, erythromycin preconditioning induced significantly increased nNOS levels and decreased HIF-1alpha levels in both mRNA and protein expression.	Erythromycin	10-22	nitric oxide synthase 1	Rattus norvegicus	71-75
24277204-4	2014	Moreover, erythromycin preconditioning induced significantly increased nNOS levels and decreased HIF-1alpha levels in both mRNA and protein expression.	Erythromycin	10-22	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	97-107
24682721-9	2014	Erythromycin induced change in CSA during distension-evoked secondary peristalsis (CSA before 212.9 +- 26.8 vs. after 180.5 +- 23.3, P &lt; 0.05).	Erythromycin	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	31-34
24682721-9	2014	Erythromycin induced change in CSA during distension-evoked secondary peristalsis (CSA before 212.9 +- 26.8 vs. after 180.5 +- 23.3, P &lt; 0.05).	Erythromycin	0-12	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	83-86
25008823-0	2014	Erythromycin-resistant genes in group A beta-haemolytic Streptococci in Chengdu, Southwestern China.	Erythromycin	0-12	amyloid beta precursor protein	Homo sapiens	38-44
24440401-6	2014	This result indicates that [14C]-erythromycin is an excellent substrate of P-gp.	Erythromycin	33-45	PGP	Canis lupus familiaris	75-79
24035278-2	2014	METHODS: This is an open-label, prospective pharmacokinetic study evaluating CYP3A activity using The Erythromycin Breath Test.	Erythromycin	102-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-82
24417241-0	2014	Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.	Erythromycin	22-34	ETS transcription factor ERG	Homo sapiens	73-77
24417241-3	2014	Experiments were conducted to determine if concomitant exposure to two potent pore hERG blockers, thioridazine and terfenadine and a weak hERG blocker, erythromycin, would result in an additive, synergistic or inhibitory effect.	Erythromycin	152-164	ETS transcription factor ERG	Homo sapiens	138-142
24417241-6	2014	KEY RESULTS: Pre-exposure of cells to erythromycin resulted in an approximately 14-22-fold rightward shift in the hERG concentration-response curve for thioridazine and terfenadine respectively.	Erythromycin	38-50	ETS transcription factor ERG	Homo sapiens	114-118
24417241-9	2014	CONCLUSIONS AND IMPLICATIONS: Pretreatment with erythromycin induced an approximately 14-22-fold reduction in hERG affinity for pore-binding drugs at concentrations of erythromycin, which by themselves only block hERG by 10% or less.	Erythromycin	48-60	ETS transcription factor ERG	Homo sapiens	110-114
24417241-9	2014	CONCLUSIONS AND IMPLICATIONS: Pretreatment with erythromycin induced an approximately 14-22-fold reduction in hERG affinity for pore-binding drugs at concentrations of erythromycin, which by themselves only block hERG by 10% or less.	Erythromycin	48-60	ETS transcription factor ERG	Homo sapiens	213-217
24417241-9	2014	CONCLUSIONS AND IMPLICATIONS: Pretreatment with erythromycin induced an approximately 14-22-fold reduction in hERG affinity for pore-binding drugs at concentrations of erythromycin, which by themselves only block hERG by 10% or less.	Erythromycin	168-180	ETS transcription factor ERG	Homo sapiens	110-114
24417241-9	2014	CONCLUSIONS AND IMPLICATIONS: Pretreatment with erythromycin induced an approximately 14-22-fold reduction in hERG affinity for pore-binding drugs at concentrations of erythromycin, which by themselves only block hERG by 10% or less.	Erythromycin	168-180	ETS transcription factor ERG	Homo sapiens	213-217
24417241-12	2014	Furthermore, these results suggest that co-administration of erythromycin may provide some reduction in cardiac liability of potent hERG-blocking drugs.	Erythromycin	61-73	ETS transcription factor ERG	Homo sapiens	132-136
25165555-10	2014	Coadministration of erythromycin with other drugs that inhibit or are metabolized by CYP3A4 or with QTc prolonging drugs should be avoided in this setting.	Erythromycin	20-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
24721407-0	2014	[Erythromycin restores oxidative stress-induced corticosteroid responsiveness of human THP-1 cells by up-regulating the expression of histone deacetylase 2].	Erythromycin	1-13	histone deacetylase 2	Homo sapiens	134-155
24721407-5	2014	RESULTS: The inhibition ratio of IL-8 in the EM group was significantly higher than that in the CSE group, but lower than that in the control group (P&lt;0.05).	Erythromycin	45-47	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
24721407-7	2014	The expression of HDAC2 protein in the EM group was higher than that in the CSE group, but lower than that in the control group (P&lt;0.05).	Erythromycin	39-41	histone deacetylase 2	Homo sapiens	18-23
24378875-5	2014	RECENT FINDINGS: Two well designed, randomized, placebo-controlled trials report that select patients treated for 1 year with erythromycin or azithromycin, in addition to usual care, have prolonged time to and lower frequency of COPD exacerbations.	Erythromycin	126-138	COPD	Homo sapiens	229-233
25045692-1	2014	In present work response surface methodology (RSM) using the miscellaneous design model was used to optimize formulations of erythromycin solid lipid nanocarriers (ERY-SLN).	Erythromycin	125-137	sarcolipin	Homo sapiens	168-171
24038489-6	2014	CYP3A4 activity was assessed by the erythromycin breath test.	Erythromycin	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
25135154-4	2014	The variances of the concentrations of cotinine, DEET and the prescription drugs carbamazepine, erythromycin and sulfamethoxazole were best explained by PC1, while the variances of the concentrations of the agricultural pesticides atrazine, metolachlor and acetochlor were best explained by PC2.	Erythromycin	96-108	ectonucleotide pyrophosphatase/phosphodiesterase 1	Homo sapiens	153-156
24296694-9	2013	When cough resolved with the treatment of cetirizine alone or in combination with erythromycin, the levels of CGRP and histamine in the induced sputum decreased significantly in 15 patients with UACS, with no obvious change in cell differential or concentration of PGE2 in the induced sputum.	Erythromycin	82-94	calcitonin related polypeptide alpha	Homo sapiens	110-114
24102384-3	2013	Erythromycin, a macrolide antibiotic, has been shown to be a moderate CYP3A4 inhibitor.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
23189978-5	2013	This activity is ligand-dependent, with short-lasting actions of motilin contrasting with longer-lasting actions of the non-selective and selective motilin receptor agonists erythromycin and GSK962040.	Erythromycin	174-186	motilin	Homo sapiens	148-155
23806146-10	2013	The toxin genes sec, seh, and enterotoxin gene cluster (egc) were significantly more prevalent among isolates of lineage ST9 (p&lt;0.001) compared to other lineages, and the ST9 isolates were more resistant to erythromycin, clindamycin, ciprofloxacin, chloramphenicol, and gentamicin.	Erythromycin	210-222	Enterotoxin	Staphylococcus aureus	30-41
23928466-7	2013	Serotypes 19A, 6A, 19F, 6B, 15A, 9V, and 14 exhibited significantly higher levels of erythromycin resistance (P&lt;0.05), while 19A, 19F, 35B, 6A, 6B, 23A, 9V, 15A, and 14 demonstrated higher rates of penicillin resistance (P&lt;0.05).	Erythromycin	85-97	SLAM family member 7	Homo sapiens	10-13
24940337-7	2013	Antibiotic susceptibility profile of ESBL isolates showed 100.0% resistance against Amoxicillin, Cotrimoxazole and Erythromycin.	Erythromycin	115-127	EsbL	Escherichia coli	37-41
24164611-4	2013	Situations discussed that result in a reduction in clearance will include: multiple organ failure in critically ill, patients with non-functioning CYP2D6 and CYP2C8/9 alleles, and CYP3A4 drug interactions with erythromycin and clarithromycin.	Erythromycin	210-222	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	180-186
23800068-7	2013	Suppression of TNFalpha signalling by tetracyclines, erythromycin and other macrolides may attenuate IKKbeta-TSC1-mediated mTORC1 activation.	Erythromycin	53-65	tumor necrosis factor	Homo sapiens	15-23
23965431-2	2013	For instance, the concentration of erythromycin, a substrate of cytochrome P450 3A4 (CYP3A4), has been reported to be elevated in patients with end-stage renal disease.	Erythromycin	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-83
23965431-2	2013	For instance, the concentration of erythromycin, a substrate of cytochrome P450 3A4 (CYP3A4), has been reported to be elevated in patients with end-stage renal disease.	Erythromycin	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
23800068-8	2013	Erythromycin attenuates ERK1/2 activity and thereby increases TSC2.	Erythromycin	0-12	mitogen-activated protein kinase 3	Homo sapiens	24-30
23800068-8	2013	Erythromycin attenuates ERK1/2 activity and thereby increases TSC2.	Erythromycin	0-12	TSC complex subunit 2	Homo sapiens	62-66
23800068-7	2013	Suppression of TNFalpha signalling by tetracyclines, erythromycin and other macrolides may attenuate IKKbeta-TSC1-mediated mTORC1 activation.	Erythromycin	53-65	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	101-108
23800068-7	2013	Suppression of TNFalpha signalling by tetracyclines, erythromycin and other macrolides may attenuate IKKbeta-TSC1-mediated mTORC1 activation.	Erythromycin	53-65	TSC complex subunit 1	Homo sapiens	109-113
23800068-7	2013	Suppression of TNFalpha signalling by tetracyclines, erythromycin and other macrolides may attenuate IKKbeta-TSC1-mediated mTORC1 activation.	Erythromycin	53-65	CREB regulated transcription coactivator 1	Mus musculus	123-129
23778904-1	2013	BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.	Erythromycin	31-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-104
23401164-4	2013	The detection limits were 0.02, 0.01, 0.01, 0.06 and 0.003 ng/muL for erythromycin, clarithromycin, doxepin, amitriptyline and clomipramine, respectively.	Erythromycin	70-82	tripartite motif containing 37	Homo sapiens	62-65
23778904-1	2013	BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.	Erythromycin	31-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
23778904-1	2013	BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.	Erythromycin	31-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	196-202
23778904-11	2013	CONCLUSION: In older adults, coprescription of clarithromycin or erythromycin with a statin that is metabolized by CYP3A4 increases the risk for statin toxicity.	Erythromycin	65-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
23667771-1	2013	AIM: To study the possible interactions of metoclopramide, domperidone and erythromycin in streptozotocin-induced diabetic mice treated with insulin by various parameters.	Erythromycin	75-87	insulin	Homo sapiens	141-148
23541215-0	2013	Synergistic effects of diosmetin with erythromycin against ABC transporter over-expressed methicillin-resistant Staphylococcus aureus (MRSA) RN4220/pUL5054 and inhibition of MRSA pyruvate kinase.	Erythromycin	38-50	ABC transporter	Staphylococcus aureus	59-74
23667771-10	2013	Erythromycin tended to decrease blood glucose level and increase serum insulin level after 1 wk of daily administration in diabetic mice.	Erythromycin	0-12	insulin	Homo sapiens	71-78
23667771-16	2013	The use of prokinetics, such as erythromycin, may be interesting in the clinic in decreasing the need for insulin in diabetic patients.	Erythromycin	32-44	insulin	Homo sapiens	106-113
23667771-11	2013	Erythromycin potentiated the effect of insulin on blood glucose level and serum insulin level whereas other prokinetic agents failed to do so after repeated dose administration in diabetic mice.	Erythromycin	0-12	insulin	Homo sapiens	39-46
23667771-17	2013	The dose of insulin may be safely decreased with erythromycin in chronic treatments.	Erythromycin	49-61	insulin	Homo sapiens	12-19
23667771-11	2013	Erythromycin potentiated the effect of insulin on blood glucose level and serum insulin level whereas other prokinetic agents failed to do so after repeated dose administration in diabetic mice.	Erythromycin	0-12	insulin	Homo sapiens	80-87
23546223-2	2013	The macrolide antibiotics including concanamycin A, erythromycin (EM), clarithromycin (CAM) and azithromycin (AZM) all blocked autophagy flux, as assessed by intracellular accumulation of LC3B-II and p62.	Erythromycin	52-64	nucleoporin 62	Mus musculus	200-203
23190027-6	2013	KEY RESULTS: Azithromycin (1-100 muM) and erythromycin (3-30 muM) concentration-dependently displaced [(125)I]-motilin binding to the motilin receptor (52 +- 7 and 58 +- 18% displacement at 100 and 30 muM respectively).	Erythromycin	42-54	latexin	Homo sapiens	61-64
23190027-6	2013	KEY RESULTS: Azithromycin (1-100 muM) and erythromycin (3-30 muM) concentration-dependently displaced [(125)I]-motilin binding to the motilin receptor (52 +- 7 and 58 +- 18% displacement at 100 and 30 muM respectively).	Erythromycin	42-54	motilin receptor	Homo sapiens	134-150
23190027-6	2013	KEY RESULTS: Azithromycin (1-100 muM) and erythromycin (3-30 muM) concentration-dependently displaced [(125)I]-motilin binding to the motilin receptor (52 +- 7 and 58 +- 18% displacement at 100 and 30 muM respectively).	Erythromycin	42-54	latexin	Homo sapiens	61-64
23190027-7	2013	Azithromycin, erythromycin and motilin concentration-dependently caused short-lived increases in intracellular [Ca(2+)] in cells expressing the motilin receptor.	Erythromycin	14-26	motilin receptor	Homo sapiens	144-160
23324807-0	2013	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.	Erythromycin	92-104	cytochrome p450 oxidoreductase	Homo sapiens	10-13
23462027-8	2013	Other antibiotics that are strong CYP3A4 inhibitors include itraconazole and telithromycin, whereas erythromycin and fluconazole are moderate inhibitors of the isoenzyme CYP3A4.	Erythromycin	100-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
23316047-7	2013	A spontaneous IS1 insertion in secA suppressed lptE14 erythromycin sensitivity by removing the C-terminal SecB-binding domain of SecA.	Erythromycin	54-66	IS1	Homo sapiens	14-17
23324807-0	2013	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.	Erythromycin	92-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
23324807-3	2013	The aim of the present study was to determine the in vivo impact of the POR*28 allele on the pharmacokinetics of the classic CYP3A phenotyping probes midazolam and erythromycin.	Erythromycin	164-176	cytochrome p450 oxidoreductase	Homo sapiens	72-75
23324807-3	2013	The aim of the present study was to determine the in vivo impact of the POR*28 allele on the pharmacokinetics of the classic CYP3A phenotyping probes midazolam and erythromycin.	Erythromycin	164-176	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-130
23324807-4	2013	Whereas midazolam is metabolized by both CYP3A4 and CYP3A5, erythromycin is exclusively oxidized by CYP3A4.	Erythromycin	60-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
23142315-0	2013	Critical residues in the transmembrane helical bundle domains of the human motilin receptor for erythromycin binding and activity.	Erythromycin	96-108	motilin receptor	Homo sapiens	75-91
23374512-10	2013	RESULTS: The vancomycin-resistant isolate CP2 was found to be resistant to oxacillin, chloramphenicol, erythromycin, rifampicin, gentamicin, tetracycline and ciprofloxacin, as well.	Erythromycin	103-115	ceruloplasmin	Homo sapiens	42-45
23142315-2	2013	Motilin and erythromycin, two chemically distinct full agonists of the motilin receptor, are known to bind to distinct regions of this receptor, based on previous systematic mutagenesis of extracellular regions that dissociated the effects on these two agents.	Erythromycin	12-24	motilin receptor	Homo sapiens	71-87
23142315-9	2013	These data support important roles of new regions in the TM domains of the motilin receptor for erythromycin action, suggesting differential mechanisms of actions by peptidyl and non-peptidyl ligands.	Erythromycin	96-108	motilin receptor	Homo sapiens	75-91
23327575-0	2013	CYP3A4 intron 6 C&gt;T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.	Erythromycin	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
23514827-5	2013	In this study, we quantitatively investigated the inhibition kinetics of MBI inhibitors, erythromycin and clarithromycin, on the CYP3A4 variants CYP3A4.1, 4.2, 4.7, 4.16, and 4.18.	Erythromycin	89-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
23514827-5	2013	In this study, we quantitatively investigated the inhibition kinetics of MBI inhibitors, erythromycin and clarithromycin, on the CYP3A4 variants CYP3A4.1, 4.2, 4.7, 4.16, and 4.18.	Erythromycin	89-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
23514827-7	2013	Both erythromycin and clarithromycin decreased the activity of CYP3A4 in a time-dependent manner.	Erythromycin	5-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
23514827-8	2013	The maximum inactivation rate constants, k(inact,max), of erythromycin for CYP3A4.2 and CYP3A4.7 were 0.5-fold that for CYP3A4.1, while that for CYP3A4.16 and CYP3A4.18 were similar to that for CYP3A4.1.	Erythromycin	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
23514827-8	2013	The maximum inactivation rate constants, k(inact,max), of erythromycin for CYP3A4.2 and CYP3A4.7 were 0.5-fold that for CYP3A4.1, while that for CYP3A4.16 and CYP3A4.18 were similar to that for CYP3A4.1.	Erythromycin	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
23514827-8	2013	The maximum inactivation rate constants, k(inact,max), of erythromycin for CYP3A4.2 and CYP3A4.7 were 0.5-fold that for CYP3A4.1, while that for CYP3A4.16 and CYP3A4.18 were similar to that for CYP3A4.1.	Erythromycin	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
23514827-8	2013	The maximum inactivation rate constants, k(inact,max), of erythromycin for CYP3A4.2 and CYP3A4.7 were 0.5-fold that for CYP3A4.1, while that for CYP3A4.16 and CYP3A4.18 were similar to that for CYP3A4.1.	Erythromycin	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
23514827-8	2013	The maximum inactivation rate constants, k(inact,max), of erythromycin for CYP3A4.2 and CYP3A4.7 were 0.5-fold that for CYP3A4.1, while that for CYP3A4.16 and CYP3A4.18 were similar to that for CYP3A4.1.	Erythromycin	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
23514827-8	2013	The maximum inactivation rate constants, k(inact,max), of erythromycin for CYP3A4.2 and CYP3A4.7 were 0.5-fold that for CYP3A4.1, while that for CYP3A4.16 and CYP3A4.18 were similar to that for CYP3A4.1.	Erythromycin	58-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
23514827-9	2013	The K(I) values of erythromycin for CYP3A4.2, 4.7, 4.16, and 4.18 were 1.2-, 0.4-, 2.2- and 0.72-fold those of CYP3A4.1, respectively.	Erythromycin	19-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
23514827-9	2013	The K(I) values of erythromycin for CYP3A4.2, 4.7, 4.16, and 4.18 were 1.2-, 0.4-, 2.2- and 0.72-fold those of CYP3A4.1, respectively.	Erythromycin	19-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-117
24852442-7	2013	However, erythromycin suppressed only the upregulation of TLR2 and TNFA.	Erythromycin	9-21	toll like receptor 2	Homo sapiens	58-62
24852442-7	2013	However, erythromycin suppressed only the upregulation of TLR2 and TNFA.	Erythromycin	9-21	tumor necrosis factor	Homo sapiens	67-71
23327575-0	2013	CYP3A4 intron 6 C&gt;T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.	Erythromycin	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
23327575-0	2013	CYP3A4 intron 6 C&gt;T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.	Erythromycin	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
22434147-3	2012	Upregulation of CYP3A4 by modafinil was associated with increased retinoic acid (RA) degradation, which could be blocked by specific CYP3A4 inhibitor erythromycin.	Erythromycin	150-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
24988396-2	2012	This study was conducted to analyse the trend of erythromycin and ofloxacin resistance among Campylobacter spp.	Erythromycin	49-61	histocompatibility minor 13	Homo sapiens	107-110
22942318-6	2012	Use of this two-step statistical evaluation is illustrated with the examination of five drugs of varying capabilities to inactivate CYP3A4: ketoconazole, erythromycin, raloxifene, rosiglitazone, and pioglitazone.	Erythromycin	154-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
22434147-3	2012	Upregulation of CYP3A4 by modafinil was associated with increased retinoic acid (RA) degradation, which could be blocked by specific CYP3A4 inhibitor erythromycin.	Erythromycin	150-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-139
22990751-0	2012	OATP1B1 polymorphism as a determinant of erythromycin disposition.	Erythromycin	41-53	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
22990751-1	2012	Previous studies have demonstrated that the pharmacokinetic profile of erythromycin, a probe for CYP3A4 activity, is affected by inhibitors or inducers of hepatic solute carriers.	Erythromycin	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
22990751-3	2012	Using stably transfected Flp-In T-Rex293 cells, erythromycin was found to be a substrate for OATP1B1*1A (wild type) with a Michaelis-Menten constant of ~13 micromol/l, and that its transport was reduced by ~50% in cells expressing OATP1B1*5 (V174A).	Erythromycin	48-60	solute carrier organic anion transporter family member 1B1	Homo sapiens	93-100
22990751-3	2012	Using stably transfected Flp-In T-Rex293 cells, erythromycin was found to be a substrate for OATP1B1*1A (wild type) with a Michaelis-Menten constant of ~13 micromol/l, and that its transport was reduced by ~50% in cells expressing OATP1B1*5 (V174A).	Erythromycin	48-60	solute carrier organic anion transporter family member 1B1	Homo sapiens	231-238
22990751-4	2012	Deficiency of the ortholog transporter Oatp1b2 in mice was associated with a 52% decrease in the metabolic rate of erythromycin (P = 0.000043).	Erythromycin	115-127	solute carrier organic anion transporter family, member 1b2	Mus musculus	39-46
22990751-5	2012	In line with these observations, in humans the c.521T&gt;C variant in SLCO1B1 (rs4149056), encoding OATP1B1*5, was associated with a decline in erythromycin metabolism (P = 0.0072).	Erythromycin	144-156	solute carrier organic anion transporter family member 1B1	Homo sapiens	70-77
22990751-5	2012	In line with these observations, in humans the c.521T&gt;C variant in SLCO1B1 (rs4149056), encoding OATP1B1*5, was associated with a decline in erythromycin metabolism (P = 0.0072).	Erythromycin	144-156	solute carrier organic anion transporter family member 1B1	Homo sapiens	100-107
22990751-6	2012	These results suggest that impairment of OATP1B1 function can alter erythromycin metabolism, independent of changes in CYP3A4 activity.	Erythromycin	68-80	solute carrier organic anion transporter family member 1B1	Homo sapiens	41-48
23543952-4	2012	The mecA gene for methicillin-resistant S. aureus (MRSA) and the ermA, ermB, ermC, and msrA genes for erythromycin-resistant strains were detected by polymerase chain reaction (PCR).	Erythromycin	102-114	ABC transporter permease protein	Staphylococcus aureus	87-91
23043378-7	2012	In addition, 30.4% of the erythromycin-resistant isolates expressed both the ermB and mef genes, whereas 69.6% expressed the ermB gene but not the mef gene.	Erythromycin	26-38	E74 like ETS transcription factor 4	Homo sapiens	86-89
22465164-10	2012	Motilin or erythromycin administration to human MR transgenic mice resulted in a decrease of serum acyl-ghrelin levels, while MR and GHSR mRNA expression in the gastrointestinal tracts were not changed.	Erythromycin	11-23	ghrelin	Mus musculus	104-111
22445438-10	2012	Erythromycin coadministration also resulted in increased mean C(max) and AUC(0-24 h) of both E2 and DNG.	Erythromycin	0-12	cystatin 12, pseudogene	Homo sapiens	93-103
22821982-0	2012	TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification.	Erythromycin	46-58	toll-like receptor 13	Mus musculus	0-5
22821982-2	2012	Here, we show that the orphan receptor TLR13 in mice recognizes a conserved 23S ribosomal RNA (rRNA) sequence that is the binding site of macrolide, lincosamide, and streptogramin group (MLS) antibiotics (including erythromycin) in bacteria.	Erythromycin	215-227	toll-like receptor 13	Mus musculus	39-44
22480862-2	2012	The present study reports on the first electrochemically-driven drug-drug interactions of human cytochrome P450 3A4 probed with erythromycin, ketoconazole, cimetidine, diclofenac and quinidine.	Erythromycin	128-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-115
22480862-4	2012	Inhibition of the turnover of its substrate, erythromycin, was subsequently measured using chronoamperometry at increasing concentrations of different known inhibitors of this enzyme namely ketoconazole, cimetidine and diclofenac for which IC(50) values of 135 nM, 80 muM and 311 muM were measured, respectively.	Erythromycin	45-57	latexin	Homo sapiens	268-271
22480862-4	2012	Inhibition of the turnover of its substrate, erythromycin, was subsequently measured using chronoamperometry at increasing concentrations of different known inhibitors of this enzyme namely ketoconazole, cimetidine and diclofenac for which IC(50) values of 135 nM, 80 muM and 311 muM were measured, respectively.	Erythromycin	45-57	latexin	Homo sapiens	280-283
22621802-10	2012	Use of human liver microsomes instead of recombinant CYP3A4 resulted in 5-fold lower k(inact)/K(I) for erythromycin.	Erythromycin	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
22760047-11	2012	ileS2 was detected in 81 of 82 phenotypically highly mupirocin-resistant strains and associated with resistance to ciprofloxacin, erythromycin, and clindamycin.	Erythromycin	130-142	isoleucyl-tRNA synthetase	Staphylococcus aureus	0-5
24031940-3	2012	Then, a food-grade expression vector, pMG-shsp, was generated by deleting the erythromycin resistance gene from pMG36e-shsp.	Erythromycin	78-90	small heat shock protein	Streptococcus thermophilus	42-46
24031940-3	2012	Then, a food-grade expression vector, pMG-shsp, was generated by deleting the erythromycin resistance gene from pMG36e-shsp.	Erythromycin	78-90	small heat shock protein	Streptococcus thermophilus	119-123
22644980-6	2012	Both erythromycin and clarithromycin have been shown to prolong the Q-T interval, an effect that appears to increase when these drugs are given with CYP3A4 inhibitors.	Erythromycin	5-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
22633097-12	2012	The protective effect of erythromycin on CS-induced emphysema and inflammation in rats is associated with a reduction in inflammation, imbalance of MMP-9/TIMP-1, and apoptosis of lung structural cells.	Erythromycin	25-37	matrix metallopeptidase 9	Rattus norvegicus	148-153
21602517-3	2012	Coadministration of ketoconazole (a potent CYP3A4 inhibitor) and erythromycin (a moderate CYP3A4 inhibitor) increased total ruxolitinib plasma exposure (AUC(0- )) by 91% and 27%, respectively, and ruxolitinib PD, as measured by the inhibition of interleukin (IL)-6-stimulated STAT3 phosphorylation in whole blood, was generally consistent with the PK observed.	Erythromycin	65-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-96
21602517-3	2012	Coadministration of ketoconazole (a potent CYP3A4 inhibitor) and erythromycin (a moderate CYP3A4 inhibitor) increased total ruxolitinib plasma exposure (AUC(0- )) by 91% and 27%, respectively, and ruxolitinib PD, as measured by the inhibition of interleukin (IL)-6-stimulated STAT3 phosphorylation in whole blood, was generally consistent with the PK observed.	Erythromycin	65-77	signal transducer and activator of transcription 3	Homo sapiens	276-281
22752920-7	2012	This study is the first to report the tcr(B) gene in enterococci isolated from Korean bovine milk and its relationship to erythromycin resistance.	Erythromycin	122-134	uncharacterized protein LOC100335800	Bos taurus	38-41
22633097-12	2012	The protective effect of erythromycin on CS-induced emphysema and inflammation in rats is associated with a reduction in inflammation, imbalance of MMP-9/TIMP-1, and apoptosis of lung structural cells.	Erythromycin	25-37	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	154-160
22000335-10	2012	Zebrafish CYP1s were strongly inhibited by erythromycin and fluoxetine.	Erythromycin	43-55	peptidylprolyl isomerase Aa (cyclophilin A)	Danio rerio	10-14
22664438-0	2012	ermA, ermC , tetM and tetK are essential for erythromycin and tetracycline resistance among methicillin-resistant Staphylococcus aureus strains isolated from a tertiary hospital in Malaysia.	Erythromycin	45-57	ErmC	Staphylococcus aureus	6-10
22123697-3	2012	The most predominant serotypes associated with erythromycin resistance in 2007-2008 included 19A (29.7%), 15A (29.2%), 6C (10.1%), 3 (5.6%), and 6A (4.5%).	Erythromycin	47-59	SLAM family member 7	Homo sapiens	93-96
22123697-7	2012	Pulsed-field gel electrophoresis analysis demonstrated that erythromycin-resistant isolates within the 19A serotype were genetically diverse and related to several circulating international clones.	Erythromycin	60-72	SLAM family member 7	Homo sapiens	103-106
21976769-9	2011	The rates of resistance (including intermediate) for hVISA were as follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.	Erythromycin	92-104	mitochondrial antiviral signaling protein	Homo sapiens	53-58
22701274-0	2012	Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation.	Erythromycin	0-12	Cd4 molecule	Rattus norvegicus	22-25
22701274-0	2012	Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation.	Erythromycin	0-12	forkhead box P3	Rattus norvegicus	26-31
22701274-8	2012	Treatment with erythromycin reduced smoking-induced inflammatory infiltrates, the levels of IL-8 and TNF-alpha in the BALF and lung damages but increased the numbers of CD4+Foxp3+ Tregs and the levels of Foxp3 transcription in the lungs, accompanied by increased levels of IL-35 in the BALF of rats.	Erythromycin	15-27	tumor necrosis factor	Rattus norvegicus	101-110
22701274-8	2012	Treatment with erythromycin reduced smoking-induced inflammatory infiltrates, the levels of IL-8 and TNF-alpha in the BALF and lung damages but increased the numbers of CD4+Foxp3+ Tregs and the levels of Foxp3 transcription in the lungs, accompanied by increased levels of IL-35 in the BALF of rats.	Erythromycin	15-27	Cd4 molecule	Rattus norvegicus	169-172
22701274-8	2012	Treatment with erythromycin reduced smoking-induced inflammatory infiltrates, the levels of IL-8 and TNF-alpha in the BALF and lung damages but increased the numbers of CD4+Foxp3+ Tregs and the levels of Foxp3 transcription in the lungs, accompanied by increased levels of IL-35 in the BALF of rats.	Erythromycin	15-27	forkhead box P3	Rattus norvegicus	173-178
22701274-8	2012	Treatment with erythromycin reduced smoking-induced inflammatory infiltrates, the levels of IL-8 and TNF-alpha in the BALF and lung damages but increased the numbers of CD4+Foxp3+ Tregs and the levels of Foxp3 transcription in the lungs, accompanied by increased levels of IL-35 in the BALF of rats.	Erythromycin	15-27	forkhead box P3	Rattus norvegicus	204-209
22000087-7	2011	In period 2, high rates of dual penicillin/erythromycin nonsusceptibility were found in serotypes 6B (77.3%), 14 (100%), 19F (100%), 23F (78%), 19A (75%), 6A (87.8%), 6C (59.3%), and 23A (78.9%).	Erythromycin	43-55	SLAM family member 7	Homo sapiens	144-147
21864659-3	2011	Uptake and dose dependent inhibition studies were performed with [(14)C] erythromycin (0.25 muCi/ml) on MDCKII-MDR1 and MDCKII-MRP2 cells.	Erythromycin	73-85	ATP binding cassette subfamily B member 1	Canis lupus familiaris	104-115
21864659-3	2011	Uptake and dose dependent inhibition studies were performed with [(14)C] erythromycin (0.25 muCi/ml) on MDCKII-MDR1 and MDCKII-MRP2 cells.	Erythromycin	73-85	ATP binding cassette subfamily C member 2	Canis lupus familiaris	127-131
21864659-10	2011	The efflux ratio of [(14)C] erythromycin lowered from 3.56 to 1.63 on MDCKII-MDR1 cells and 4.93 to 1.26 on MDCKII-MRP2 cells.	Erythromycin	28-40	ATP binding cassette subfamily C member 2	Canis lupus familiaris	115-119
21864659-13	2011	A decrease (20%) in [(14)C] erythromycin uptake further confirmed the elevated functional activity of P-gp and MRP2.	Erythromycin	28-40	phosphoglycolate phosphatase	Homo sapiens	102-106
21864659-10	2011	The efflux ratio of [(14)C] erythromycin lowered from 3.56 to 1.63 on MDCKII-MDR1 cells and 4.93 to 1.26 on MDCKII-MRP2 cells.	Erythromycin	28-40	ATP binding cassette subfamily B member 1	Canis lupus familiaris	77-81
22094097-0	2011	[Protective effects of erythromycin on human bronchial epithelial cells impaired by interleukin-4].	Erythromycin	23-35	interleukin 4	Homo sapiens	84-97
21864659-13	2011	A decrease (20%) in [(14)C] erythromycin uptake further confirmed the elevated functional activity of P-gp and MRP2.	Erythromycin	28-40	ATP binding cassette subfamily C member 2	Homo sapiens	111-115
22009620-11	2011	CYP3A is probably one of the most important isoenzymes since it contributes to at least the partial transformation of 60% of drugs that undergo oxidation: erythromycin and clarithromycin are CYP3A4 substrates.	Erythromycin	155-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
22009620-11	2011	CYP3A is probably one of the most important isoenzymes since it contributes to at least the partial transformation of 60% of drugs that undergo oxidation: erythromycin and clarithromycin are CYP3A4 substrates.	Erythromycin	155-167	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-197
21832258-3	2011	In the 384-well plate CYP3A4 inhibition assay, the known inhibitors 1-aminobenzotriazole, erythromycin, ketoconazole, and verapamil were found to cause extensive (maximum inhibition of &gt;80%), dose-dependent, statistically significant inhibition of LIPA metabolism.	Erythromycin	90-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-28
21563953-7	2011	vanA-Enterococcus faecium isolates were recovered from 4 of 103 tested samples, and they showed glycopeptide and erythromycin resistances.	Erythromycin	113-125	Vancomycin Teicoplanin A-type resistance protein VanA / D-alanine--D-alanine ligase	Enterococcus faecium	0-4
22032892-5	2011	Erythromycin resistance genes (ermA, ermB, ermC, msrA and mef) were analysed by multiplex PCR and disinfectant-resistant genes (qacA, qacB, and qacC) were studied by PCR-RFLP.	Erythromycin	0-12	ErmC	Staphylococcus aureus	43-47
22032892-5	2011	Erythromycin resistance genes (ermA, ermB, ermC, msrA and mef) were analysed by multiplex PCR and disinfectant-resistant genes (qacA, qacB, and qacC) were studied by PCR-RFLP.	Erythromycin	0-12	ABC transporter permease protein	Staphylococcus aureus	49-53
22032892-6	2011	RESULTS: The frequency of erythromycin resistance genes in S. aureus was: ermA+ 7.7%, ermB+ 13.7%, ermC+ 6% and msrA+ 10.2%.	Erythromycin	26-38	ErmC	Staphylococcus aureus	99-103
22032892-6	2011	RESULTS: The frequency of erythromycin resistance genes in S. aureus was: ermA+ 7.7%, ermB+ 13.7%, ermC+ 6% and msrA+ 10.2%.	Erythromycin	26-38	ABC transporter permease protein	Staphylococcus aureus	112-116
21718348-5	2011	For example, exposure to 16 mug mL-1 erythromycin for 3 h increased pre-tmRNA and tmRNA by 18- and 6-fold, respectively.	Erythromycin	37-49	L1 cell adhesion molecule	Mus musculus	32-36
21618542-1	2011	(14)C-erythromycin breath test has been utilized to evaluate the extent of CYP3A activity in vivo.	Erythromycin	6-18	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	75-80
21618542-3	2011	In this study, we employed erythromycin labeled with (13)C ((13)C-EM), a nonradioactive stable isotope, as an in vivo probe of breath test to evaluate CYP3A-mediated drug interactions in rats.	Erythromycin	27-39	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	151-156
22094097-1	2011	OBJECTIVE: To study the protective effects and mechanisms of erythromycin on human bronchial epithelial (HBE) cells damaged by interleukin-4.	Erythromycin	61-73	interleukin 4	Homo sapiens	127-140
22094097-10	2011	CONCLUSION: Erythromycin has protective effects on HBE cells damaged by IL-4.	Erythromycin	12-24	interleukin 4	Homo sapiens	72-76
21708354-8	2011	Erythromycin-treated mice exposed to cigarette smoke showed a trend of lower mRNA levels of KC and TNF-alpha in the lung tissue than those in the vehicle-treated mice, although the statistical significance was not achieved (P = 0.057).	Erythromycin	0-12	tumor necrosis factor	Mus musculus	99-108
21722087-17	2011	With this assay, time and concentration dependent inhibition of CYP3A4 were observed for 1-aminobenzotriazole and erythromycin.	Erythromycin	114-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-70
21708354-9	2011	Our data demonstrated that erythromycin prevented lung inflammation induced by cigarette smoke, in parallel to the reduced mRNA levels of KC and TNF-alpha.	Erythromycin	27-39	tumor necrosis factor	Mus musculus	145-154
21336720-12	2011	The antitumor mechanism of erythromycin might involve regulating the expression of c-Myc and p21 (WAF1/Cip1) proteins.	Erythromycin	27-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	83-88
22041779-0	2011	[The effect of erythromycin on transforming growth factor-beta(1) and secretory leukocyte proteinase inhibitor in a rat model of chronic obstructive pulmonary disease].	Erythromycin	15-27	transforming growth factor, beta 1	Rattus norvegicus	31-65
22041779-11	2011	Airway inflammation was inhibited by erythromycin which was able to reduce the inhibitory effect of TGF-beta(1)to SLPI, indicating a partial protective effect of erythromycin.	Erythromycin	37-49	transforming growth factor, beta 1	Rattus norvegicus	100-111
22041779-11	2011	Airway inflammation was inhibited by erythromycin which was able to reduce the inhibitory effect of TGF-beta(1)to SLPI, indicating a partial protective effect of erythromycin.	Erythromycin	37-49	secretory leukocyte peptidase inhibitor	Rattus norvegicus	114-118
21451505-0	2011	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.	Erythromycin	45-57	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	10-15
21451505-0	2011	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.	Erythromycin	45-57	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	17-21
21451505-2	2011	By means of a transporter screen, erythromycin was identified as a substrate for the transporter ABCC2 (MRP2) and its murine ortholog, Abcc2.	Erythromycin	34-46	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	97-102
21451505-2	2011	By means of a transporter screen, erythromycin was identified as a substrate for the transporter ABCC2 (MRP2) and its murine ortholog, Abcc2.	Erythromycin	34-46	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	104-108
21451505-2	2011	By means of a transporter screen, erythromycin was identified as a substrate for the transporter ABCC2 (MRP2) and its murine ortholog, Abcc2.	Erythromycin	34-46	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	135-140
21451505-3	2011	Because these proteins are highly expressed on the biliary surface of hepatocytes, we hypothesized that impaired Abcc2 function may influence the rate of hepatobiliary excretion and thereby enhance erythromycin metabolism.	Erythromycin	198-210	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	113-118
21451505-5	2011	Next, in a cohort of 108 human subjects, we observed that homozygosity for a common reduced-function variant in ABCC2 (rs717620) was also linked to an increase in erythromycin metabolism but was not correlated with the clearance of midazolam.	Erythromycin	163-175	ATP binding cassette subfamily C member 2	Homo sapiens	112-117
21451505-6	2011	These results suggest that impaired ABCC2 function can alter erythromycin metabolism, independent of changes in CYP3A4 activity.	Erythromycin	61-73	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	36-41
21484263-0	2011	Synergic effects of beta-estradiol and erythromycin on hERG currents.	Erythromycin	39-51	ETS transcription factor ERG	Homo sapiens	55-59
21484263-7	2011	With simultaneous application of 10 muM erythromycin, which is known to block hERG currents but not in low doses, the blocking effects of beta-estradiol on hERG currents were enhanced.	Erythromycin	40-52	ETS transcription factor ERG	Homo sapiens	78-82
21484263-7	2011	With simultaneous application of 10 muM erythromycin, which is known to block hERG currents but not in low doses, the blocking effects of beta-estradiol on hERG currents were enhanced.	Erythromycin	40-52	ETS transcription factor ERG	Homo sapiens	156-160
21484263-8	2011	Namely, hERG currents were inhibited maximally to 45.8% of control with an IC50 of 59 nM (P&lt;0.02) by beta-estradiol with 10 muM erythromycin.	Erythromycin	131-143	ETS transcription factor ERG	Homo sapiens	8-12
21484263-9	2011	We conclude here that a significant block of hERG currents by beta-estradiol may account for the sex-related differences in LQTS and the synergic effects of beta-estradiol and erythromycin indicate a higher risk of drug-induced TDP in women than men.	Erythromycin	176-188	ETS transcription factor ERG	Homo sapiens	45-49
21422854-2	2011	METHODS: This was a secondary analysis of a randomized trial of metronidazole and erythromycin for the prevention of preterm birth among women with a positive fetal fibronectin test.	Erythromycin	82-94	fibronectin 1	Homo sapiens	165-176
21242274-10	2011	Erythromycin (the strongest inhibitor of cytochrome P450 3A4) was most strongly associated with hypotension (odds ratio [OR] 5.8, 95% confidence interval [CI] 2.3-15.0), followed by clarithromycin (OR 3.7, 95% CI 2.3-6.1).	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-60
21207936-2	2011	Resonance Raman (RR) spectroscopy is used to help define active site structural responses of nanodisc-incorporated CYP3A4 to the binding of three substrates: bromocriptine (BC), erythromycin (ERY), and testosterone (TST).	Erythromycin	192-195	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
21336720-12	2011	The antitumor mechanism of erythromycin might involve regulating the expression of c-Myc and p21 (WAF1/Cip1) proteins.	Erythromycin	27-39	cyclin dependent kinase inhibitor 1A	Homo sapiens	93-96
21336720-12	2011	The antitumor mechanism of erythromycin might involve regulating the expression of c-Myc and p21 (WAF1/Cip1) proteins.	Erythromycin	27-39	cyclin dependent kinase inhibitor 1A	Homo sapiens	98-102
21336720-12	2011	The antitumor mechanism of erythromycin might involve regulating the expression of c-Myc and p21 (WAF1/Cip1) proteins.	Erythromycin	27-39	cyclin dependent kinase inhibitor 1A	Homo sapiens	103-107
20858227-10	2010	The erm(B) gene was demonstrated in all six erythromycin-resistant vanA strains.	Erythromycin	44-56	VanA	Enterococcus faecalis	67-71
21056681-10	2011	A low concentration of erythromycin (1 mug/ml), but not dexamethasone (100 muM), inhibited TGF-beta1-induced VEGF production.	Erythromycin	23-35	transforming growth factor beta 1	Homo sapiens	91-100
21056681-10	2011	A low concentration of erythromycin (1 mug/ml), but not dexamethasone (100 muM), inhibited TGF-beta1-induced VEGF production.	Erythromycin	23-35	vascular endothelial growth factor A	Homo sapiens	109-113
20977453-6	2010	MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate).	Erythromycin	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
20977453-6	2010	MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate).	Erythromycin	42-54	potassium voltage-gated channel subfamily A member 5	Homo sapiens	27-32
20977453-6	2010	MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate).	Erythromycin	42-54	ATP binding cassette subfamily B member 1	Homo sapiens	59-63
20731779-3	2010	The present study aimed to test the hypothesis that motilin receptor agonist erythromycin alters the synaptic inputs of preganglionic gastric vagal motoneurons (GVMs) located in the dorsal motor nucleus of the vagus (DMV).	Erythromycin	77-89	motilin	Rattus norvegicus	52-59
20855838-3	2010	The erythromycin breath test was evaluated to determine hepatic activity of cytochrome P450 3A4 (CYP3A4), the main docetaxel-metabolizing enzyme.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-95
20855838-3	2010	The erythromycin breath test was evaluated to determine hepatic activity of cytochrome P450 3A4 (CYP3A4), the main docetaxel-metabolizing enzyme.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103
21103422-2	2010	One macrolide, erythromycin (ERY), is associated with possible sudden cardiac death from QT prolongation due to P450 iso-enzyme inhibition.	Erythromycin	15-27	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	112-116
21103422-2	2010	One macrolide, erythromycin (ERY), is associated with possible sudden cardiac death from QT prolongation due to P450 iso-enzyme inhibition.	Erythromycin	29-32	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	112-116
20697309-6	2010	RESULTS: POR A287P and R457H had low activity with all substrates; Q153R had 76-94% of wild-type (WT) activity with midazolam and erythromycin, but 129-150% activity with testosterone and quinidine.	Erythromycin	130-142	cytochrome p450 oxidoreductase	Homo sapiens	9-12
21311417-13	2011	CONCLUSION: Aspiration and sclerotherapy with alcohol and erythromycin yielded a relatively high recurrence rate in cyst with a bloody aspirate and high CA125 levels in cyst fluid.	Erythromycin	58-70	mucin 16, cell surface associated	Homo sapiens	153-158
21362305-8	2011	The effects of dexamethasone and erythromycin were observed in LPS-induced NCI-H292 cells.	Erythromycin	33-45	toll-like receptor 4	Mus musculus	63-66
21362305-11	2011	Dexamethasone and erythromycin decreased caspase-3 activity in LPS-induced NCI-H292 cells.	Erythromycin	18-30	caspase 3	Homo sapiens	41-50
21362305-11	2011	Dexamethasone and erythromycin decreased caspase-3 activity in LPS-induced NCI-H292 cells.	Erythromycin	18-30	toll-like receptor 4	Mus musculus	63-66
21221501-2	2010	This study evaluated the safety and efficacy of prophylactic low-dose oral erythromycin, a motilin agonist, as a prokinetic agent in reducing the incidence of this problem.	Erythromycin	75-87	motilin	Homo sapiens	91-98
20669013-1	2010	PURPOSE: To assess the impacts of erythromycin on the pharmacokinetics of voriconazole and its association with CYP2C19 genotypes in healthy Chinese male subjects.	Erythromycin	34-46	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	112-119
20669013-9	2010	In addition, significant increases in AUC(0-24) and AUC(0-infinity) and decreases in oral clearance of voriconazole after erythromycin treatment were observed in CYP2C19 HEMs and PMs (p &lt; 0.05, respectively), but not in CYP2C19 EMs.	Erythromycin	122-134	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	162-169
20669013-10	2010	CONCLUSION: Both CYP2C19 genotypes and CYP3A4 inhibitor erythromycin can influence the plasma concentration of voriconazole, and erythromycin increases plasma concentration of voriconazole in a CYP2C19 genotype-dependent manner.	Erythromycin	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
20669013-10	2010	CONCLUSION: Both CYP2C19 genotypes and CYP3A4 inhibitor erythromycin can influence the plasma concentration of voriconazole, and erythromycin increases plasma concentration of voriconazole in a CYP2C19 genotype-dependent manner.	Erythromycin	129-141	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	194-201
20500052-3	2010	Our objectives were to determine the occurrence of tcrB in fecal enterococci from weaned piglets fed diets with a normal supplemental level (16.5 ppm) or an elevated supplemental level (125 ppm) of copper and to determine the association of tcrB with copper, erythromycin, and vancomycin resistance.	Erythromycin	259-271	T cell receptor beta chain protein	Sus scrofa	51-55
20621639-1	2010	In this study five macrolide antibiotics (azithromycin, erythromycin, clarithromycin, roxithromycin and telithromycin) were compared based on their ability to interact with human MDR1 (ABCB1, P-glycoprotein), studied from two main aspects: by determining the influence of macrolide antibiotics on MDR1 function, as well as the influence of MDR1 on macrolide accumulation in MES-SA/Dx5 cells overexpressing human MDR1.	Erythromycin	56-68	ATP binding cassette subfamily B member 1	Homo sapiens	179-183
21244734-2	2010	The purpose of this study was to determine the effect of macrolides (erythromycin [EM] and roxithromycin [RXM]) on the differentiation of fibroblasts into myofibroblasts and extracellular matrix accumulation in transforming growth factor (TGF) beta1-induced nasal polyp-derived fibroblasts (NPDFs) and to determine if NADPH oxidase (Nox) 4 and reactive oxygen species (ROS) are involved in the aforementioned processes.	Erythromycin	69-81	transforming growth factor beta 1	Homo sapiens	211-249
20621639-4	2010	Expression of MDR1 on cells decreased macrolide accumulation in cells from 2- to 80-fold with the most pronounced change observed for azithromycin and erythromycin.	Erythromycin	151-163	ATP binding cassette subfamily B member 1	Homo sapiens	14-18
19914010-13	2010	All t127, ST1 isolates were resistant to tetracycline-ciprofloxacin-erythromycin.	Erythromycin	68-80	syndecan binding protein	Homo sapiens	10-13
21038022-13	2010	Erythromycin given in group II decreased the levels of IL-8 and ICAM-1.	Erythromycin	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	55-59
21038022-13	2010	Erythromycin given in group II decreased the levels of IL-8 and ICAM-1.	Erythromycin	0-12	intercellular adhesion molecule 1	Homo sapiens	64-70
20573570-6	2010	[(14)C] Erythromycin was selected as a model substrate for P-gp and MRP2 whereas Hoechst 33342 was employed as a substrate for BCRP.	Erythromycin	8-20	PGP	Canis lupus familiaris	59-63
20573570-6	2010	[(14)C] Erythromycin was selected as a model substrate for P-gp and MRP2 whereas Hoechst 33342 was employed as a substrate for BCRP.	Erythromycin	8-20	ATP binding cassette subfamily C member 2	Canis lupus familiaris	68-72
20007296-6	2010	CYP3A activity was also assessed by the N-demethylation of erythromycin.	Erythromycin	59-71	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	0-5
20023051-2	2010	In the clinical program for ximelagatran development, an unexpected effect of erythromycin on the pharmacokinetics of the direct thrombin inhibitor ximelagatran and its metabolites was detected.	Erythromycin	78-90	coagulation factor II, thrombin	Homo sapiens	129-137
20023051-9	2010	The results also suggest that inhibition of hepatic P-gp is involved in the erythromycin-ximelagatran interaction seen in clinical studies.	Erythromycin	76-88	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
19797607-0	2010	Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.	Erythromycin	23-35	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	14-19
20887636-5	2010	Motilin agonists, such as erythromycin, are effective gastrokinetic drugs in the critically ill. Cholecystokinin and peptide YY concentrations are elevated in both the fasting and postprandial states, and are likely to contribute to slow gastric emptying.	Erythromycin	26-38	motilin	Homo sapiens	0-7
20887636-5	2010	Motilin agonists, such as erythromycin, are effective gastrokinetic drugs in the critically ill. Cholecystokinin and peptide YY concentrations are elevated in both the fasting and postprandial states, and are likely to contribute to slow gastric emptying.	Erythromycin	26-38	cholecystokinin	Homo sapiens	97-112
19797607-2	2010	This study was designed to examine the accuracy of in vitro-derived parameters for the prediction of inhibition of CYP3A by erythromycin (ERY).	Erythromycin	124-136	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	115-120
19797607-2	2010	This study was designed to examine the accuracy of in vitro-derived parameters for the prediction of inhibition of CYP3A by erythromycin (ERY).	Erythromycin	138-141	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	115-120
20881376-9	2010	Total cells in the sputum and neutrophil elastase in sputum supernatant were also significantly decreased in those treated with erythromycin compared with the placebo group (p = 0.021 and p = 0.024, respectively).	Erythromycin	128-140	elastase, neutrophil expressed	Homo sapiens	30-49
20724802-8	2010	Using paclitaxel as a known P-gp substrate, erythromycin demonstrated only partial P-gp inhibitory capacity, maintaining an efflux ratio over 100.	Erythromycin	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
20724802-8	2010	Using paclitaxel as a known P-gp substrate, erythromycin demonstrated only partial P-gp inhibitory capacity, maintaining an efflux ratio over 100.	Erythromycin	44-56	ATP binding cassette subfamily B member 1	Homo sapiens	83-87
20208392-3	2010	Among the inhibitors studied, erythromycin and clarithromycin exhibited markedly weaker MBI effects on CYP3A activity in rat and mouse liver microsomes compared to human liver microsomes.	Erythromycin	30-42	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	103-108
19801894-0	2009	Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.	Erythromycin	51-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
19464769-3	2009	Compared with 4""-carbamate analogs, 11,12-cyclic carbonate-4""-carbamate analogs exhibited improved activity against erythromycin-resistant Staphylococcus pneumoniae encoded by the mef gene or the erm and mef genes, and 11,4""-di-O-arylalkylcarbamoyl analogs showed greatly improved activity (0.25-0.5 microg/mL) against erythromycin-resistant Staphylococcus pneumoniae encoded by the erm gene.	Erythromycin	118-130	E74 like ETS transcription factor 4	Homo sapiens	182-185
19464769-3	2009	Compared with 4""-carbamate analogs, 11,12-cyclic carbonate-4""-carbamate analogs exhibited improved activity against erythromycin-resistant Staphylococcus pneumoniae encoded by the mef gene or the erm and mef genes, and 11,4""-di-O-arylalkylcarbamoyl analogs showed greatly improved activity (0.25-0.5 microg/mL) against erythromycin-resistant Staphylococcus pneumoniae encoded by the erm gene.	Erythromycin	118-130	E74 like ETS transcription factor 4	Homo sapiens	206-209
19575604-4	2009	Erythromycin is a CYP3A4 inhibitor.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
19502290-0	2009	Erythromycin-induced CXCR4 expression on microvascular endothelial cells.	Erythromycin	0-12	C-X-C motif chemokine receptor 4	Homo sapiens	21-26
19502290-3	2009	However, the effects of EM on endothelial cells and especially their expression of CXCR4 have not been fully evaluated.	Erythromycin	24-26	C-X-C motif chemokine receptor 4	Homo sapiens	83-88
19502290-4	2009	In this study, we demonstrated that EM markedly induced CXCR4 surface expression on microvascular endothelial cells in vitro and lung capillary endothelial cells in vivo.	Erythromycin	36-38	C-X-C motif chemokine receptor 4	Homo sapiens	56-61
19679235-7	2009	Comparing antibiotic susceptibilities according to the serotype, the 19A isolates appeared to be the least susceptible to penicillin (3.2%) and erythromycin (4.5%), followed by serotypes 19F and 14.	Erythromycin	144-156	SLAM family member 7	Homo sapiens	69-72
19801894-1	2009	Inhibitory effects of ketoconazole (KTZ), cimetidine (CIM), and erythromycin (ERY) were examined on CYP3A activities.	Erythromycin	64-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
19801894-1	2009	Inhibitory effects of ketoconazole (KTZ), cimetidine (CIM), and erythromycin (ERY) were examined on CYP3A activities.	Erythromycin	78-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
19500694-0	2009	In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells.	Erythromycin	20-32	TNF superfamily member 11	Homo sapiens	36-41
19694743-5	2009	Hepatic CYP3A4 activity was evaluated by the (14)C-erythromycin breath test (ERMBT) and the ABCB1 and CYP2D6 genetic polymorphisms were determined by the TaqMan allelic discrimination assay and long polymerase chain reaction, respectively.	Erythromycin	51-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14
19500694-0	2009	In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells.	Erythromycin	20-32	tumor necrosis factor	Homo sapiens	78-87
19500694-2	2009	The present study aimed to examine the effects of erythromycin (EM) on the activation of RANKL, correlation with NF-kappaB expression, proliferation and apoptosis of human Jurkat T cells.	Erythromycin	50-62	TNF superfamily member 11	Homo sapiens	89-94
19225542-5	2009	Erythromycin, a P-450 inhibitor, may interfere with FGFR2 signaling by its inhibitory effect on retinoid catabolism.	Erythromycin	0-12	fibroblast growth factor receptor 2	Homo sapiens	52-57
19318426-6	2009	On the contrary, Ucn II mRNA was increased by TNF-alpha alone and Ang II with tempol, and the TNF-alpha-induced increase in Ucn II mRNA was abolished by erythromycin and PDTC.	Erythromycin	153-165	tumor necrosis factor	Homo sapiens	94-103
19262986-0	2009	Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis.	Erythromycin	22-34	vascular endothelial growth factor A	Mus musculus	58-62
19262986-0	2009	Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis.	Erythromycin	22-34	FMS-like tyrosine kinase 1	Mus musculus	63-68
19262986-2	2009	The purpose of this study is to investigate the effect of erythromycin (EM) on ultra high molecular weight polyethylene (UHMWPE) particle-induced VEGF/VEGF receptor 1 (Flt-1) gene production and inflammatory osteolysis in a mouse model.	Erythromycin	58-70	vascular endothelial growth factor A	Mus musculus	146-150
19262986-2	2009	The purpose of this study is to investigate the effect of erythromycin (EM) on ultra high molecular weight polyethylene (UHMWPE) particle-induced VEGF/VEGF receptor 1 (Flt-1) gene production and inflammatory osteolysis in a mouse model.	Erythromycin	58-70	vascular endothelial growth factor A	Mus musculus	151-155
19262986-2	2009	The purpose of this study is to investigate the effect of erythromycin (EM) on ultra high molecular weight polyethylene (UHMWPE) particle-induced VEGF/VEGF receptor 1 (Flt-1) gene production and inflammatory osteolysis in a mouse model.	Erythromycin	58-70	FMS-like tyrosine kinase 1	Mus musculus	168-173
19262986-10	2009	EM treatment significantly improved UHMWPE particle-induced tissue inflammation, reduced VEGF/Flt-1 protein expression, and diminished the number of TRAP(+) cells, as well as the implanted bone resorption.	Erythromycin	0-2	vascular endothelial growth factor A	Mus musculus	89-93
19262986-10	2009	EM treatment significantly improved UHMWPE particle-induced tissue inflammation, reduced VEGF/Flt-1 protein expression, and diminished the number of TRAP(+) cells, as well as the implanted bone resorption.	Erythromycin	0-2	FMS-like tyrosine kinase 1	Mus musculus	94-99
19318426-6	2009	On the contrary, Ucn II mRNA was increased by TNF-alpha alone and Ang II with tempol, and the TNF-alpha-induced increase in Ucn II mRNA was abolished by erythromycin and PDTC.	Erythromycin	153-165	urocortin 2	Homo sapiens	124-130
19293388-7	2009	Human CYP3A inhibitors erythromycin (0.5 mM), ketoconazole (0.5 microM), and troleandomycin (0.01-1 mM), but not the CYP2C inhibitor, sulfaphenazole (3 microM), significantly inhibited the depletion of NFV in hepatic S-9 fractions and expressed rhesus CYP3A64 enzyme.	Erythromycin	23-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-11
19131424-10	2009	When the complete orf2 was cloned, it conferred high-level resistance to erythromycin and azithromycin, and the resistance property could be partially inhibited using the efflux inhibitor Phe-Arg beta-naphthylamide dihydrochloride.	Erythromycin	73-85	hypothetical protein	Escherichia coli	18-22
19052724-16	2009	A concentration of 800 mg/L erythromycin medium caused an increase of the expression of CD34 (+6%), E-selectin (+5%), ICAM-1 (+14%) and VCAM-1 (+5%).	Erythromycin	28-40	CD34 molecule	Homo sapiens	88-92
19052724-16	2009	A concentration of 800 mg/L erythromycin medium caused an increase of the expression of CD34 (+6%), E-selectin (+5%), ICAM-1 (+14%) and VCAM-1 (+5%).	Erythromycin	28-40	selectin E	Homo sapiens	100-110
19052724-16	2009	A concentration of 800 mg/L erythromycin medium caused an increase of the expression of CD34 (+6%), E-selectin (+5%), ICAM-1 (+14%) and VCAM-1 (+5%).	Erythromycin	28-40	intercellular adhesion molecule 1	Homo sapiens	118-124
19052724-16	2009	A concentration of 800 mg/L erythromycin medium caused an increase of the expression of CD34 (+6%), E-selectin (+5%), ICAM-1 (+14%) and VCAM-1 (+5%).	Erythromycin	28-40	vascular cell adhesion molecule 1	Homo sapiens	136-142
19052724-18	2009	At a concentration of 400 mg/L medium clarithromycin induced a similar effect as erythromycin at twice this concentration: CD34 (+5%), E-selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%).	Erythromycin	81-93	CD34 molecule	Homo sapiens	123-127
19405994-3	2009	CPU0213 is metabolized mainly by cytochrome P450 (CYP)3A, thus, erythromycin, an inhibitor of CYP3A, could affect its effects by raising its plasma levels.	Erythromycin	64-76	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	94-99
18958406-1	2009	PURPOSE: The objectives were (i) to test in vivo functional activity of MRP2 on rabbit corneal epithelium and (ii) to evaluate modulation of P-gp and MRP2 mediated efflux of erythromycin when co-administered with corticosteroids.	Erythromycin	174-186	canalicular multispecific organic anion transporter 1	Oryctolagus cuniculus	150-154
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	37-49	ATP binding cassette subfamily B member 1	Canis lupus familiaris	62-66
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	37-49	ATP binding cassette subfamily C member 2	Canis lupus familiaris	76-80
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	37-49	PGP	Canis lupus familiaris	203-207
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	37-49	ATP binding cassette subfamily C member 2	Canis lupus familiaris	212-216
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	171-183	ATP binding cassette subfamily B member 1	Canis lupus familiaris	62-66
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	171-183	ATP binding cassette subfamily C member 2	Canis lupus familiaris	76-80
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	171-183	PGP	Canis lupus familiaris	203-207
18958406-5	2009	RESULTS: Bi-directional transport of erythromycin across MDCK-MDR1 and MDCK-MRP2 cells showed significant difference between BL-AP and AP-BL permeability, suggesting that erythromycin is a substrate for P-gp and MRP2.	Erythromycin	171-183	ATP binding cassette subfamily C member 2	Canis lupus familiaris	212-216
18958406-8	2009	Even, steroids inhibited P-gp and MRP2 mediated efflux with maximum increase in k(a), AUC(0-infinity), C(max) and C(last) values of erythromycin, observed with 6alpha-methyl prednisolone.	Erythromycin	132-144	PGP	Canis lupus familiaris	25-29
18958406-8	2009	Even, steroids inhibited P-gp and MRP2 mediated efflux with maximum increase in k(a), AUC(0-infinity), C(max) and C(last) values of erythromycin, observed with 6alpha-methyl prednisolone.	Erythromycin	132-144	ATP binding cassette subfamily C member 2	Canis lupus familiaris	34-38
18958406-10	2009	Steroids were able to significantly inhibit both P-gp and MRP2 mediated efflux of erythromycin.	Erythromycin	82-94	PGP	Canis lupus familiaris	49-53
18958406-10	2009	Steroids were able to significantly inhibit both P-gp and MRP2 mediated efflux of erythromycin.	Erythromycin	82-94	ATP binding cassette subfamily C member 2	Canis lupus familiaris	58-62
18654747-7	2009	Cytochrome P450 3A4 (CYP3A4) activity was determined by an erythromycin breath test (EBT) prior to diflomotecan administration in cycles 1 and 2.	Erythromycin	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
18654747-7	2009	Cytochrome P450 3A4 (CYP3A4) activity was determined by an erythromycin breath test (EBT) prior to diflomotecan administration in cycles 1 and 2.	Erythromycin	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
19356389-11	2009	CONCLUSIONS: Co-administration of erythromycin (a moderate CYP3A4 inhibitor) and roflumilast does not require dose adjustment of roflumilast.	Erythromycin	34-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
19197244-0	2009	Erythromycin resistance by L4/L22 mutations and resistance masking by drug efflux pump deficiency.	Erythromycin	0-12	ribosomal protein L22	Homo sapiens	30-33
19197244-1	2009	We characterized the effects of classical erythromycin resistance mutations in ribosomal proteins L4 and L22 of the large ribosomal subunit on the kinetics of erythromycin binding.	Erythromycin	159-171	ribosomal protein L22	Homo sapiens	105-108
19197244-3	2009	The growth-inhibitory action of erythromycin was characterized for bacterial populations with wild-type and L22-mutated ribosomes in drug efflux pump deficient and proficient backgrounds.	Erythromycin	32-44	ribosomal protein L22	Homo sapiens	108-111
19197244-4	2009	The L22 mutation conferred reduced erythromycin susceptibility in the drug efflux pump proficient, but not deficient, background.	Erythromycin	35-47	ribosomal protein L22	Homo sapiens	4-7
19414330-5	2009	RESULTS: Three ligand accessible regions (region 1-3) were present in erythromycin-bound CYP3A4, and these dipole moments indicated the same features as ketoconazole- or metyrapone-bound CYP3A4 molecules.	Erythromycin	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95
19414330-5	2009	RESULTS: Three ligand accessible regions (region 1-3) were present in erythromycin-bound CYP3A4, and these dipole moments indicated the same features as ketoconazole- or metyrapone-bound CYP3A4 molecules.	Erythromycin	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	187-193
19567187-0	2009	[Effects of erythromycin on the synthesis of interleukin-8 and gamma-glutamylcysteine synthetase induced by 4-hydroxynonenal in the bronchial epithelial cells].	Erythromycin	12-24	C-X-C motif chemokine ligand 8	Homo sapiens	45-58
18509327-4	2009	However, the simultaneous presence of the CYP3A4*1B and CYP3A5*1A alleles was associated with a 64% increase in docetaxel clearance (P = 0.0015), independent of both sex and CYP3A activity (as determined using the erythromycin breath test).	Erythromycin	214-226	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
18509327-4	2009	However, the simultaneous presence of the CYP3A4*1B and CYP3A5*1A alleles was associated with a 64% increase in docetaxel clearance (P = 0.0015), independent of both sex and CYP3A activity (as determined using the erythromycin breath test).	Erythromycin	214-226	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	56-62
18509327-4	2009	However, the simultaneous presence of the CYP3A4*1B and CYP3A5*1A alleles was associated with a 64% increase in docetaxel clearance (P = 0.0015), independent of both sex and CYP3A activity (as determined using the erythromycin breath test).	Erythromycin	214-226	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-47
19567187-0	2009	[Effects of erythromycin on the synthesis of interleukin-8 and gamma-glutamylcysteine synthetase induced by 4-hydroxynonenal in the bronchial epithelial cells].	Erythromycin	12-24	glutamate-cysteine ligase catalytic subunit	Homo sapiens	63-96
19567187-1	2009	OBJECTIVE: This study was to explore the role of erythromycin on the synthesis of interleukin-8 (IL-8) and gamma-GCS treated by 4-hydroxynonenal (4-HNE) in bronchial epithelial cells (16-HBE).	Erythromycin	49-61	C-X-C motif chemokine ligand 8	Homo sapiens	82-95
19567187-1	2009	OBJECTIVE: This study was to explore the role of erythromycin on the synthesis of interleukin-8 (IL-8) and gamma-GCS treated by 4-hydroxynonenal (4-HNE) in bronchial epithelial cells (16-HBE).	Erythromycin	49-61	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
19567187-5	2009	(3) The effects of PD98059 and erythromycin on the expression of gamma-GCS, gamma-GCS mRNA, IL-8 and erythromycin on AP-1 combining activity by the 4-HNE were all detected.	Erythromycin	31-43	C-X-C motif chemokine ligand 8	Homo sapiens	92-96
19567187-13	2009	Erythromycin could inhibit the synthesis of IL-8 by blocking AP-1 pathway.	Erythromycin	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	44-48
19554195-6	2009	Erythromycin has been shown to decrease the rate of COPD exacerbations.	Erythromycin	0-12	COPD	Homo sapiens	52-56
19076222-3	2009	ermC and ermA genes predominated within erythromycin-resistant Staphylococcus aureus isolates with iMLS(B) phenotype and cMLS(B) phenotype, respectively.	Erythromycin	40-52	ErmC	Staphylococcus aureus	0-4
19076222-4	2009	Among erythromycin-resistant CoNS isolates, half of the strains showed the iMTS or MS/msrA association, and ermC gene predominated among isolates with MLS(B) phenotype.	Erythromycin	6-18	ABC transporter permease protein	Staphylococcus aureus	86-90
19076222-4	2009	Among erythromycin-resistant CoNS isolates, half of the strains showed the iMTS or MS/msrA association, and ermC gene predominated among isolates with MLS(B) phenotype.	Erythromycin	6-18	ErmC	Staphylococcus aureus	108-112
18183036-3	2008	Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT).	Erythromycin	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-14
19248230-8	2009	Concentration dependent decrease of this secretion was obtained by the P-gp inhibitors verapamil, erythromycin and quinidine, while no effect was evident by the MRP2 inhibitor MK-571 and the BCRP inhibitor FTC, indicating that P-gp is the transporter mediates the intestinal efflux of cimetidine and famotidine.	Erythromycin	98-110	phosphoglycolate phosphatase	Homo sapiens	71-75
18710913-3	2008	Mitochondrial activity was involved as indicated by mitochondrial depolarization and increased hLf resistance of cells preincubated with sordarin or erythromycin, the latter of which inhibits protein synthesis in mitoribosomes.	Erythromycin	149-161	HLF transcription factor, PAR bZIP family member	Homo sapiens	95-98
18703021-7	2008	A number of Pgp substrates (quinidine, amprenavir, irinotecan, topotecan, atorvastatin and erythromycin) induced net digoxin secretion, as did the non-Pgp substrate artemisinin.	Erythromycin	91-103	ATP binding cassette subfamily B member 1	Homo sapiens	12-15
18928592-9	2008	Both of garlicin and erythromycin alone could down-regulate the expression of mdr1 and P-gp of K562/A02 and elevate the intracellular concentrations of ADM in K562/A02 cells.	Erythromycin	21-33	ATP binding cassette subfamily B member 1	Homo sapiens	78-82
18928592-9	2008	Both of garlicin and erythromycin alone could down-regulate the expression of mdr1 and P-gp of K562/A02 and elevate the intracellular concentrations of ADM in K562/A02 cells.	Erythromycin	21-33	phosphoglycolate phosphatase	Homo sapiens	87-91
18719105-0	2008	Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBPbeta.	Erythromycin	0-12	CCAAT enhancer binding protein beta	Homo sapiens	130-139
18490434-3	2008	We have previously noted a correlation between basal CYP3A activity and the inductive effects of dexamethasone using the erythromycin breath test (ERBT).	Erythromycin	121-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
18509328-3	2008	In cellular models overexpressing 10 different solute carriers, erythromycin uptake was significantly increased by OATP1A2 (P &lt; 0.005) and OATP1B3 (P &lt; 0.01).	Erythromycin	64-76	solute carrier organic anion transporter family member 1A2	Homo sapiens	115-122
18509328-3	2008	In cellular models overexpressing 10 different solute carriers, erythromycin uptake was significantly increased by OATP1A2 (P &lt; 0.005) and OATP1B3 (P &lt; 0.01).	Erythromycin	64-76	solute carrier organic anion transporter family member 1B3	Homo sapiens	142-149
18761689-2	2008	Clinical isolates with increased resistance to erythromycin and azithromycin frequently harbour mutations in the mtrR structural gene, which encodes a repressor of the mtrCDE operon, or the mtrR promoter region.	Erythromycin	47-59	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Mus musculus	113-117
18761689-2	2008	Clinical isolates with increased resistance to erythromycin and azithromycin frequently harbour mutations in the mtrR structural gene, which encodes a repressor of the mtrCDE operon, or the mtrR promoter region.	Erythromycin	47-59	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Mus musculus	190-194
18718006-3	2008	Erythromycin, a non-peptide motilin receptor agonist, induces phase 3 of the migrating motor complex (MMC) in the antro-duodenum and also reduces oro-cecal transit time.	Erythromycin	0-12	motilin	Homo sapiens	28-35
17922273-0	2008	Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test.	Erythromycin	65-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	32-38
17922273-4	2008	CYP3A4 activity was determined using the erythromycin breath test (EBT) in each patient prior to their beginning with an LHRH-agonist (leuprolide or goserelin).	Erythromycin	41-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18505790-9	2008	In summary, nafcillin, dicloxacillin, cephradine, tetracycline, sulfixoxazole, erythromycin, clindamycin, and griseofulvin exhibit a clear propensity to induce CYP3A4 and warrant further clinical investigation.	Erythromycin	79-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
17826359-6	2008	Using erythromycin and testosterone as substrates, we demonstrated that CYP3A catalysis exhibited non-Michaelis-Menten kinetics in GCL cells, and that V(max)/K(m) values were significantly increased due to rifampicin-treatment.	Erythromycin	6-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
18495583-7	2008	mecA were detected in all the methicillin-resistant S. aureus strains, and ermA and/or ermC in 97.7% of the S. aureus strains with erythromycin resistance.	Erythromycin	131-143	rRNA methylase Erm(A)	Staphylococcus aureus	75-79
18495583-9	2008	mecA, ermA, and ermC genes are among the predominant genetic determinants for the resistance to oxacillin and erythromycin in S. aureus isolates in Guangzhou.	Erythromycin	110-122	rRNA methylase Erm(A)	Staphylococcus aureus	6-10
17870192-7	2008	The rank order of potency determined for these agonists was similar to that found for the human motilin receptor, with motilin being more potent than erythromycin.	Erythromycin	150-162	motilin receptor	Canis lupus familiaris	96-112
17870192-7	2008	The rank order of potency determined for these agonists was similar to that found for the human motilin receptor, with motilin being more potent than erythromycin.	Erythromycin	150-162	motilin	Homo sapiens	96-103
18473749-3	2008	A recent study indicates that CYP3A4 undergoes dramatic conformational changes upon binding to ketoconazole or erythromycin with a differential but substantial (&gt;80%) increase in the active site volume, providing a structural basis for ligand promiscuity of CYP3A4.	Erythromycin	111-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36
18473749-3	2008	A recent study indicates that CYP3A4 undergoes dramatic conformational changes upon binding to ketoconazole or erythromycin with a differential but substantial (&gt;80%) increase in the active site volume, providing a structural basis for ligand promiscuity of CYP3A4.	Erythromycin	111-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	261-267
18212111-1	2008	The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes.	Erythromycin	202-214	C-X-C motif chemokine ligand 8	Homo sapiens	18-31
18212111-1	2008	The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes.	Erythromycin	202-214	F2R like trypsin receptor 1	Homo sapiens	61-90
18212111-1	2008	The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes.	Erythromycin	202-214	interleukin 1 beta	Homo sapiens	114-131
18355581-1	2008	Mitemcinal is an erythromycin derivative, which acts as an agonist of the motilin receptor.	Erythromycin	17-29	motilin receptor	Rattus norvegicus	74-90
18054184-1	2008	This study aims at evaluating the potential of SMA-ethanol as enteric coating polymer for erythromycin tablets.	Erythromycin	90-102	survival of motor neuron 1, telomeric	Homo sapiens	47-50
18096134-3	2008	We therefore compared the mechanisms involved in the intracellular trafficking of the MTLR after stimulation with motilin, erythromycin-A (EM-A) or ABT-229.	Erythromycin	123-137	Mlnr	Cricetulus griseus	86-90
21279172-3	2008	The concomitant use of either CYP3A4 inducer rifampicin or CYP3A4 inhibitor erythromycin may influence the results of MEGX test.	Erythromycin	76-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
21279172-4	2008	Hence, the objective of this study was to evaluate the effect of a CYP3A4 inhibitor erythromycin and inducer rifampicin on the MEGX test.	Erythromycin	84-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
18503189-4	2008	Deletion of crp significantly increased the resistance of the E. coli strain to oxacillin, azithromycin, erythromycin and crystal violet.	Erythromycin	105-117	catabolite gene activator protein	Escherichia coli	12-15
18358279-2	2008	Erythromycin is a motilin agonist, a hormone that induces gastrointestinal contractions.	Erythromycin	0-12	motilin	Homo sapiens	18-25
18339018-0	2008	Erythromycin attenuates MUC5AC synthesis and secretion in cultured human tracheal cells infected with RV14.	Erythromycin	0-12	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	24-30
18339018-6	2008	RESULTS: Erythromycin blocked RV14-induced MUC5AC protein overproduction and hypersecretion, and also blocked RV14-induced p44/42 MAPK activation in the cells.	Erythromycin	9-21	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	43-49
18339018-6	2008	RESULTS: Erythromycin blocked RV14-induced MUC5AC protein overproduction and hypersecretion, and also blocked RV14-induced p44/42 MAPK activation in the cells.	Erythromycin	9-21	interferon induced protein 44	Homo sapiens	123-126
18339018-7	2008	CONCLUSIONS: Erythromycin may attenuate RV14-induced MUC5AC overproduction and hypersecretion by blocking the p44/42 MAPK pathway or its upstream regulators.	Erythromycin	13-25	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	53-59
18339018-7	2008	CONCLUSIONS: Erythromycin may attenuate RV14-induced MUC5AC overproduction and hypersecretion by blocking the p44/42 MAPK pathway or its upstream regulators.	Erythromycin	13-25	interferon induced protein 44	Homo sapiens	110-113
17870192-6	2008	Expression of the dog motilin receptor in CHO cells promoted the typical cellular responses to the agonists, motilin and erythromycin.	Erythromycin	121-133	motilin	Canis lupus familiaris	22-29
18032475-2	2008	Motilin and erythromycin, two chemically distinct full agonists of the motilin receptor, are known to bind to distinct regions of this receptor, based on previous systematic mutagenesis of extracellular regions that dissociated the effects on these two agents.	Erythromycin	12-24	motilin receptor	Homo sapiens	71-87
17582410-6	2008	In isolated intestinal bulb and mid/distal intestine preparations, ghrelin, motilin, and the motilin receptor agonist erythromycin all evoked contraction; these responses ranged between 9% and 51% of the contractions evoked by carbachol (10(-6) M).	Erythromycin	118-130	motilin	Rattus norvegicus	93-100
18759121-6	2008	The frequency of erythromycin genes was: ermA (+) 22.8 %, ermB (+) 45.7, ermC (+) 17.1, msrA (+) 28.6.	Erythromycin	17-29	ErmC	Staphylococcus aureus	73-77
18759121-6	2008	The frequency of erythromycin genes was: ermA (+) 22.8 %, ermB (+) 45.7, ermC (+) 17.1, msrA (+) 28.6.	Erythromycin	17-29	ABC transporter permease protein	Staphylococcus aureus	88-92
17464949-0	2007	Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.	Erythromycin	104-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
18260305-8	2008	These results suggest that erythromycin therapy may be useful for the control of lower respiratory tract infections in patients with XLA.	Erythromycin	27-39	Bruton tyrosine kinase	Homo sapiens	133-136
18057758-1	2007	In the imine aldol reactions of 1 with aromatic aldehydes using magnesium salts in the presence of amines, the threo/erythro ratios of products increased in the order Mg(ClO4)2&gt;MgI2&gt;MgBr2&gt;MgCl2&gt;Mg(OTf)2 and N,N,N",N"-tetramethylethylenediamine (TMEDA)&gt;Et3N.	Erythromycin	117-124	POU class 2 homeobox 2	Homo sapiens	209-214
17585116-0	2007	Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.	Erythromycin	36-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-70
17585116-1	2007	The aim of the present study was to estimate the time course change in cytochrome P450 3A (CYP3A) activity during repeated doses of erythromycin.	Erythromycin	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-89
17585116-1	2007	The aim of the present study was to estimate the time course change in cytochrome P450 3A (CYP3A) activity during repeated doses of erythromycin.	Erythromycin	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
17585116-7	2007	The relationship between the duration of erythromycin treatment and total clearance of midazolam indicated that a plateau level of CYP3A inhibition can be achieved by 4 days or more of erythromycin treatment.	Erythromycin	41-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-136
17585116-7	2007	The relationship between the duration of erythromycin treatment and total clearance of midazolam indicated that a plateau level of CYP3A inhibition can be achieved by 4 days or more of erythromycin treatment.	Erythromycin	185-197	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-136
17585116-8	2007	The repeated treatment with erythromycin yields CYP3A inhibition in a duration-dependent manner.	Erythromycin	28-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-53
17585116-9	2007	A 4-day course of erythromycin treatment produces 90% or more of the maximal inhibition of CYP3A in humans.	Erythromycin	18-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
17464949-7	2007	The erythromycin breath test (ERMBT) was performed on 81 patients as an in vivo phenotypic assessment of CYP3A activity.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-110
18074444-3	2007	Using the patch clamp technique on the human ether-a-gogo-related gene (HERG) current, the rank order for blockade of the HERG-current (IC(50)) was: sparfloxacin (44 microM)&gt;telithromycin=moxifloxacin=erythromycin (+/-100 microM).	Erythromycin	204-216	potassium voltage-gated channel subfamily H member 2	Homo sapiens	72-76
18074444-3	2007	Using the patch clamp technique on the human ether-a-gogo-related gene (HERG) current, the rank order for blockade of the HERG-current (IC(50)) was: sparfloxacin (44 microM)&gt;telithromycin=moxifloxacin=erythromycin (+/-100 microM).	Erythromycin	204-216	potassium voltage-gated channel subfamily H member 2	Homo sapiens	122-126
18201586-6	2007	CYP3A4 activity was estimated by the percentage of administered (14)C exhaled in a single-breath collection after the test dose of erythromycin underwent demethylation by CYP3A4.	Erythromycin	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
18201586-6	2007	CYP3A4 activity was estimated by the percentage of administered (14)C exhaled in a single-breath collection after the test dose of erythromycin underwent demethylation by CYP3A4.	Erythromycin	131-143	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	171-177
17762710-4	2007	Motilin at 10 nM depolarized Purkinje cells of the rat cerebellum, and this was mimicked by the motilin receptor agonist erythromycin.	Erythromycin	121-133	motilin	Rattus norvegicus	0-7
17762710-4	2007	Motilin at 10 nM depolarized Purkinje cells of the rat cerebellum, and this was mimicked by the motilin receptor agonist erythromycin.	Erythromycin	121-133	motilin	Rattus norvegicus	96-103
17361125-1	2007	The erythromycin breath test (EBT) is a standard test used to evaluate the extent of CYP3A4 activity.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-91
17495418-3	2007	In this study, we have shown the ion suppression of 1"-hydroxymidazolam (analyte) and dextrorphan (IS) by erythromycin, as an example, which may cause over- or underestimation of CYP3A4 inhibition.	Erythromycin	106-118	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	179-185
17296622-8	2007	The IC50 values for the inhibition of OATP1B3-mediated BSP uptake were 11 microM for telithromycin, 32 microM for clarithromycin, 34 microM for erythromycin, and 37 microM for roxithromycin.	Erythromycin	144-156	solute carrier organic anion transporter family member 1B3	Homo sapiens	38-45
17277051-6	2007	Analysis of the chromosomal insertion frequency using a recombinant IS256 element tagged with an erythromycin marker showed an almost three-times-higher transposition frequency in a Deltasigma(B) strain.	Erythromycin	97-109	IS256, transposase	Staphylococcus aureus	68-73
17216287-0	2007	QSAR models for predicting the activity of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A using quantum chemical properties.	Erythromycin	125-139	gonadotropin releasing hormone 1	Homo sapiens	55-92
17216287-0	2007	QSAR models for predicting the activity of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A using quantum chemical properties.	Erythromycin	125-139	gonadotropin releasing hormone 1	Homo sapiens	94-98
17484517-5	2007	Clinically established CYP3A4 inhibitors including itraconazole, ketoconazole, erythromycin and clarithromycin inhibited the elimination of IM in HLM.	Erythromycin	79-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
17419396-5	2007	We reported the inhibitory effects of glucocorticosteroids on rhinovirus infection, the major cause of common colds, and the inhibitory effects of L-carbocisteine and erythromycin on COPD exacerbations and rhinovirus infection.	Erythromycin	167-179	COPD	Homo sapiens	183-187
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Erythromycin	78-90	chemokine (C-X-C motif) ligand 2	Mus musculus	117-156
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Erythromycin	92-94	chemokine (C-X-C motif) ligand 2	Mus musculus	117-156
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Erythromycin	92-94	interleukin 6	Mus musculus	158-171
17324565-2	2007	Production of IL-6 was significantly decreased by treatment with CAM or EM in a dose-dependent manner, but the inhibitory effect of CAM was significantly weaker than that of EM.	Erythromycin	72-74	interleukin 6	Mus musculus	14-18
17093012-1	2007	In the United States, approximately 30% of Streptococcus pneumoniae isolates are macrolide (erythromycin [ERY]) resistant (ERSP), most commonly due to expression of the mef(A) gene previously associated with lower-level ERY resistance (ERYr; MIC=1 to 4 microg/ml).	Erythromycin	92-104	E74 like ETS transcription factor 4	Homo sapiens	169-172
17093012-1	2007	In the United States, approximately 30% of Streptococcus pneumoniae isolates are macrolide (erythromycin [ERY]) resistant (ERSP), most commonly due to expression of the mef(A) gene previously associated with lower-level ERY resistance (ERYr; MIC=1 to 4 microg/ml).	Erythromycin	106-109	E74 like ETS transcription factor 4	Homo sapiens	169-172
17592529-9	2007	administration of EM, a motilin receptor agonist, stimulated the gastric motility of diabetic rats.	Erythromycin	18-20	motilin	Rattus norvegicus	24-31
18027988-4	2007	RESULTS: All macrolides inhibited P-glycoprotein-mediated digoxin transport, with concentrations producing 50% inhibition (IC(50)) values of 1.8, 4.1, 15.4, 21.8 and 22.7 micromol/L for telithromycin, clarithromycin, roxithromycin, azithromycin and erythromycin, respectively.	Erythromycin	249-261	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
17061983-7	2007	IL17-induced IL8 production was decreased by both erythromycin and azithromycin.	Erythromycin	50-62	interleukin 17A	Homo sapiens	0-4
17061983-7	2007	IL17-induced IL8 production was decreased by both erythromycin and azithromycin.	Erythromycin	50-62	C-X-C motif chemokine ligand 8	Homo sapiens	13-16
17056262-1	2007	The substrate for selective substitution in the C10-methyl group in erythromycin A derivatives was 10,11-anhydro-6O-methyl-descladinosylerythromycin.	Erythromycin	68-82	homeobox C10	Homo sapiens	48-51
17165505-5	2006	RESULTS: Erythromycin could significantly enhance PDP and PTP values in the rabbit (P &lt; 0.001).	Erythromycin	9-21	tyrosine-protein phosphatase non-receptor type 13	Oryctolagus cuniculus	58-61
17083930-5	2007	[14C]-erythromycin which is a proven substrate for MRP-2 was selected as a model drug for functional expression studies.	Erythromycin	6-18	canalicular multispecific organic anion transporter 1	Oryctolagus cuniculus	51-56
17460944-8	2007	However, the ratio of serum total IgE to IgG2a levels was significantly increased in erythromycin-treated mice relative to that found either in LFK-treated mice or in erythromycin-treated mice with LFK supplementation.	Erythromycin	85-97	immunoglobulin heavy variable V1-9	Mus musculus	41-46
17083011-8	2006	In contrast, there was killing of ingested GAS after exposure of epithelial cells to either erythromycin or azithromycin.	Erythromycin	92-104	gastrin	Homo sapiens	43-46
16563685-7	2007	81.8% of the erythromycin-resistant strains carried the ermB gene.	Erythromycin	13-25	erythromycin resistance protein	Enterococcus faecalis	56-60
17054943-3	2006	Using the patch clamp technique on the human ether-a-gogo-related gene (HERG) current, the rank order for blockade of the HERG-current (IC(50)) was: sparfloxacin (44 microM)&gt;telithromycin=moxifloxacin=erythromycin (+/-100 microM).	Erythromycin	204-216	potassium voltage-gated channel subfamily H member 2	Homo sapiens	72-76
17054943-3	2006	Using the patch clamp technique on the human ether-a-gogo-related gene (HERG) current, the rank order for blockade of the HERG-current (IC(50)) was: sparfloxacin (44 microM)&gt;telithromycin=moxifloxacin=erythromycin (+/-100 microM).	Erythromycin	204-216	potassium voltage-gated channel subfamily H member 2	Homo sapiens	122-126
17313833-0	2006	[Erythromycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].	Erythromycin	1-13	potassium voltage-gated channel subfamily H member 2	Homo sapiens	44-48
17313833-1	2006	OBJECTIVE: To investigate the effects of erythromycin on the proliferation of the human ether-a-go-go related gene (HERG) K(+) channel highly expressing cancer cells and its synergy with antitumor chemotherapeutic agents.	Erythromycin	41-53	potassium voltage-gated channel subfamily H member 2	Homo sapiens	116-120
17313833-15	2006	Erythromycin inhibited the secretion of MMP-2 from HT-29 cells in a dose-dependent manner.	Erythromycin	0-12	matrix metallopeptidase 2	Homo sapiens	40-45
17313833-18	2006	CONCLUSION: Erythromycin inhibits the proliferation and induces the apoptosis of cancer cells with high HERG K(+) channel expression.	Erythromycin	12-24	potassium voltage-gated channel subfamily H member 2	Homo sapiens	104-108
17070443-0	2006	A motilin agonist, erythromycin, decreases circulating growth hormone levels in normal subjects but not in diabetic subjects.	Erythromycin	19-31	motilin	Homo sapiens	2-9
17070443-0	2006	A motilin agonist, erythromycin, decreases circulating growth hormone levels in normal subjects but not in diabetic subjects.	Erythromycin	19-31	growth hormone 1	Homo sapiens	55-69
17070443-1	2006	Erythromycin (EM) is a common antibiotic known to be a specific agonist of motilin receptors.	Erythromycin	0-12	motilin	Homo sapiens	75-82
17070443-1	2006	Erythromycin (EM) is a common antibiotic known to be a specific agonist of motilin receptors.	Erythromycin	14-16	motilin	Homo sapiens	75-82
16844145-1	2006	Freshly isolated peripheral blood lymphocytes from control rats were found to catalyze the N-demethylation of erythromycin, known to be mediated by cytochrome P450 3A (CYP3A) isoenzymes in rat liver.	Erythromycin	110-122	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	148-166
16844145-1	2006	Freshly isolated peripheral blood lymphocytes from control rats were found to catalyze the N-demethylation of erythromycin, known to be mediated by cytochrome P450 3A (CYP3A) isoenzymes in rat liver.	Erythromycin	110-122	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	168-173
16918719-2	2006	We studied the effect of co-administration of fluvoxamine (CYP1A2 inhibitor) and erythromycin (CYP3A4 inhibitor) on the pharmacokinetics of lidocaine in a double-blind, randomized, three-way cross-over study.	Erythromycin	81-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
16954191-4	2006	Here, we present crystal structures of human CYP3A4 in complex with two well characterized drugs: ketoconazole and erythromycin.	Erythromycin	115-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
16954191-6	2006	The structures represent two distinct open conformations of CYP3A4 because ketoconazole and erythromycin induce different types of coordinate shifts.	Erythromycin	92-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66
16954191-7	2006	The binding of two molecules of ketoconazole to the CYP3A4 active site and the clear indication of multiple binding modes for erythromycin has implications for the interpretation of the atypical kinetic data often displayed by CYP3A4.	Erythromycin	126-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	227-233
16918719-11	2006	The concomitant use of both fluvoxamine and a CYP3A4 inhibitor like erythromycin may further increase plasma lidocaine concentrations.	Erythromycin	68-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52
16679387-4	2006	To address this issue, we investigated the effects of P450 inhibitors (cimetidine, sulfaphenazole, erythromycin, nifedipine, and ketoconazole) on the UGT2B7-catalyzed formation of morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-6-G).	Erythromycin	99-111	UDP glucuronosyltransferase family 2 member B7	Homo sapiens	150-156
16842395-1	2006	AIMS: To evaluate the effects of combined antiretroviral drugs (HAART) on liver CYP3A4 activity using the [(14)C-N-methyl]-erythromycin breath test (ERMBT).	Erythromycin	123-135	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
16679385-6	2006	Tienilic acid selectively inhibited CYP2C9-dependent diclofenac 4"-hydroxylation activity, and erythromycin, troleandomycin, and fluoxetine inhibited CYP3A4-dependent midazolam 1"-hydroxylation in a time- and concentration-dependent manner.	Erythromycin	95-107	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
16673044-4	2006	The ability of rat brain microsomes to catalyze the demethylation of erythromycin, known to be mediated by CYP3A isoenzymes in liver and significant increase in the activity of erythromycin demethylase (EMD) following pretreatment with dexamethasone or PCN have indicated that CYP3A isoenzymes expressed in brain are functionally active.	Erythromycin	69-81	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	107-112
16614168-3	2006	Each drug caused dose-dependent inhibition of the rapidly activating delayed rectifier potassium current encoded by the human ether-a-go-go-related gene (hERG) with IC20 concentrations of 31 microM (moxifloxacin), 21 microM (erythromycin), and 11 microM (telithromycin).	Erythromycin	225-237	ETS transcription factor ERG	Homo sapiens	154-158
16842099-2	2006	The relative levels of Abeta peptide were reduced after exposure of mice to paroxetine (N=5), NAC (N=7), and erythromycin (N=7) relative to matched placebo counterparts.	Erythromycin	109-121	amyloid beta (A4) precursor protein	Mus musculus	23-28
16673044-4	2006	The ability of rat brain microsomes to catalyze the demethylation of erythromycin, known to be mediated by CYP3A isoenzymes in liver and significant increase in the activity of erythromycin demethylase (EMD) following pretreatment with dexamethasone or PCN have indicated that CYP3A isoenzymes expressed in brain are functionally active.	Erythromycin	69-81	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	277-282
16414224-1	2006	Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes.	Erythromycin	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-117
17001844-0	2006	[Investigation of erythromycin resistance and resistance phenotypes in group A beta hemolytic streptococci].	Erythromycin	18-30	amyloid beta precursor protein	Homo sapiens	77-83
17007374-1	2006	OBJECTIVE: To study the effect of erythromycin on apoptosis and expression of Bax and Bcl-2 of epithelial cell in nasal polyps.	Erythromycin	34-46	BCL2 associated X, apoptosis regulator	Homo sapiens	78-81
17007374-1	2006	OBJECTIVE: To study the effect of erythromycin on apoptosis and expression of Bax and Bcl-2 of epithelial cell in nasal polyps.	Erythromycin	34-46	BCL2 apoptosis regulator	Homo sapiens	86-91
17007374-8	2006	Expression of Bax of epithelial cell cultured with erythromycin was significantly higher than that in the controls (P &lt; 0.05).	Erythromycin	51-63	BCL2 associated X, apoptosis regulator	Homo sapiens	14-17
17007374-10	2006	CONCLUSIONS: Erythromycin promoted expression of Bax and apoptosis of epithelial cell in nasal polyps.	Erythromycin	13-25	BCL2 associated X, apoptosis regulator	Homo sapiens	49-52
16759093-4	2006	We targeted erythromycin A (EA) as a membrane-binding compound because it is pointed out that the drug interacts with lysosomal membranes, inhibits phospholipase A, and consequently induces phospholipidosis as a side effect.	Erythromycin	12-26	phospholipase A and acyltransferase 1	Homo sapiens	148-163
16759093-4	2006	We targeted erythromycin A (EA) as a membrane-binding compound because it is pointed out that the drug interacts with lysosomal membranes, inhibits phospholipase A, and consequently induces phospholipidosis as a side effect.	Erythromycin	28-30	phospholipase A and acyltransferase 1	Homo sapiens	148-163
16793594-5	2006	When pretreated with the antibody against motilin receptor in Hank"s solution, the effect of 10 microg/ml erythromycin was almost inhibited completely.	Erythromycin	106-118	motilin receptor	Rattus norvegicus	42-58
16793594-6	2006	CONCLUSION: Motilin can increase [Ca(2+)]i, and erythromycin also has this effect by binding to motilin receptor.	Erythromycin	48-60	motilin receptor	Rattus norvegicus	96-112
16732092-3	2006	They also investigated whether tolerance induction by erythromycin involves transcriptional and translational changes of cerebral B-cell leukemia/lymphoma-2 (bcl-2) expression.	Erythromycin	54-66	BCL2, apoptosis regulator	Rattus norvegicus	130-156
16732092-7	2006	RESULTS: Erythromycin improved postischemic neuronal survival in hippocampal CA1 and CA3 sectors and reduced functional deficit, with 12 h being the most efficient pretreatment interval.	Erythromycin	9-21	carbonic anhydrase 1	Rattus norvegicus	77-80
16732092-7	2006	RESULTS: Erythromycin improved postischemic neuronal survival in hippocampal CA1 and CA3 sectors and reduced functional deficit, with 12 h being the most efficient pretreatment interval.	Erythromycin	9-21	carbonic anhydrase 3	Rattus norvegicus	85-88
16732092-8	2006	Bcl-2 mRNA in hippocampus was transiently up-regulated 6 h after erythromycin, but neuronal Bcl-2 protein remained unchanged.	Erythromycin	65-77	BCL2, apoptosis regulator	Rattus norvegicus	0-5
16732092-10	2006	Changes in bcl-2 expression after erythromycin were small and transient.	Erythromycin	34-46	BCL2, apoptosis regulator	Rattus norvegicus	11-16
16414224-1	2006	Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes.	Erythromycin	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-125
16414224-1	2006	Thirty samples of Indonesian medicinal plants were tested for their mechanism-based inhibition on cytochrome P450 3A4 (CYP3A4) and CYP2D6 via erythromycin N-demethylation and dextromethorphan O-demethylation activities in human liver microsomes.	Erythromycin	142-154	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	131-137
16446155-3	2006	Here we used whole-cell patch-clamp recording at 37 degrees C from heterologously expressed HERG channels in a mammalian cell line to show that erythromycin either produces a rapid open-state-dependent HERG channel inhibition, or components of both open-state-dependent and closed-state-dependent inhibition.	Erythromycin	144-156	potassium voltage-gated channel subfamily H member 2	Homo sapiens	202-206
16525545-4	2006	An understanding of the chirality at C-9 was expected to throw light on the mechanism of acid-catalysed degradation of erythromycin A, a subject that has been debated in the literature over several decades.	Erythromycin	119-133	complement C9	Homo sapiens	37-40
16446155-0	2006	Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652.	Erythromycin	0-12	potassium voltage-gated channel subfamily H member 2	Homo sapiens	26-30
16446155-3	2006	Here we used whole-cell patch-clamp recording at 37 degrees C from heterologously expressed HERG channels in a mammalian cell line to show that erythromycin either produces a rapid open-state-dependent HERG channel inhibition, or components of both open-state-dependent and closed-state-dependent inhibition.	Erythromycin	144-156	potassium voltage-gated channel subfamily H member 2	Homo sapiens	92-96
16531413-11	2006	Alanine replacements for each of the potentially important amino acid residues in the perimembranous segments revealed that residues Gly36, Pro103, Leu109, and Phe332 were responsible for the selective negative impact on motilin biological activity, while responding normally to erythromycin.	Erythromycin	279-291	motilin	Homo sapiens	221-228
16455803-0	2006	Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.	Erythromycin	13-25	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	92-106
16455803-1	2006	A pharmacokinetic interaction between erythromycin and ximelagatran, an oral direct thrombin inhibitor, was demonstrated in this study in healthy volunteers.	Erythromycin	38-50	coagulation factor II	Rattus norvegicus	84-92
16455803-2	2006	To investigate possible interaction mechanisms, the effects of erythromycin on active transport mediated by P-glycoprotein (P-gp) in vitro in Caco-2 and P-gp-over-expressing Madin-Darby canine kidney-human multidrug resistance-1 cell preparations and on biliary excretion of melagatran in rats were studied.	Erythromycin	63-75	PGP	Canis lupus familiaris	108-122
16455803-2	2006	To investigate possible interaction mechanisms, the effects of erythromycin on active transport mediated by P-glycoprotein (P-gp) in vitro in Caco-2 and P-gp-over-expressing Madin-Darby canine kidney-human multidrug resistance-1 cell preparations and on biliary excretion of melagatran in rats were studied.	Erythromycin	63-75	PGP	Canis lupus familiaris	124-128
16455803-7	2006	Erythromycin inhibited P-gp-mediated transport of both ximelagatran and melagatran in vitro and decreased the biliary excretion of melagatran in the rat.	Erythromycin	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	23-27
16455803-8	2006	These results indicate that the mechanism of the pharmacokinetic interaction between oral ximelagatran and erythromycin may involve inhibition of transport proteins, possibly P-gp, resulting in decreased melagatran biliary excretion and increased bioavailability of melagatran.	Erythromycin	107-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	175-179
16223937-16	2005	The single erythromycin-resistant isolate harboured msr(A/B) genes conferring the M resistance phenotype.	Erythromycin	11-23	ABC transporter permease protein	Staphylococcus aureus	52-59
16416302-3	2006	METHODS: The in vitro kinetic constants of CYP3A inactivation (K (I) and k (inact)) were estimated by varying the time of pre-incubation and the concentration of troleandomycin, erythromycin, clarithromycin, roxithromycin or azithromycin.	Erythromycin	178-190	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
17340992-0	2006	[The frequency of the occurrence of genes ermA, ermB, ermC and msrA/B among methicillin-resistant Staphylococcus aureus strains resistant to erythromycin].	Erythromycin	141-153	ErmC	Staphylococcus aureus	54-58
17340992-0	2006	[The frequency of the occurrence of genes ermA, ermB, ermC and msrA/B among methicillin-resistant Staphylococcus aureus strains resistant to erythromycin].	Erythromycin	141-153	ABC transporter permease protein	Staphylococcus aureus	63-67
17340994-0	2006	[MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].	Erythromycin	45-57	solute carrier family 9 member A6	Homo sapiens	68-72
16454691-9	2006	Erythromycin, midazolam and cortisol are commonly used to monitor in vivo hepatic CYP3A activity.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87
16231067-7	2005	Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues.	Erythromycin	0-12	intercellular adhesion molecule 1	Rattus norvegicus	102-108
16305291-6	2005	MEASUREMENTS AND MAIN RESULTS: Hepatic CYP3A4 activity was measured by using the erythromycin breath test on days 1 (baseline) and 15.	Erythromycin	81-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	39-45
16231067-8	2005	The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment.	Erythromycin	192-204	transforming growth factor, beta 1	Rattus norvegicus	36-41
16231067-8	2005	The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment.	Erythromycin	192-204	transforming growth factor, beta 1	Rattus norvegicus	57-66
16268908-0	2005	The effects of erythromycin on the viability and the secretion of TNF-alpha and TGF-beta1 and expression of connexin43 by human pleural mesothelial cells.	Erythromycin	15-27	tumor necrosis factor	Homo sapiens	66-75
16268908-0	2005	The effects of erythromycin on the viability and the secretion of TNF-alpha and TGF-beta1 and expression of connexin43 by human pleural mesothelial cells.	Erythromycin	15-27	transforming growth factor beta 1	Homo sapiens	80-89
16268908-7	2005	The secretion of both TNF-alpha and TGF-beta(1) by HMPC increased significantly when they were incubated with 100 mg/L erythromycin for 3 or 5 days.	Erythromycin	119-131	tumor necrosis factor	Homo sapiens	22-31
16268908-7	2005	The secretion of both TNF-alpha and TGF-beta(1) by HMPC increased significantly when they were incubated with 100 mg/L erythromycin for 3 or 5 days.	Erythromycin	119-131	transforming growth factor beta 1	Homo sapiens	36-47
16268908-8	2005	The levels of connexin43 in HPMC decreased after incubation with 100 mg/L erythromycin and no relationship was observed between the levels and incubation time.	Erythromycin	74-86	gap junction protein alpha 1	Homo sapiens	14-24
16268908-9	2005	CONCLUSIONS: Erythromycin injures HPMC in a dose- and time-dependent manner and results in the secretion of TNF-alpha and TGF-beta(1).	Erythromycin	13-25	tumor necrosis factor	Homo sapiens	108-117
16268908-9	2005	CONCLUSIONS: Erythromycin injures HPMC in a dose- and time-dependent manner and results in the secretion of TNF-alpha and TGF-beta(1).	Erythromycin	13-25	transforming growth factor beta 1	Homo sapiens	122-133
16268908-11	2005	Furthermore, erythromycin decreased the levels of connexin43 in HPMC, which could possibly affect the response of HPMC to pleurodesis with erythromycin.	Erythromycin	13-25	gap junction protein alpha 1	Homo sapiens	50-60
16268908-11	2005	Furthermore, erythromycin decreased the levels of connexin43 in HPMC, which could possibly affect the response of HPMC to pleurodesis with erythromycin.	Erythromycin	139-151	gap junction protein alpha 1	Homo sapiens	50-60
16185302-4	2005	Drugs acting at motilin (erythromycin) and cholecystokinin-1 (dexloxiglumide) receptors accelerate gastric emptying.	Erythromycin	25-37	motilin	Homo sapiens	16-23
16148051-8	2005	The production of mRNA and protein of human beta-defensin-1 and human beta-defensin-2 was significantly increased by erythromycin.	Erythromycin	117-129	defensin beta 1	Homo sapiens	44-59
16148051-8	2005	The production of mRNA and protein of human beta-defensin-1 and human beta-defensin-2 was significantly increased by erythromycin.	Erythromycin	117-129	defensin beta 4B	Homo sapiens	70-85
16126782-0	2005	Development of a real-time PCR assay on the Roche Light-Cycler for the detection of erm and mef erythromycin resistance genes in beta-haemolytic streptococci.	Erythromycin	96-108	E74 like ETS transcription factor 4	Homo sapiens	92-95
16086867-0	2005	[Correlation of HERG K+ channel protein expression to chemosensitivity of tumor cells to doxorubicin and its modulation by erythromycin].	Erythromycin	123-135	potassium voltage-gated channel subfamily H member 2	Homo sapiens	16-20
15997121-1	2005	Erythromycin, an antibiotic agent, is known to be a motilin receptor agonist.	Erythromycin	0-12	motilin	Homo sapiens	52-59
15812674-0	2005	HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.	Erythromycin	90-102	potassium voltage-gated channel subfamily H member 2	Homo sapiens	0-4
15812674-10	2005	Erythromycin, a HERG K+ channel blocker, suppressed the growth of various cancer cells and the potency was correlated with HERG expression levels.	Erythromycin	0-12	potassium voltage-gated channel subfamily H member 2	Homo sapiens	16-20
15812674-10	2005	Erythromycin, a HERG K+ channel blocker, suppressed the growth of various cancer cells and the potency was correlated with HERG expression levels.	Erythromycin	0-12	potassium voltage-gated channel subfamily H member 2	Homo sapiens	123-127
15812674-13	2005	There were synergistic effects between erythromycin and vincristine, paclitaxel, and hydroxy-camptothecin, and chemosensitivity was correlated with HERG expression level.	Erythromycin	39-51	potassium voltage-gated channel subfamily H member 2	Homo sapiens	148-152
16007523-2	2005	Like erythromycin, it may interact with other drugs by interfering with metabolism by cytochrome P450 enzymes and with the P-glycoprotein transporter system.	Erythromycin	5-17	ATP binding cassette subfamily B member 1	Homo sapiens	123-137
16051125-4	2005	RESULTS: Erythromycin (100 micromol/L) produced no block of I(hERG) at 22 degrees C but produced significant block at 37 degrees C. Extent of block of I(hERG) increased linearly (r = 0.46, P &lt; .01) as temperature increased between 36 degrees C and 42 degrees C. To assess physiologic relevance, action potential duration (APD) was recorded at temperatures between 36 degrees C and 42 degrees C in neonatal ventricular myocytes.	Erythromycin	9-21	ETS transcription factor ERG	Homo sapiens	153-157
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	24-36	ETS transcription factor ERG	Homo sapiens	55-59
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	24-36	potassium voltage-gated channel subfamily H member 2	Homo sapiens	122-127
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	24-36	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	24-36	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	24-36	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	potassium voltage-gated channel subfamily H member 2	Homo sapiens	122-127
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	potassium voltage-gated channel subfamily H member 2	Homo sapiens	122-127
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	ETS transcription factor ERG	Homo sapiens	160-164
16051125-6	2005	Under these conditions, erythromycin rapidly blocked I(hERG) even at 22 degrees C. The F656C mutation in the distal S6 of KCNH2 completely abrogated block of I(hERG) measured at 37 degrees C. CONCLUSION: Progressively greater block of hERG and prolongation of APD by erythromycin was observed at temperatures between 36 and 42 degrees C. Temperature-dependent block of I(hERG) is explained by temperature-dependent access of erythromycin to the intracellular binding site at F656.	Erythromycin	267-279	ETS transcription factor ERG	Homo sapiens	160-164
15997121-6	2005	After a single oral administration, erythromycin caused a significant increase in plasma gastrin-like immunoreactive substance (IS) levels at 60 min.	Erythromycin	36-48	gastrin	Homo sapiens	89-96
15997121-11	2005	The plasma motilin-IS levels were increased after 1 week of oral administration of erythromycin compared with preadministration.	Erythromycin	83-95	motilin	Homo sapiens	11-18
15997121-12	2005	These results suggest that the pharmacologic effects of erythromycin in promoting gastric emptying are closely related to changes in plasma motilin-IS levels.	Erythromycin	56-68	motilin	Homo sapiens	140-147
16037621-0	2005	Effect of erythromycin on homocysteine-induced extracellular matrix metalloproteinase-2 production in cultured rat vascular smooth muscle cells.	Erythromycin	10-22	matrix metallopeptidase 2	Rattus norvegicus	61-87
15983224-0	2005	Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.	Erythromycin	0-12	glucagon	Homo sapiens	65-88
15983224-14	2005	However, when erythromycin was added to GLP-1, insulin concentrations were similar to those in placebo experiments.	Erythromycin	14-26	insulin	Homo sapiens	47-54
15983224-15	2005	The suppression of meal-related increments in glucagon secretion by GLP-1 was reversed by erythromycin (P &lt; 0.001).	Erythromycin	90-102	glucagon	Homo sapiens	68-73
15983224-19	2005	Intravenous erythromycin counteracts the deceleration of gastric emptying caused by GLP-1, probably by interacting with the parasympathetic nervous system (pancreatic polypeptide responses).	Erythromycin	12-24	glucagon	Homo sapiens	84-89
15917522-10	2005	All but one of these clindamycin-susceptible, erythromycin-resistant ST-8 strains showed no induction of clindamycin resistance.	Erythromycin	46-58	Oncogene OVC (ovarian adenocarcinoma oncogene)	Homo sapiens	69-73
15940460-9	2005	Treatment with both doses of erythromycin significantly reduced the gastric t1/2: 70 mg, 98 min (IQR 88-112); 200 mg, 86 min (75-104); vs. placebo, 122 min (102-190) (p&lt;0.05).	Erythromycin	29-41	interleukin 1 receptor like 1	Homo sapiens	76-84
16037621-10	2005	The findings of the present study suggested that the beneficial effect of erythromycin on vascular disease processes might be due to its inhibitory effect on the Hcyinduced production of MMP-2 in VSMCs.	Erythromycin	74-86	matrix metallopeptidase 2	Rattus norvegicus	187-192
16037621-3	2005	In the present study we investigated the effects of erythromycin on the production of homocysteineinduced extracellular matrix metalloproteinase-2 (MMP-2) in cultured rat vascular smooth muscle cells (VSMCs).	Erythromycin	52-64	matrix metallopeptidase 2	Rattus norvegicus	120-146
16037621-3	2005	In the present study we investigated the effects of erythromycin on the production of homocysteineinduced extracellular matrix metalloproteinase-2 (MMP-2) in cultured rat vascular smooth muscle cells (VSMCs).	Erythromycin	52-64	matrix metallopeptidase 2	Rattus norvegicus	148-153
16037621-7	2005	Increased production of MMP-2 induced by homocysteine was reduced by extracellularly added erythromycin in a dose-dependent manner.	Erythromycin	91-103	matrix metallopeptidase 2	Rattus norvegicus	24-29
16037621-9	2005	Extracellularly added erythromycin decreased homocysteine-induced MMP-2 secretion.	Erythromycin	22-34	matrix metallopeptidase 2	Rattus norvegicus	66-71
15885263-8	2005	Administration of either azithromycin or erythromycin at different dosage (10, 20 and 40 mg/kg orally, daily for 5 consecutive days) significantly (P &lt; 0.05) reduced the colonic damage, MPO and NOS activities as well as TNFalpha level.	Erythromycin	41-53	myeloperoxidase	Rattus norvegicus	189-192
15885263-8	2005	Administration of either azithromycin or erythromycin at different dosage (10, 20 and 40 mg/kg orally, daily for 5 consecutive days) significantly (P &lt; 0.05) reduced the colonic damage, MPO and NOS activities as well as TNFalpha level.	Erythromycin	41-53	tumor necrosis factor	Rattus norvegicus	223-231
15708966-0	2005	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver.	Erythromycin	92-104	solute carrier family 22 member 7	Homo sapiens	24-51
15845683-9	2005	Concomitant use of both fluvoxamine and a CYP3A4 inhibitor such as erythromycin can further increase plasma lidocaine concentrations by decreasing its clearance.	Erythromycin	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-48
15845683-2	2005	We studied the effect of coadministration of the antidepressant fluvoxamine (CYP1A2 inhibitor) and antimicrobial drug erythromycin (CYP3A4 inhibitor) on lidocaine pharmacokinetics in a double-blind, randomized, three-way crossover study.	Erythromycin	118-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
15911369-1	2005	In this issue of Chemistry &amp; Biology, Francisco Malpartida and colleagues [1] report the formation of novel polyene amide derivatives upon transformation of the producer strain with SCP2*-derived vectors carrying the erythromycin resistance gene ermE.	Erythromycin	221-233	sterol carrier protein 2	Homo sapiens	186-190
15708966-3	2005	The purpose of this study was to investigate the interaction of theophylline with erythromycin mediated by hOat2 using a Xenopus laevis oocyte expression system.	Erythromycin	82-94	solute carrier family 22 member 7	Homo sapiens	107-112
15708966-4	2005	When expressed in Xenopus oocytes, hOat2 mediated the transport of theophylline and erythromycin.	Erythromycin	84-96	solute carrier family 22 member 7	Homo sapiens	35-40
15708966-6	2005	The apparent K(m) values for the uptake of hOat2 that mediated the transport of theophylline and erythromycin were 12.6 muM and 18.5 muM, respectively.	Erythromycin	97-109	solute carrier family 22 member 7	Homo sapiens	43-48
15708966-6	2005	The apparent K(m) values for the uptake of hOat2 that mediated the transport of theophylline and erythromycin were 12.6 muM and 18.5 muM, respectively.	Erythromycin	97-109	latexin	Homo sapiens	120-123
15708966-6	2005	The apparent K(m) values for the uptake of hOat2 that mediated the transport of theophylline and erythromycin were 12.6 muM and 18.5 muM, respectively.	Erythromycin	97-109	latexin	Homo sapiens	133-136
15708966-7	2005	The hOat2-mediated uptake of [(14)C]theophylline and [(14)C]erythromycin was cis-inhibited by adding erythromycin and theophylline, respectively.	Erythromycin	60-72	solute carrier family 22 member 7	Homo sapiens	4-9
15708966-8	2005	Our present findings suggest that hOat2 may, at least in part, be involved in the theophylline-erythromycin interaction in the human liver.	Erythromycin	95-107	solute carrier family 22 member 7	Homo sapiens	34-39
16012077-4	2005	The formation of 4-hydroxyestazolam from estazolam in pooled human liver microsomes was significantly inhibited by itraconazole and erythromycin, specific CYP3A4 inhibitors, in a dose-dependent manner, with IC50 values of 1.1 and 12.8 microM, respectively.	Erythromycin	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
15665859-6	2005	Erythromycin pretreatment also prevented lung P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA upregulation in response to airway challenge with LPS.	Erythromycin	0-12	vascular cell adhesion molecule 1	Rattus norvegicus	117-150
15974925-4	2005	The relative levels of Abeta peptide levels were reduced after exposure of mice to paroxetine (N=5), NAC (N=7), and erythromycin (N=7) relative to matched placebo counterparts.	Erythromycin	116-128	amyloid beta (A4) precursor protein	Mus musculus	23-28
15726980-4	2005	PCR and sequence analysis revealed the presence of an ermC gene in 2 of the 25 Micrococcaceae strains investigated for their resistance to erythromycin and/or spiramycin.	Erythromycin	139-151	ErmC	Staphylococcus aureus	54-58
15665859-5	2005	Erythromycin pretreatment (30 mg kg(-1) day(-1) for 1 week) reduced the lipopolysaccharide (LPS; intratracheal, 0.4 mg kg(-1))-induced increase in neutrophil count and elastase activity in the bronchoalveolar lavage fluid (BALF) and lung tissue myeloperoxidase activity, but failed to decrease tumor necrosis factor-alpha and macrophage-inflammatory protein-2 augmented levels in BALF.	Erythromycin	0-12	tumor necrosis factor	Rattus norvegicus	294-321
16061006-0	2005	[Effects of erythromycin on hydrogen peroxide-induced interleukin-8 synthesis and regulation of glutathione in human bronchial epithelial cells].	Erythromycin	12-24	C-X-C motif chemokine ligand 8	Homo sapiens	54-67
16061006-1	2005	OBJECTIVE: To study the effects of erythromycin on Hydrogen peroxide (H2O2)-induced interleukin-8 synthesis and regulation of glutathione in human bronchial epithelial cells.	Erythromycin	35-47	C-X-C motif chemokine ligand 8	Homo sapiens	84-97
16061006-8	2005	CONCLUSION: Erythromycin inhibits oxidant-mediated IL-8 levels through down-regulation of NF-kB and AP-1 binding in HBE, which can further influence the synthesis of GSH and expression gamma-GCS in HBE.	Erythromycin	12-24	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
16061006-8	2005	CONCLUSION: Erythromycin inhibits oxidant-mediated IL-8 levels through down-regulation of NF-kB and AP-1 binding in HBE, which can further influence the synthesis of GSH and expression gamma-GCS in HBE.	Erythromycin	12-24	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-104
15755792-5	2005	Articles providing descriptions of pharmacology, safety, and effectiveness of metoclopramide and erythromycin for the treatment of gastroesophageal reflux (GER) were also used in this review.	Erythromycin	97-109	GER	Homo sapiens	156-159
15665859-5	2005	Erythromycin pretreatment (30 mg kg(-1) day(-1) for 1 week) reduced the lipopolysaccharide (LPS; intratracheal, 0.4 mg kg(-1))-induced increase in neutrophil count and elastase activity in the bronchoalveolar lavage fluid (BALF) and lung tissue myeloperoxidase activity, but failed to decrease tumor necrosis factor-alpha and macrophage-inflammatory protein-2 augmented levels in BALF.	Erythromycin	0-12	C-X-C motif chemokine ligand 2	Rattus norvegicus	326-359
15665859-6	2005	Erythromycin pretreatment also prevented lung P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA upregulation in response to airway challenge with LPS.	Erythromycin	0-12	vascular cell adhesion molecule 1	Rattus norvegicus	152-158
15665859-6	2005	Erythromycin pretreatment also prevented lung P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA upregulation in response to airway challenge with LPS.	Erythromycin	0-12	selectin P	Rattus norvegicus	46-56
15665859-13	2005	Immunohistochemical analysis showed that LPS exposure of the mesentery for 4 h caused a significant enhancement in P-selectin, E-selectin, ICAM-1 and VCAM-1 expression that was downregulated by erythromycin pretreatment.	Erythromycin	194-206	selectin P	Rattus norvegicus	115-125
15665859-6	2005	Erythromycin pretreatment also prevented lung P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA upregulation in response to airway challenge with LPS.	Erythromycin	0-12	selectin E	Rattus norvegicus	58-68
15665859-13	2005	Immunohistochemical analysis showed that LPS exposure of the mesentery for 4 h caused a significant enhancement in P-selectin, E-selectin, ICAM-1 and VCAM-1 expression that was downregulated by erythromycin pretreatment.	Erythromycin	194-206	selectin E	Rattus norvegicus	127-137
15665859-6	2005	Erythromycin pretreatment also prevented lung P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA upregulation in response to airway challenge with LPS.	Erythromycin	0-12	intercellular adhesion molecule 1	Rattus norvegicus	70-103
15665859-13	2005	Immunohistochemical analysis showed that LPS exposure of the mesentery for 4 h caused a significant enhancement in P-selectin, E-selectin, ICAM-1 and VCAM-1 expression that was downregulated by erythromycin pretreatment.	Erythromycin	194-206	intercellular adhesion molecule 1	Rattus norvegicus	139-145
15665859-6	2005	Erythromycin pretreatment also prevented lung P-selectin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) mRNA upregulation in response to airway challenge with LPS.	Erythromycin	0-12	intercellular adhesion molecule 1	Rattus norvegicus	105-111
15665859-13	2005	Immunohistochemical analysis showed that LPS exposure of the mesentery for 4 h caused a significant enhancement in P-selectin, E-selectin, ICAM-1 and VCAM-1 expression that was downregulated by erythromycin pretreatment.	Erythromycin	194-206	vascular cell adhesion molecule 1	Rattus norvegicus	150-156
15665859-15	2005	Flow cytometry analysis indicated that erythromycin pretreatment inhibited LPS-induced CD11b augmented expression in rat neutrophils.	Erythromycin	39-51	integrin subunit alpha M	Rattus norvegicus	87-92
15665859-17	2005	In conclusion, erythromycin inhibits leukocyte recruitment in the lung and this effect appears mediated through downregulation of CAM expression.	Erythromycin	15-27	calmodulin 1	Rattus norvegicus	130-133
16163420-12	2005	In the presence of allergy to or treatment failure with betalactam drugs and/or positive serology for Mycoplasma, Chlamydia or Legionella sp it is recommended to add: erythromycin 500 mg QID, IV or oral, oral clarithromycin 500 mg BID, or oral azythromycin 500 mg once a day.	Erythromycin	167-179	BH3 interacting domain death agonist	Homo sapiens	231-234
15466163-11	2005	These agents exhibited dose-dependent decreases in CYP3A4 activity with IC(50) values of 0.3 microM for ketoconazole, 108 microM for erythromycin, and 15.5 microg/ml for kava.	Erythromycin	133-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
15599502-6	2005	When quetiapine is co-administered with CYP3A inhibitors such as erythromycin, the dosing regimen should be modified according to quetiapine TDM.	Erythromycin	65-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-45
15464990-0	2004	The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis.	Erythromycin	39-51	negative elongation factor complex member C/D	Homo sapiens	55-58
16217857-13	2005	The maximum concentrations found in influents of a STP was 470 ng/L for estriol and 1200 ng/L for erythromycin.	Erythromycin	98-110	thyroid hormone receptor interactor 10	Homo sapiens	51-54
15383492-7	2004	CYP3A5-catalyzed erythromycin N-demethylation, total flunitrazepam hydroxylation, testosterone 6beta-hydroxylation, and terfenadine alcohol formation occurred with an intrinsic clearance that was less than 65% that of CYP3A4.	Erythromycin	17-29	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
15383492-7	2004	CYP3A5-catalyzed erythromycin N-demethylation, total flunitrazepam hydroxylation, testosterone 6beta-hydroxylation, and terfenadine alcohol formation occurred with an intrinsic clearance that was less than 65% that of CYP3A4.	Erythromycin	17-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	218-224
15342469-3	2004	An extract of Schisandra fruit has been shown with a potent inhibitory effect on human liver microsomal erythromycin N-demethylation activity mediated by cytochrome P450 3A4 (CYP3A4).	Erythromycin	104-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-173
15342469-3	2004	An extract of Schisandra fruit has been shown with a potent inhibitory effect on human liver microsomal erythromycin N-demethylation activity mediated by cytochrome P450 3A4 (CYP3A4).	Erythromycin	104-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-181
15638086-4	2004	There was a statistically significant (p &lt; 0.05) increase in serum BSP levels with CYP3A and P-gp substrates and/or inhibitors, cyclosporine-A, nitrendipine, quinidine, indinavir, daxorubicin, etoposide and erythromycin by 27%, 35%, 32%, 12%, 5%, 22%, and 106%, respectively.	Erythromycin	210-222	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	86-91
15543082-1	2004	The purpose of this study was to determine the interactions of erythromycin and various fluoroquinolones with P-glycoprotein (P-gp) and in turn assess their effects on transport kinetics across a model cell monolayer.	Erythromycin	63-75	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
15543082-1	2004	The purpose of this study was to determine the interactions of erythromycin and various fluoroquinolones with P-glycoprotein (P-gp) and in turn assess their effects on transport kinetics across a model cell monolayer.	Erythromycin	63-75	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
15543082-4	2004	Transport of erythromycin was then studied with P-gp saturable concentrations of fluoroquinolones.	Erythromycin	13-25	ATP binding cassette subfamily B member 1	Homo sapiens	48-52
15353245-6	2004	pharmacokinetics was assessed in controls and in rats pre-treated with erythromycin (100 mg/kg) as a P-glycoprotein inhibitor.	Erythromycin	71-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	101-115
15377640-8	2004	However, when CYP3A4 and CYP3A5 were incubated simultaneously with erythromycin, both enzymes appeared to contribute to the formation of a MI complex.	Erythromycin	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
15286055-11	2004	Our results suggest that CMPF can directly inhibit the uptake of Ery by inhibiting Oatp2, whereas IS is more likely to inhibit the enzymatic metabolism of Ery.	Erythromycin	65-68	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	83-88
15389671-0	2004	TNF alpha measurement in rat and human whole blood as an in vitro method to assay pyrogens and its inhibition by dexamethasone and erythromycin.	Erythromycin	131-143	tumor necrosis factor	Rattus norvegicus	0-9
15377640-1	2004	The objectives of this study were to characterize and compare the reversible inhibition and time-dependent inactivation of cytochromes P450 3A4 and 3A5 (CYP3A4 and CYP3A5) by erythromycin, diltiazem, and nicardipine.	Erythromycin	175-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	153-159
15377640-8	2004	However, when CYP3A4 and CYP3A5 were incubated simultaneously with erythromycin, both enzymes appeared to contribute to the formation of a MI complex.	Erythromycin	67-79	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	25-31
15377640-1	2004	The objectives of this study were to characterize and compare the reversible inhibition and time-dependent inactivation of cytochromes P450 3A4 and 3A5 (CYP3A4 and CYP3A5) by erythromycin, diltiazem, and nicardipine.	Erythromycin	175-187	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	164-170
15377640-9	2004	Additional experiments revealed that erythromycin caused a comparable type I spectral change when bound to CYP3A5 and CYP3A4 (Ks=48 microM and 52 microM, respectively).	Erythromycin	37-49	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	107-113
15377640-9	2004	Additional experiments revealed that erythromycin caused a comparable type I spectral change when bound to CYP3A5 and CYP3A4 (Ks=48 microM and 52 microM, respectively).	Erythromycin	37-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
15377640-11	2004	In conclusion, erythromycin, diltiazem, and nicardipine were weaker inhibitors of CYP3A5 and inactivated the enzyme at a slower rate than their respective effects on CYP3A4.	Erythromycin	15-27	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	82-88
15465268-5	2004	In contrast, the proportion of MRSA susceptible to erythromycin progressively increased from 7.0% to 32.5% (P &lt; 0.001).	Erythromycin	51-63	solute carrier family 9 member A6	Homo sapiens	31-35
15175422-8	2004	Erythromycin exhibited significant efflux out of MDCK-MDR1 cells, suggesting that erythromycin is a good substrate for P-gp.	Erythromycin	0-12	ATP binding cassette subfamily B member 1	Canis lupus familiaris	49-58
15175422-8	2004	Erythromycin exhibited significant efflux out of MDCK-MDR1 cells, suggesting that erythromycin is a good substrate for P-gp.	Erythromycin	0-12	PGP	Canis lupus familiaris	119-123
15175422-8	2004	Erythromycin exhibited significant efflux out of MDCK-MDR1 cells, suggesting that erythromycin is a good substrate for P-gp.	Erythromycin	82-94	ATP binding cassette subfamily B member 1	Canis lupus familiaris	49-58
15175422-8	2004	Erythromycin exhibited significant efflux out of MDCK-MDR1 cells, suggesting that erythromycin is a good substrate for P-gp.	Erythromycin	82-94	PGP	Canis lupus familiaris	119-123
15175422-15	2004	Thus, P-gp is found to be active in vivo, and it restricts topical erythromycin absorption across the cornea, which can be inhibited by known P-gp inhibitors.	Erythromycin	67-79	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	6-10
15175422-15	2004	Thus, P-gp is found to be active in vivo, and it restricts topical erythromycin absorption across the cornea, which can be inhibited by known P-gp inhibitors.	Erythromycin	67-79	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	142-146
15465268-10	2004	The increase of erythromycin-susceptibility within MRSA was caused by the emergence of clone C. Non-epidemic strains were more frequently susceptible to ofloxacin (31.8% vs. 1.1%) and tobramycin (45.4% vs. 16.8%) than epidemic strains.	Erythromycin	16-28	solute carrier family 9 member A6	Homo sapiens	51-55
15595151-1	2004	A study of medical records found that combining the antibiotic erythromycin with strong inhibitors of the liver enzyme CYP3A increased the risk of sudden death from cardiac causes--probably by abnormally raising the blood levels of erythromycin.	Erythromycin	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-124
15595151-1	2004	A study of medical records found that combining the antibiotic erythromycin with strong inhibitors of the liver enzyme CYP3A increased the risk of sudden death from cardiac causes--probably by abnormally raising the blood levels of erythromycin.	Erythromycin	232-244	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-124
15385083-7	2004	hERG inhibition measured using a 2-s step-pulse protocol underestimated erythromycin potency compared with results obtained with a step-ramp protocol.	Erythromycin	72-84	ETS transcription factor ERG	Homo sapiens	0-4
15364545-6	2004	On the other hand, CYP4F11 was a better catalyst than CYP4F3A for many drugs such as erythromycin, benzphetamine, ethylmorphine, chlorpromazine, and imipramine.	Erythromycin	85-97	cytochrome P450 family 4 subfamily F member 11	Homo sapiens	19-26
15364545-7	2004	Erythromycin was the most efficient substrate for CYP4F11, with a Km of 125 microM and Vmax of 830 pmol min(-1) nmol(-1) P450.	Erythromycin	0-12	cytochrome P450 family 4 subfamily F member 11	Homo sapiens	50-57
15364545-9	2004	The model of CYP4F11 presents a more open access channel that may explain the ability to metabolize large molecules like erythromycin.	Erythromycin	121-133	cytochrome P450 family 4 subfamily F member 11	Homo sapiens	13-20
15356306-2	2004	Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death.	Erythromycin	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-70
15356306-2	2004	Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death.	Erythromycin	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
15356306-2	2004	Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death.	Erythromycin	8-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-148
15356306-2	2004	Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death.	Erythromycin	169-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-70
15356306-2	2004	Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death.	Erythromycin	169-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
15356306-2	2004	Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death.	Erythromycin	169-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-148
15184586-1	2004	The hyaluronate lyase (HL) gene of Staphylococcus aureus 8325-4 (hysA) was inactivated in vitro with the insertion of the erythromycin determinant, ermC, from plasmid pE194.	Erythromycin	122-134	AT695_RS06415	Staphylococcus aureus	4-21
15476327-11	2004	TGF-beta1 may play an important role during the process of airway remodeling, and could be influenced by early drugs intervention such as budesonide and erythromycin, which may imply their potency in the treatment of COPD.	Erythromycin	153-165	transforming growth factor, beta 1	Rattus norvegicus	0-9
15155239-1	2004	We determined the prevalence of erythromycin-resistant bacteria in the oral cavity and identified mef and erm(B) as the most common resistance determinants.	Erythromycin	32-44	E74 like ETS transcription factor 4	Homo sapiens	98-101
16108601-0	2004	[Erythromycin intensifies Toll-like receptor 2 expression on dendritic cells].	Erythromycin	1-13	toll like receptor 2	Homo sapiens	26-46
16108608-0	2004	[Effect of EM201, an in vivo metabolite of erythromycin (EM), on signal transduction of IL-2 receptor].	Erythromycin	43-55	interleukin 2 receptor subunit beta	Homo sapiens	88-102
16108610-0	2004	[Analysis of gene expression of erythromycin-treated, activated human monocytes by employing the Long SAGE method].	Erythromycin	32-44	sarcoma antigen 1	Homo sapiens	102-106
15184586-1	2004	The hyaluronate lyase (HL) gene of Staphylococcus aureus 8325-4 (hysA) was inactivated in vitro with the insertion of the erythromycin determinant, ermC, from plasmid pE194.	Erythromycin	122-134	AT695_RS06415	Staphylococcus aureus	23-25
15184586-1	2004	The hyaluronate lyase (HL) gene of Staphylococcus aureus 8325-4 (hysA) was inactivated in vitro with the insertion of the erythromycin determinant, ermC, from plasmid pE194.	Erythromycin	122-134	ErmC	Staphylococcus aureus	148-152
15006412-0	2004	Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A.	Erythromycin	125-139	gonadotropin releasing hormone 1	Homo sapiens	55-92
15099589-2	2004	Using a modified patch-clamp technique in combination with an ultrafast system for solution exchange we investigated the functional interaction of gentamicin, penicillin G, tetracycline, erythromycin and ceftriaxone with nAChR transiently transfected into HEK293 cells as a potential molecular target.	Erythromycin	187-199	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	221-226
15099589-3	2004	Gentamicin, penicillin G, tetracycline and erythromycin induced a combination of open channel and competitive block of nAChR channel currents whereas ceftriaxone had no effect.	Erythromycin	43-55	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	119-124
15370956-5	2004	Midazolam metabolism was also inhibited in vitro by typical chemical inhibitors of CYP3A, such as ketoconazole, erythromycin and diltiazem, and the apparent K(i) values for ketoconazole, erythromycin and diltiazem were 0.127, 94.2 and 29.6 microM, respectively.	Erythromycin	112-124	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-88
15370957-7	2004	Ketoconazole and erythromycin, typical CYP3A inhibitors, demonstrated extensive inhibition of midazolam metabolism in DEX-treated female rat liver microsomes, and the apparent K(i) values were 0.088 and 91.2 microM, respectively.	Erythromycin	17-29	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	39-44
15499175-2	2004	In untreated and olive oil-treated (control) rats, hepatic CYP3A activities evaluated by erythromycin metabolism in vitro increased several-fold from age 2 to 9 weeks in males.	Erythromycin	89-101	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	59-64
15105108-0	2004	Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation.	Erythromycin	52-64	nuclear factor kappa B subunit 1	Homo sapiens	156-177
15105108-3	2004	To elucidate the molecular mechanisms of its action, we studied here the effects of erythromycin (EM) and its new derivative, EM703, which shows no antibacterial action, on the activation of the transcription factor nuclear factor-kappaB (NF-kappaB) in human bronchial epithelial cells.	Erythromycin	84-96	nuclear factor kappa B subunit 1	Homo sapiens	216-237
14551160-7	2004	On the other hand, pretreatment of TNF-alpha-stimulated A549 cells by erythromycin, clarithromycin, azithromycin, or dexamethasone, but not josamycin, decreased the neutrophil survival-enhancing effects in a dose-dependent manner.	Erythromycin	70-82	tumor necrosis factor	Homo sapiens	35-44
14551160-9	2004	Erythromycin, clarithromycin, azithromycin, and dexamethasone inhibited TNF-alpha-induced GM-CSF expression in A549 cells at both the protein and messenger RNA levels.	Erythromycin	0-12	tumor necrosis factor	Homo sapiens	72-81
14551160-9	2004	Erythromycin, clarithromycin, azithromycin, and dexamethasone inhibited TNF-alpha-induced GM-CSF expression in A549 cells at both the protein and messenger RNA levels.	Erythromycin	0-12	colony stimulating factor 2	Homo sapiens	90-96
15006412-0	2004	Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A.	Erythromycin	125-139	gonadotropin releasing hormone 1	Homo sapiens	94-98
15006412-1	2004	Antibacterial SAR for a series of macrolides derived from erythromycin A that are potent LHRH antagonists was developed in an attempt to eliminate the antibiotic activities of these compounds.	Erythromycin	58-72	sarcosine dehydrogenase	Homo sapiens	14-17
15006412-1	2004	Antibacterial SAR for a series of macrolides derived from erythromycin A that are potent LHRH antagonists was developed in an attempt to eliminate the antibiotic activities of these compounds.	Erythromycin	58-72	gonadotropin releasing hormone 1	Homo sapiens	89-93
15058617-4	2004	RESULTS: The antibiotics erythromycin and clarithromycin are potent inhibitors of CYP3A4 and can increase blood levels and toxicity of CYP3A4 substrates.	Erythromycin	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-141
15129974-6	2004	In weakly alkaline conditions, hydroxide ion appeared to catalyze the hydrolysis of the lactonyl ester bond of erythromycin A-6,9-hemiketal by the pseudo-first-order kinetics, and the C13 --&gt; C11 translactonization and internal dehydration reactions subsequently occurred to form pseudoerythromycin A enol ether.	Erythromycin	111-125	homeobox C13	Homo sapiens	184-187
15129974-6	2004	In weakly alkaline conditions, hydroxide ion appeared to catalyze the hydrolysis of the lactonyl ester bond of erythromycin A-6,9-hemiketal by the pseudo-first-order kinetics, and the C13 --&gt; C11 translactonization and internal dehydration reactions subsequently occurred to form pseudoerythromycin A enol ether.	Erythromycin	111-125	RNA polymerase III subunit K	Homo sapiens	195-198
15006778-6	2004	Furthermore, all tet(M)-containing enterococci also harbored a member of the Tn916-Tn1545 conjugative transposon family, of which 12 erythromycin-resistant isolates also contained the erm(B) gene.	Erythromycin	133-145	erythromycin resistance protein	Enterococcus faecalis	184-190
15058617-4	2004	RESULTS: The antibiotics erythromycin and clarithromycin are potent inhibitors of CYP3A4 and can increase blood levels and toxicity of CYP3A4 substrates.	Erythromycin	25-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
14994385-0	2004	Erythromycin suppresses the expression of cyclooxygenase-2 in rheumatoid synovial cells.	Erythromycin	0-12	prostaglandin-endoperoxide synthase 2	Homo sapiens	42-58
14994385-1	2004	OBJECTIVE: To investigate whether erythromycin (EM) can suppress the expression of cyclooxygenase-2 (COX-2) in rheumatoid synovial cells, and determine the mechanisms involved.	Erythromycin	34-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-99
14994385-1	2004	OBJECTIVE: To investigate whether erythromycin (EM) can suppress the expression of cyclooxygenase-2 (COX-2) in rheumatoid synovial cells, and determine the mechanisms involved.	Erythromycin	34-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	101-106
14994385-1	2004	OBJECTIVE: To investigate whether erythromycin (EM) can suppress the expression of cyclooxygenase-2 (COX-2) in rheumatoid synovial cells, and determine the mechanisms involved.	Erythromycin	48-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	83-99
14994385-1	2004	OBJECTIVE: To investigate whether erythromycin (EM) can suppress the expression of cyclooxygenase-2 (COX-2) in rheumatoid synovial cells, and determine the mechanisms involved.	Erythromycin	48-50	prostaglandin-endoperoxide synthase 2	Homo sapiens	101-106
14971889-0	2004	Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues.	Erythromycin	74-88	gonadotropin releasing hormone 1	Rattus norvegicus	11-48
14709940-5	2004	CYP3A4 activity was evaluated for each subject at baseline and following each antidepressant using the erythromycin breath test (EBT) and by the pharmacokinetics of alprazolam (ALPZ) after 2-mg dose of oral ALPZ.	Erythromycin	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
14729754-0	2004	Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis.	Erythromycin	18-30	intercellular adhesion molecule 1	Homo sapiens	63-69
14729754-7	2004	RESULTS: Despite constitutive expression of ICAM-1 (34%) in HUVEC, 6250 mg/L of dicloxacillin or erythromycin significantly increased the number of cells with ICAM-1 expression by 37% and 30%, respectively.	Erythromycin	97-109	intercellular adhesion molecule 1	Homo sapiens	44-50
14729754-7	2004	RESULTS: Despite constitutive expression of ICAM-1 (34%) in HUVEC, 6250 mg/L of dicloxacillin or erythromycin significantly increased the number of cells with ICAM-1 expression by 37% and 30%, respectively.	Erythromycin	97-109	intercellular adhesion molecule 1	Homo sapiens	159-165
14678339-7	2004	This included estimates of CYP3A4 function in each patient using the erythromycin breath test (1/tmax).	Erythromycin	69-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-33
15287700-2	2004	The selectivity of the methylation of the C-6 OH group is studied on erythromycin A derivatives.	Erythromycin	69-83	complement C6	Homo sapiens	42-45
14707025-5	2004	The erythromycin breath test was used to measure CYP3A4 activity in vivo in 25 of the healthy volunteers.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
14656655-0	2004	Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.	Erythromycin	0-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	96-105
15621665-3	2004	In the presence of digoxin, secretory transport of vinblastine and erythromycin, substrates for both Pgp and cytochrome P450 3A4 (CYP3A4), was significantly reduced, whereas absorptive transport was unaffected.	Erythromycin	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	101-104
15621665-3	2004	In the presence of digoxin, secretory transport of vinblastine and erythromycin, substrates for both Pgp and cytochrome P450 3A4 (CYP3A4), was significantly reduced, whereas absorptive transport was unaffected.	Erythromycin	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-128
15621665-3	2004	In the presence of digoxin, secretory transport of vinblastine and erythromycin, substrates for both Pgp and cytochrome P450 3A4 (CYP3A4), was significantly reduced, whereas absorptive transport was unaffected.	Erythromycin	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	130-136
14656655-9	2004	The inhibition of inflammatory osteoclastogenesis by EM treatment was further confirmed by an osteoclast (OC) formation assay using primary cultures of mouse bone marrow progenitor cells stimulated with macrophage colony-stimulating factor and RANK ligand (RANKL).	Erythromycin	53-55	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	244-255
14656655-9	2004	The inhibition of inflammatory osteoclastogenesis by EM treatment was further confirmed by an osteoclast (OC) formation assay using primary cultures of mouse bone marrow progenitor cells stimulated with macrophage colony-stimulating factor and RANK ligand (RANKL).	Erythromycin	53-55	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	257-262
14616411-1	2003	AIMS: The antibiotic erythromycin is a potent inhibitor of cytochrome P450 CYP3A4 metabolism.	Erythromycin	21-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
14616424-9	2003	The CYP3A4 inhibitors ketoconazole and erythromycin increased F to approximately 100% and ketoconazole decreased CL by 67.5%.	Erythromycin	39-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	4-10
15040110-6	2003	After cultured with erythromycin, the expression of Bax protein increased (P &lt; 0.05), but the expression of Bcl-xL and Fas protein had not changed.	Erythromycin	20-32	BCL2 associated X, apoptosis regulator	Homo sapiens	52-55
14674677-0	2003	Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.	Erythromycin	46-58	potassium voltage-gated channel subfamily H member 2	Homo sapiens	85-89
14674677-4	2003	Exposure of cells to erythromycin reduced the HERG encoded potassium current in a concentration dependent manner with an IC50 of 38.9 +/- 1.2 microM and Hill Slope factor of 0.4 +/- 0.1.	Erythromycin	21-33	potassium voltage-gated channel subfamily H member 2	Homo sapiens	46-50
14674677-7	2003	The results of this study document that both erythromycin and clarithromycin significantly inhibit the HERG potassium current at clinically relevant concentrations.	Erythromycin	45-57	potassium voltage-gated channel subfamily H member 2	Homo sapiens	103-107
15040110-6	2003	After cultured with erythromycin, the expression of Bax protein increased (P &lt; 0.05), but the expression of Bcl-xL and Fas protein had not changed.	Erythromycin	20-32	BCL2 like 1	Homo sapiens	111-117
15040110-8	2003	And a possible mechaism which erythromycin promote the apoptosis of eosinophils is increase the expression of Bax.	Erythromycin	30-42	BCL2 associated X, apoptosis regulator	Homo sapiens	110-113
12960287-3	2003	The clinical range of macrolides (i.e., erythromycin, roxithromycin, and clarithromycin) preferentially inhibited nuclear factor-kappaB activation mediated by reactive oxygen intermediates, inducing cAMP-dependent signaling [i.e., cAMP and cAMP-responsive element-binding protein (CREB)] by "primed" but not "resting" leukocytes.	Erythromycin	40-52	cAMP responsive element binding protein 1	Homo sapiens	240-279
14602600-1	2003	The erythromycin resistance gene ermB has been found in a variety of gram-positive bacteria.	Erythromycin	4-16	ermB	Clostridium perfringens	33-37
12960287-3	2003	The clinical range of macrolides (i.e., erythromycin, roxithromycin, and clarithromycin) preferentially inhibited nuclear factor-kappaB activation mediated by reactive oxygen intermediates, inducing cAMP-dependent signaling [i.e., cAMP and cAMP-responsive element-binding protein (CREB)] by "primed" but not "resting" leukocytes.	Erythromycin	40-52	cAMP responsive element binding protein 1	Homo sapiens	281-285
14743973-0	2003	Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats.	Erythromycin	36-48	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	10-24
14743973-1	2003	Effect of P-glycoprotein (P-gp) inhibitors erythromycin (Ery) and cyclosporin A(CsA) on brain pharmacokinetics of nimodipine (NMD) in rats was studied.	Erythromycin	43-55	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	26-30
14743973-1	2003	Effect of P-glycoprotein (P-gp) inhibitors erythromycin (Ery) and cyclosporin A(CsA) on brain pharmacokinetics of nimodipine (NMD) in rats was studied.	Erythromycin	57-60	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	26-30
12909563-0	2003	Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.	Erythromycin	87-99	ATP binding cassette subfamily B member 1	Homo sapiens	49-52
12909563-8	2003	It is concluded that the combined oral and intravenous erythromycin breath and urine test is a reliable and noninvasive test to measure phenotypic intestinal and hepatic CYP3A4 and PGP activity and may be a promising tool for prediction of drug interactions and dose adjustment of many pharmacotherapeutics in clinical practice, e.g., immunosuppressive agents after renal transplantation.	Erythromycin	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176
12829454-5	2003	CAM and erythromycin significantly inhibited spontaneous and tumor necrosis factor-alpha (20 ng/ml)-induced mucus secretion from NCI-H292 cells at 10-6 to 10-7 M and from human nasal epithelial cells at 10-4 to 10-5 M. MUC5AC messenger RNA expression was also significantly inhibited.	Erythromycin	8-20	tumor necrosis factor	Homo sapiens	61-88
12909563-8	2003	It is concluded that the combined oral and intravenous erythromycin breath and urine test is a reliable and noninvasive test to measure phenotypic intestinal and hepatic CYP3A4 and PGP activity and may be a promising tool for prediction of drug interactions and dose adjustment of many pharmacotherapeutics in clinical practice, e.g., immunosuppressive agents after renal transplantation.	Erythromycin	55-67	ATP binding cassette subfamily B member 1	Homo sapiens	181-184
12829454-5	2003	CAM and erythromycin significantly inhibited spontaneous and tumor necrosis factor-alpha (20 ng/ml)-induced mucus secretion from NCI-H292 cells at 10-6 to 10-7 M and from human nasal epithelial cells at 10-4 to 10-5 M. MUC5AC messenger RNA expression was also significantly inhibited.	Erythromycin	8-20	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	219-225
12888595-10	2003	The eight erythromycin-resistant GGS and GCS isolates of this study presented seven unrelated PFGE patterns.	Erythromycin	10-22	sulfatase modifying factor 2	Homo sapiens	94-98
12958193-9	2003	CYP3a13 protein expressed in vitro can metabolize clinically active drugs ethylmorphine and erythromycin, as well as benzphetamine.	Erythromycin	92-104	cytochrome P450, family 3, subfamily a, polypeptide 13	Mus musculus	0-7
12843151-4	2003	Serum dexamethasone levels decreased by 66 +/- 4%, and the erythromycin breath test measurements increased by 27 +/- 8%, indicating increased CYP3A4 activity during troglitazone treatment.	Erythromycin	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-148
12958653-7	2003	It can be concluded that erythromycin promote gastric emptying of gastroparetic rats; DRD3 and NPYY5 may be involved in prokinetic action of erythromycin; and targets other than motilin receptor of erythromycin might exist as prokinetics.	Erythromycin	141-153	dopamine receptor D3	Rattus norvegicus	86-90
12958653-7	2003	It can be concluded that erythromycin promote gastric emptying of gastroparetic rats; DRD3 and NPYY5 may be involved in prokinetic action of erythromycin; and targets other than motilin receptor of erythromycin might exist as prokinetics.	Erythromycin	141-153	dopamine receptor D3	Rattus norvegicus	86-90
12944022-13	2003	Resistance to erythromycin and clindamycin was highest among SGB isolates with M-phenotypes (mef) representing the majority (59.1%) of strains.	Erythromycin	14-26	E74 like ETS transcription factor 4	Homo sapiens	93-96
12732843-6	2003	Hepatic CYP3A phenotype was characterized with the erythromycin breath test, and enzyme induction capacity was evaluated with a short course of rifampin (600 mg/d for 6 days).	Erythromycin	51-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-13
12771600-5	2003	INTERVENTIONS: Cytochrome P450 3A4 activity was estimated using the carbon-14 [14C]erythromycin breath test (ERMBT) before surgery and 24, 48, and 72 hrs after surgery.	Erythromycin	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-34
14679760-0	2003	[Suppressive effect of erythromycin on LPS-induced NF-kappa B activation in mouse lung].	Erythromycin	23-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	51-61
12682802-2	2003	Erythromycin is a potent inhibitor of CYP3A4 that markedly increases circulating levels of some other HMG-CoA reductase inhibitors.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
12738139-0	2003	Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women.	Erythromycin	48-60	fibronectin 1	Homo sapiens	110-121
12679738-6	2003	Erythromycin is a known inhibitor of CYP3A.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-42
14679762-0	2003	[Influence of erythromycin and the metabolite, EM201 on IL-2 receptor signaling].	Erythromycin	14-26	interleukin 2	Homo sapiens	56-60
12670694-6	2003	Constructs formed with the msr(A) and mph(C) genes, and with the msr(A), mph(C) and erm(Y) genes, showed erythromycin-inactivating activity, but another construct built with the mph(C) gene alone failed to show such activity.	Erythromycin	105-117	ABC transporter permease protein	Staphylococcus aureus	65-71
12901826-0	2003	[The effects of erythromycin on the secretion of tumor necrosis factor-alpha and transforming growth factor-beta1 and expression of connexin 43 in human pleural mesothelial cells].	Erythromycin	16-28	tumor necrosis factor	Homo sapiens	49-76
12901826-0	2003	[The effects of erythromycin on the secretion of tumor necrosis factor-alpha and transforming growth factor-beta1 and expression of connexin 43 in human pleural mesothelial cells].	Erythromycin	16-28	transforming growth factor beta 1	Homo sapiens	81-113
12901826-1	2003	OBJECTIVES: To investigate the effects of erythromycin on secretion of tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta(1) (TGF-beta(1)), and the level of connexin 43 in human pleural mesothelial cells (HPMC), and to explore the mechanism of pleurodesis.	Erythromycin	42-54	tumor necrosis factor	Homo sapiens	71-98
12901826-1	2003	OBJECTIVES: To investigate the effects of erythromycin on secretion of tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta(1) (TGF-beta(1)), and the level of connexin 43 in human pleural mesothelial cells (HPMC), and to explore the mechanism of pleurodesis.	Erythromycin	42-54	tumor necrosis factor	Homo sapiens	100-109
12901826-4	2003	RESULTS: The secretion of TNF-alpha by HMPC increased after incubation with 100 mg/L erythromycin for 3 or 5 days, and the secretion of TGF-beta(1) increased markedly after incubation with lower or higher concentrations of erythromycin.	Erythromycin	85-97	tumor necrosis factor	Homo sapiens	26-35
12901826-4	2003	RESULTS: The secretion of TNF-alpha by HMPC increased after incubation with 100 mg/L erythromycin for 3 or 5 days, and the secretion of TGF-beta(1) increased markedly after incubation with lower or higher concentrations of erythromycin.	Erythromycin	223-235	transforming growth factor beta 1	Homo sapiens	136-147
12901826-5	2003	The levels of connexin 43 in HPMC decreased after stimulation with 100 mg/L erythromycin, but no relationship was observed between the levels and the stimulation time.	Erythromycin	76-88	gap junction protein alpha 1	Homo sapiens	14-25
12901826-6	2003	CONCLUSIONS: HPMC incubated with erythromycin showed increased secretion of TNF-alpha and TGF-beta(1), which may be one of the mechanisms for erythromycin pleurodesis.	Erythromycin	33-45	tumor necrosis factor	Homo sapiens	76-85
12901826-6	2003	CONCLUSIONS: HPMC incubated with erythromycin showed increased secretion of TNF-alpha and TGF-beta(1), which may be one of the mechanisms for erythromycin pleurodesis.	Erythromycin	33-45	transforming growth factor beta 1	Homo sapiens	90-101
12901826-6	2003	CONCLUSIONS: HPMC incubated with erythromycin showed increased secretion of TNF-alpha and TGF-beta(1), which may be one of the mechanisms for erythromycin pleurodesis.	Erythromycin	142-154	tumor necrosis factor	Homo sapiens	76-85
12901826-6	2003	CONCLUSIONS: HPMC incubated with erythromycin showed increased secretion of TNF-alpha and TGF-beta(1), which may be one of the mechanisms for erythromycin pleurodesis.	Erythromycin	142-154	transforming growth factor beta 1	Homo sapiens	90-101
12901826-7	2003	Erythromycin decreased the level of connexin 43 in HPMC, and this effect may be a response of the cells to the stimulus.	Erythromycin	0-12	gap junction protein alpha 1	Homo sapiens	36-47
12949438-6	2003	Serious cases by coadministration of CYP3A inhibitors resulting in acute hepatitis, hypotension, rhabdomyolyis, torsade de pointes, sedation, or ergotism are presented: interactions with azole antifungals (ketoconazole, itraconazole, fluconazole), HIV protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir), macrolide antibiotics (clarithromycin, erythromycin), and grapefruit juice.	Erythromycin	359-371	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-42
12688833-13	2003	Drugs that inhibit CYP3A4 (such as erythromycin) and/or the renal transport system (such as triamterene) may interact with dofetilide.	Erythromycin	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
12591038-1	2003	OBJECTIVE: Erythromycin is a motilin agonist that greatly increases the fractional rate of gastric emptying.	Erythromycin	11-23	motilin	Homo sapiens	29-36
14727939-7	2003	Significant drug interactions are observed when cilostazol is coadministered with other agents that inhibit cytochrome P450 (CYP) 3A4 (e.g. erythromycin or diltiazem) or CYP2C19 (e.g. omeprazole).	Erythromycin	140-152	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-133
12856827-7	2003	CONCLUSION: Our results suggest that erythromycin could increase contractile frequency and tension of non-pregnant uterine smooth muscle via histamine H1 receptor and calcium channel.	Erythromycin	37-49	histamine receptor H 1	Rattus norvegicus	141-162
12517885-1	2003	Of 120 erythromycin-resistant pneumococci isolated in Italian hospitals, 39 (32.5%) were M-type isolates, carrying the mef gene alone.	Erythromycin	7-19	E74 like ETS transcription factor 4	Homo sapiens	119-122
12475623-4	2003	At 512 microg/ml none of the compounds displayed any antibacterial activity but individually in combination with tetracycline and erythromycin, a two-fold potentiation of the activities of these antibiotics was observed against two strains of S. aureus that were highly resistant to these agents due to the presence of the multidrug efflux mechanisms Tet(K) (tetracycline resistance) and Msr(A) (macrolide resistance).	Erythromycin	130-142	ABC transporter permease protein	Staphylococcus aureus	388-394
12828863-7	2003	On the other hand, RV infection is inhibited by treatment with soluble ICAM-1, and by reduction of ICAM-1 expression in the airway epithelial cells after treatment with erythromycin.	Erythromycin	169-181	intercellular adhesion molecule 1	Homo sapiens	99-105
12583550-7	2002	With erythromycin there was a trend for increased survival with the multiple-dose regimen, with significantly higher survival when concentrations exceeding the MIC were maintained for a longer time period.	Erythromycin	5-17	microphthalmia Japan	Mus musculus	160-163
12583550-8	2002	These results indicate that the time during which serum concentrations exceeding the MIC value of the pathogen is an important parameter for efficacy for erythromycin.	Erythromycin	154-166	microphthalmia Japan	Mus musculus	85-88
12426516-0	2002	Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.	Erythromycin	79-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
12376329-8	2002	Hepatic CYP1A2 and CYP3A4 activities were assessed by the caffeine and erythromycin breath tests, respectively.	Erythromycin	71-83	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	8-14
12376329-8	2002	Hepatic CYP1A2 and CYP3A4 activities were assessed by the caffeine and erythromycin breath tests, respectively.	Erythromycin	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
12428665-13	2002	This suggests that 1 of the prokinetic actions of erythromycin in horses is likely to be secondary to binding on motilin receptors.	Erythromycin	50-62	motilin	Equus caballus	113-120
12426516-13	2002	The erythromycin-rifampin interaction cannot be attributed to CYP3A4 induction alone and probably also reflected intestinal P-glycoprotein induction.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
12426516-13	2002	The erythromycin-rifampin interaction cannot be attributed to CYP3A4 induction alone and probably also reflected intestinal P-glycoprotein induction.	Erythromycin	4-16	ATP binding cassette subfamily B member 1	Homo sapiens	124-138
12426516-0	2002	Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.	Erythromycin	79-91	ATP binding cassette subfamily B member 1	Homo sapiens	24-38
12065749-8	2002	A wide range of structurally unrelated organic anions inhibited mOAT2-mediated glutarate uptake especially erythromycin, a potent inhibitor.	Erythromycin	107-119	solute carrier family 22 (organic anion transporter), member 7	Mus musculus	64-69
12177794-7	2002	Cancer patients with an acute phase response (C-reactive protein &gt;10 mg x l(-1), n=26) had reduced metabolism as measured with the erythromycin breath test 1/T(MAX) (Kruskal-Wallis Anova, P=0.0062) as compared to controls (C-reactive protein &lt; or =10 mg x l(-1), n=14) Indeed, metabolism was significantly associated with C-reactive protein over the whole concentration range of this acute-phase marker (r=-0.64, Spearman Rank Correlation, P&lt;0.00001).	Erythromycin	134-146	C-reactive protein	Homo sapiens	46-64
12214558-2	2002	The ability of naftidrofuryl and erythromycin to inhibit retinol liberation by retinyl ester hydrolase (REH) in vitro suggests an ability to interfere with vitamin A metabolism in vivo, particularly during hepatic processing.	Erythromycin	33-45	carboxylesterase 1C	Rattus norvegicus	79-102
12184732-4	2002	However, CYP activities toward 7-ethoxycoumarin, benzphetamine, N-nitrosodimethylamine, erythromycin and nifedipine, and conjugation activities of UGT and GST were not affected.	Erythromycin	88-100	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	9-12
12108869-4	2002	Ceftazidime, tobramycin, and gentamycin slightly inhibited purified HNE activity whereas erythromycin and colistin significantly stimulated purified HNE and PE (395 and 557%, respectively).	Erythromycin	89-101	elastase, neutrophil expressed	Homo sapiens	149-152
12019067-6	2002	ErmN monomethylation predictably confers high resistance to the lincosamides clindamycin and lincomycin, intermediate resistance to the macrolides clarithromycin and erythromycin, and low resistance to the streptogramin B pristinamycin IA.	Erythromycin	166-178	ermin	Homo sapiens	0-4
23008668-7	2002	In healthy school children GAS was found in 15 out of 465 (3%).In the patients group GAS was sensitive to penicillin in 14(48%), erythromycin in 27(93%), and cefaclor in 28(96%) CONCLUSION: Although the prevalence of GAS among healthy children was similar to international studies, the GAS infection was high among children with acute tonsillitis and pharyngitis.	Erythromycin	129-141	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	85-88
23008668-7	2002	In healthy school children GAS was found in 15 out of 465 (3%).In the patients group GAS was sensitive to penicillin in 14(48%), erythromycin in 27(93%), and cefaclor in 28(96%) CONCLUSION: Although the prevalence of GAS among healthy children was similar to international studies, the GAS infection was high among children with acute tonsillitis and pharyngitis.	Erythromycin	129-141	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	85-88
23008668-5	2002	GAS from patients was tested for sentivity to penicillin, erythromycin, and cefaclor.	Erythromycin	58-70	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	0-3
23008668-7	2002	In healthy school children GAS was found in 15 out of 465 (3%).In the patients group GAS was sensitive to penicillin in 14(48%), erythromycin in 27(93%), and cefaclor in 28(96%) CONCLUSION: Although the prevalence of GAS among healthy children was similar to international studies, the GAS infection was high among children with acute tonsillitis and pharyngitis.	Erythromycin	129-141	galactosamine (N-acetyl)-6-sulfatase	Homo sapiens	85-88
11908635-3	2002	We report here that 1 mg bovine lactoferrin (bLf)/mL significantly hindered the in vitro invasion of cultured epithelial cells by GAS isolated from patients suffering from pharyngitis and completely inhibited the invasiveness of GAS pretreated with subinhibiting concentrations of erythromycin or ampicillin.	Erythromycin	281-293	lactotransferrin	Bos taurus	32-43
11948540-6	2002	The CYP3A2 antisense 22-mer AVI-4472 (5"-GAGCTGAAAGCAGGTCCATCCC-3") caused a sequence-dependent reduction of approximately five-fold in the rat liver CYP3A2 protein levels and erythromycin demethylation activity in 24 h following oral administration at a dose of 2 mg/kg.	Erythromycin	176-188	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	4-10
11851636-9	2002	Erythromycin caused a statistically significant reduction in midazolam clearance from the original value of 3.8 to 2.5 (95% CI for the difference -2.27, -0.35) ml kg-1 min-1.	Erythromycin	0-12	CD59 molecule (CD59 blood group)	Homo sapiens	168-173
11851636-13	2002	CONCLUSIONS: It is concluded that there is a significant correlation between lignocaine and midazolam clearances but this correlation is lost after CYP3A4 inhibition by erythromycin.	Erythromycin	169-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-154
11956054-4	2002	Erythromycin reduced the supernatant RV14 titers, RV14 RNA, the susceptibility to RV14 infection, and the production of ICAM-1 and cytokines.	Erythromycin	0-12	intercellular adhesion molecule 1	Homo sapiens	120-126
11956054-5	2002	Erythromycin also reduced the supernatant RV2 titers, RV2 RNA, the susceptibility to RV2 infection, and cytokine production, although the inhibitory effects of erythromycin on the expression of the low-density lipoprotein receptor, the minor RV receptor, were small.	Erythromycin	0-12	low density lipoprotein receptor	Homo sapiens	198-230
11956054-5	2002	Erythromycin also reduced the supernatant RV2 titers, RV2 RNA, the susceptibility to RV2 infection, and cytokine production, although the inhibitory effects of erythromycin on the expression of the low-density lipoprotein receptor, the minor RV receptor, were small.	Erythromycin	160-172	low density lipoprotein receptor	Homo sapiens	198-230
11956054-7	2002	These results suggest that erythromycin inhibits infection by the major RV subgroup by reducing ICAM-1 and infection by both RV subgroups by blocking the RV RNA entry into the endosomes.	Erythromycin	27-39	intercellular adhesion molecule 1	Homo sapiens	96-102
11956054-8	2002	Erythromycin may also modulate airway inflammation by reducing the production of proinflammatory cytokines and ICAM-1 induced by RV infection.	Erythromycin	0-12	intercellular adhesion molecule 1	Homo sapiens	111-117
11862493-2	2002	Here, we report that moderate overexpression of the msh1-R813W or msh1-G776D allele, in strains which also carry the wild-type MSH1 allele, slightly increases the frequency of mutations conferring resistance to erythromycin (E(r)) and elevates the frequency of alterations within a polyGT tract present in mitochondrial DNA (mtDNA).	Erythromycin	211-223	mismatch repair ATPase MSH1	Saccharomyces cerevisiae S288C	52-56
11862493-2	2002	Here, we report that moderate overexpression of the msh1-R813W or msh1-G776D allele, in strains which also carry the wild-type MSH1 allele, slightly increases the frequency of mutations conferring resistance to erythromycin (E(r)) and elevates the frequency of alterations within a polyGT tract present in mitochondrial DNA (mtDNA).	Erythromycin	211-223	mismatch repair ATPase MSH1	Saccharomyces cerevisiae S288C	66-70
11862493-2	2002	Here, we report that moderate overexpression of the msh1-R813W or msh1-G776D allele, in strains which also carry the wild-type MSH1 allele, slightly increases the frequency of mutations conferring resistance to erythromycin (E(r)) and elevates the frequency of alterations within a polyGT tract present in mitochondrial DNA (mtDNA).	Erythromycin	211-223	mismatch repair ATPase MSH1	Saccharomyces cerevisiae S288C	127-131
12036391-7	2002	The often-described higher hepatic clearance in women compared with men for substrates of CYP3A and P-glycoprotein, such as erythromycin and verapamil, may be explained by increased intrahepatocellular substrate availability due to lower hepatic P-glycoprotein activity in women relative to men.	Erythromycin	124-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-95
12169044-1	2002	OBJECTIVE: To evaluate the bioavailability, cardiac safety and tolerability of desloratadine when given in combination with the CYP3A4 inhibitor erythromycin.	Erythromycin	145-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
11724091-7	2001	CYP3A4 is the main isoenzyme responsible for metabolism of erythromycin and verapamil.	Erythromycin	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
15618695-6	2002	Furafylline and erythromycin, both mechanism based inhibitors, strongly inhibited CYP1A2 and CYP3A4 activity, respectively and their inhibitory effects increased depending on the preincubation time.	Erythromycin	16-28	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	82-88
15618695-6	2002	Furafylline and erythromycin, both mechanism based inhibitors, strongly inhibited CYP1A2 and CYP3A4 activity, respectively and their inhibitory effects increased depending on the preincubation time.	Erythromycin	16-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
12195877-6	2002	Dicloxacillin (odds ratio 5.74) and erythromycin (odds ratio 5.33) had the greatest tendency to cause phlebitis in univariate, multivariate and Cox regression analyses.	Erythromycin	36-48	cytochrome c oxidase subunit 8A	Homo sapiens	144-147
11709325-2	2001	The typical substrates for P glycoprotein, i.e., cyclosporine, colchicine, and erythromycin, inhibited the biliary clearance of rhodamine-123, whereas a substrate for organic cation transporter, cimetidine, did not inhibit clearance, suggesting that rhodamine-123 is transported mainly by P glycoprotein.	Erythromycin	79-91	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	289-303
11709325-2	2001	The typical substrates for P glycoprotein, i.e., cyclosporine, colchicine, and erythromycin, inhibited the biliary clearance of rhodamine-123, whereas a substrate for organic cation transporter, cimetidine, did not inhibit clearance, suggesting that rhodamine-123 is transported mainly by P glycoprotein.	Erythromycin	79-91	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	27-41
11708916-0	2001	Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.	Erythromycin	6-18	complement C6	Homo sapiens	64-67
11724091-8	2001	Both drugs are potent inhibitors of CYP3A4 and of P-glycoprotein; this may be the basis for the pharmacokinetic interaction between erythromycin and verapamil.	Erythromycin	132-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
11724091-8	2001	Both drugs are potent inhibitors of CYP3A4 and of P-glycoprotein; this may be the basis for the pharmacokinetic interaction between erythromycin and verapamil.	Erythromycin	132-144	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
11503008-1	2001	OBJECTIVE: Our objective was to investigate the potential for relevant pharmacotherapeutic interaction between cytochrome P4503A4 (CYP3A4)-inhibiting agents such as erythromycin and the dopamine agonist alpha-dihydroergocryptine (DHEC).	Erythromycin	165-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	111-129
11719731-9	2001	The erythromycin breath test also correlated with the CYP3A protein level (Spearman correlation coefficient: R = 0.60, R (2) = 0.36; P =.01).	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-59
11719731-10	2001	CONCLUSION: Our data support the erythromycin breath test as a specific in vivo assay of CYP3A activity in humans.	Erythromycin	33-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-94
11598080-5	2001	To study the function of this protein, an erythromycin resistance determinant [erm(AM)] was inserted within the abpA gene of S. gordonii strains Challis and FAS4 by allelic exchange, resulting in abpA mutant strains Challis-E1 and FAS4-E1.	Erythromycin	42-54	filamin C	Homo sapiens	112-116
11598080-5	2001	To study the function of this protein, an erythromycin resistance determinant [erm(AM)] was inserted within the abpA gene of S. gordonii strains Challis and FAS4 by allelic exchange, resulting in abpA mutant strains Challis-E1 and FAS4-E1.	Erythromycin	42-54	filamin C	Homo sapiens	196-200
11836874-6	2001	The concomitant use of statins with drugs that inhibit CYP3A4 (cyclosporin, erythromycin, clarithromycin, itraconazole, and ketoconazole), may result in increased plasma concentrations of HMG-CoA reductase inhibitors leading occasionally to myotoxicity.	Erythromycin	76-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
11640917-15	2001	Progesterone and testosterone protected CYP3A6 against inactivation competitively with respect to inactivator, erythromycin non-competitively and 17beta-estradiol showed a mixed type of protection.	Erythromycin	111-123	cytochrome P450 3A6	Oryctolagus cuniculus	40-46
11719731-0	2001	Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.	Erythromycin	20-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
11719731-2	2001	The erythromycin breath test is an in vivo assay of hepatic CYP3A activity, but the method has never been directly validated.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-65
11719731-3	2001	The aim of the study was to investigate whether an early postoperative erythromycin breath test correlated with the hepatic CYP3A protein level and catalytic activity in liver transplant recipients.	Erythromycin	71-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-129
11694455-0	2001	Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics.	Erythromycin	43-55	elastase, neutrophil expressed	Homo sapiens	20-39
11759110-0	2001	Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro.	Erythromycin	0-12	heparanase	Homo sapiens	82-92
11759110-5	2001	In addition, we examined the effect of erythromycin (EM) and clarithromycin (CAM), which are 14-membered ring macrolide antibiotics that act as biological response modifiers, on the expression of heparanase mRNA induced by growth factors.	Erythromycin	39-51	heparanase	Homo sapiens	196-206
11759110-5	2001	In addition, we examined the effect of erythromycin (EM) and clarithromycin (CAM), which are 14-membered ring macrolide antibiotics that act as biological response modifiers, on the expression of heparanase mRNA induced by growth factors.	Erythromycin	53-55	heparanase	Homo sapiens	196-206
11557910-1	2001	OBJECTIVE: Our objective was to investigate ethnic differences in the oral pharmacokinetics of nifedipine and erythromycin, both typical cytochrome P4503A (CYP3A) substrates, in Koreans and Caucasians and to identify the nature of any correlations between the pharmacokinetic parameters of the two drugs.	Erythromycin	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143
11557910-1	2001	OBJECTIVE: Our objective was to investigate ethnic differences in the oral pharmacokinetics of nifedipine and erythromycin, both typical cytochrome P4503A (CYP3A) substrates, in Koreans and Caucasians and to identify the nature of any correlations between the pharmacokinetic parameters of the two drugs.	Erythromycin	110-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	156-161
11557910-9	2001	CONCLUSIONS: Koreans showed significantly lower oral clearances of nifedipine and erythromycin, probably because of genetic differences attributed to the CYP3A enzymes.	Erythromycin	82-94	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	154-159
11503008-1	2001	OBJECTIVE: Our objective was to investigate the potential for relevant pharmacotherapeutic interaction between cytochrome P4503A4 (CYP3A4)-inhibiting agents such as erythromycin and the dopamine agonist alpha-dihydroergocryptine (DHEC).	Erythromycin	165-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
11158732-4	2001	To test the hypothesis, we evaluated the potential of erythromycin to modulate the release of eosinophil chemoattractants from the human lung fibroblast cell line HFL-1.	Erythromycin	54-66	complement factor H related 1	Homo sapiens	163-168
11745918-6	2001	The ex vivo measures were CYP3A6 activity (N-demethylation of erythromycin and hydroxylation of triazolam) and CYP3A content in rabbit hepatic microsomes preparations.	Erythromycin	62-74	cytochrome P450 3A6	Oryctolagus cuniculus	26-32
11566017-1	2001	GM-611 is an erythromycin derivative that acts as an agonist at the motilin receptor.	Erythromycin	13-25	motilin receptor	Oryctolagus cuniculus	68-84
11310804-7	2001	The macrolide resistance determinant in 89% of erythromycin-resistant strains tested (penicillin-susceptible and penicillin-resistant) was the erm gene, both the erm and mef genes were simultaneously found in 6%, and mef alone in 3.4%.	Erythromycin	47-59	E74 like ETS transcription factor 4	Homo sapiens	170-173
11310804-7	2001	The macrolide resistance determinant in 89% of erythromycin-resistant strains tested (penicillin-susceptible and penicillin-resistant) was the erm gene, both the erm and mef genes were simultaneously found in 6%, and mef alone in 3.4%.	Erythromycin	47-59	E74 like ETS transcription factor 4	Homo sapiens	217-220
11405512-0	2001	Erythromycin attenuates an experimental model of chronic bronchiolitis via augmenting monocyte chemoattractant protein-1.	Erythromycin	0-12	C-C motif chemokine 2	Oryctolagus cuniculus	86-120
11405512-7	2001	MCP-1 blockade abolished the protective effect of EM, as neutralization of MCP-1 with anti-MCP-1 antibodies reduced the EM-induced increase in the number of macrophages in BALF, and augmented size of the granulomatous lesions, as compared to control.	Erythromycin	50-52	corticostatin-3	Oryctolagus cuniculus	0-5
11405512-7	2001	MCP-1 blockade abolished the protective effect of EM, as neutralization of MCP-1 with anti-MCP-1 antibodies reduced the EM-induced increase in the number of macrophages in BALF, and augmented size of the granulomatous lesions, as compared to control.	Erythromycin	50-52	corticostatin-3	Oryctolagus cuniculus	75-80
11405512-7	2001	MCP-1 blockade abolished the protective effect of EM, as neutralization of MCP-1 with anti-MCP-1 antibodies reduced the EM-induced increase in the number of macrophages in BALF, and augmented size of the granulomatous lesions, as compared to control.	Erythromycin	50-52	corticostatin-3	Oryctolagus cuniculus	75-80
11405512-8	2001	The results of the present study suggest that erythromycin attenuates the pulmonary granuloma formation, at least in part, by increasing the production of monocyte chemoattractant protein-1.	Erythromycin	46-58	C-C motif chemokine 2	Oryctolagus cuniculus	155-189
11241027-0	2001	Effect of erythromycin on matrix metalloproteinase-9 and cell migration.	Erythromycin	10-22	matrix metallopeptidase 9	Homo sapiens	26-52
11241027-2	2001	To investigate the mechanism of this anti-inflammatory effect, we studied the relationship between the concentration of EM and matrix metalloproteinase-9 (MMP-9) activity, which is important in cell migration.	Erythromycin	120-122	matrix metallopeptidase 9	Homo sapiens	127-153
11241027-2	2001	To investigate the mechanism of this anti-inflammatory effect, we studied the relationship between the concentration of EM and matrix metalloproteinase-9 (MMP-9) activity, which is important in cell migration.	Erythromycin	120-122	matrix metallopeptidase 9	Homo sapiens	155-160
11282624-7	2001	The companion pCOM1 is a repB-deficient pCD4 derivative that carries an erythromycin resistance gene as a dominant selection marker.	Erythromycin	72-84	repB	Lactococcus lactis	25-29
11325589-8	2001	CONCLUSIONS: These results demonstrate that the epimerising activity associated with module 1 of the erythromycin PKS can be conferred on module 5 merely by transfer of the KS1 domain.	Erythromycin	101-113	zinc finger protein 382	Homo sapiens	173-176
11259570-6	2001	LAAM and nor-LAAM metabolism was inhibited by the CYP3A4-selective inhibitors troleandomycin, erythromycin, ketoconazole, and midazolam.	Erythromycin	94-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56
11158732-6	2001	Erythromycin attenuated the release of these cytokines and eosinophil chemotactic activity by the HFL-1.	Erythromycin	0-12	complement factor H related 1	Homo sapiens	98-103
11158732-8	2001	Erythromycin therapy also suppressed eotaxin mRNA significantly.	Erythromycin	0-12	C-C motif chemokine ligand 11	Homo sapiens	37-44
11159804-4	2001	In vitro metabolism study of erythromycin in microsomal suspensions indicated the 9.7-fold increase of CYP3A activity in the liver, but not in the intestine, by DEX pretreatment.	Erythromycin	29-41	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	103-108
11286023-5	2001	Erythromycin, a macrolide antibiotic, at a concentration of 100 microM inhibited the activation of ORCC induced by IFN-gamma.	Erythromycin	0-12	interferon gamma	Homo sapiens	115-124
11406010-3	2001	Erythromycin (EM) is a motilin agonist with prokinetic effect at low doses (1-3mg/kg).	Erythromycin	0-12	motilin	Homo sapiens	23-30
11439890-0	2001	[Effects of erythromycin on the Pseudomonas-induced rabbit diffuse panbronchiolitis model--the improvements in granuloma-like lesions with increasing production of MCP-1].	Erythromycin	12-24	corticostatin-3	Oryctolagus cuniculus	164-169
11439893-0	2001	[Effects of erythromycin on matrix metalloproteinase-9(MMP-9)and cell migration].	Erythromycin	12-24	matrix metallopeptidase 9	Homo sapiens	28-54
11439893-0	2001	[Effects of erythromycin on matrix metalloproteinase-9(MMP-9)and cell migration].	Erythromycin	12-24	matrix metallopeptidase 9	Homo sapiens	55-60
11327195-1	2001	The erythromycin breath test (EBT) is a putative probe of cytochrome P450 (CYP) 3A4 activity in vivo.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-83
11406010-3	2001	Erythromycin (EM) is a motilin agonist with prokinetic effect at low doses (1-3mg/kg).	Erythromycin	14-16	motilin	Homo sapiens	23-30
11245331-0	2001	Emergence of group A beta-hemolytic streptococci resistant to erythromycin in Athens, Greece.	Erythromycin	62-74	amyloid beta precursor protein	Homo sapiens	19-25
11129052-5	2000	Production of erythromycin A was obtained in both cases, showing that both proteins serve analogous functions in the biosynthetic pathways to dTDP-L-daunosamine and dTDP-L-mycarose, respectively.	Erythromycin	14-28	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	142-146
11284926-5	2000	The C11-C12 carbamate ketolides are able to overcome efflux and hydrolysis mechanisms of resistance and possess additional mechanisms of action at the ribosome level in comparison with erythromycin A.	Erythromycin	185-199	RNA polymerase III subunit K	Homo sapiens	4-7
11354818-6	2000	Like in other Indian studies, resistance to cotrimoxazole, erythromycin, gentamicin, other penicillins and cephalosporins appeared to be a common feature for MRSA isolates in the present study.	Erythromycin	59-71	solute carrier family 9 member A6	Homo sapiens	158-162
11125847-3	2000	Resveratrol, erythromycin and troleandomycin inactivated CYP3A4 at a similar rate (as reflected by k(inact)) whereas the binding affinity to CYP3A4 (as reflected by K(I)) was in the order of: troleandomycin &gt; erythromycin &gt; resveratrol.	Erythromycin	13-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
11125847-3	2000	Resveratrol, erythromycin and troleandomycin inactivated CYP3A4 at a similar rate (as reflected by k(inact)) whereas the binding affinity to CYP3A4 (as reflected by K(I)) was in the order of: troleandomycin &gt; erythromycin &gt; resveratrol.	Erythromycin	212-224	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
11125847-4	2000	(K(I) and k(inact) for CYP3A4 inactivation by resveratrol, erythromycin and troleandomycin are 20 microM and 0.20 min(-1), 5.3 microM and 0.12 min(-1) and 0.18 microM and 0.15 min(-1), respectively.)	Erythromycin	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
11100940-4	2000	CYP activity in vivo was evaluated with breath tests using substrates specific for different isoenzymes: caffeine (CYP1A2), aminopyrine (CYP2C11), nitrosodimethylamine (CYP2E1), and erythromycin (CYP3A).	Erythromycin	182-194	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-3
11038159-6	2000	In vivo cytochrome P450 activity was evaluated with breath tests using substrates for different isoenzymes: caffeine (CYP1A2), aminopyrine (CYP2C11), and erythromycin (CYP3A2).	Erythromycin	154-166	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	8-23
11038159-6	2000	In vivo cytochrome P450 activity was evaluated with breath tests using substrates for different isoenzymes: caffeine (CYP1A2), aminopyrine (CYP2C11), and erythromycin (CYP3A2).	Erythromycin	154-166	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	168-174
11038159-11	2000	In rats with CRF, there was a 35% reduction in the aminopyrine (CYP2C11) and the erythromycin (CYP3A2) breath tests compared with control animals (P &lt;.001).	Erythromycin	81-93	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	95-101
11284050-6	2001	CYP3A25 was catalytically active in the 6 beta-hydroxylation of testosterone and the N-demethylation of benzphetamine and erythromycin.	Erythromycin	122-134	cytochrome P450, family 3, subfamily a, polypeptide 25	Mus musculus	0-7
11822776-8	2001	A qacC harboring S. epidermidis strain (St.17) also hybridized to tetK (tetracycline resistance) and ermB (erythromycin resistance) genes.	Erythromycin	107-119	QacC	Staphylococcus epidermidis	2-6
11813507-16	2001	The antibiotic erythromycin-A (EM-A) binds to the motilin receptor and induces contractions with the same regional and species specificity as motilin.	Erythromycin	15-29	motilin	Homo sapiens	50-57
11813507-16	2001	The antibiotic erythromycin-A (EM-A) binds to the motilin receptor and induces contractions with the same regional and species specificity as motilin.	Erythromycin	15-29	motilin	Homo sapiens	142-149
11813507-16	2001	The antibiotic erythromycin-A (EM-A) binds to the motilin receptor and induces contractions with the same regional and species specificity as motilin.	Erythromycin	31-35	motilin	Homo sapiens	50-57
11813507-21	2001	Erythromycin and its derivatives act as motilin agonists with clinically useful prokinetic potential.	Erythromycin	0-12	motilin	Homo sapiens	40-47
10915793-7	2000	The purified P450MT2 showed a preference for adrenodoxin + adrenodoxin reductase electron donor system and exhibited high erythromycin N-demethylation activity.	Erythromycin	122-134	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	13-20
11129052-5	2000	Production of erythromycin A was obtained in both cases, showing that both proteins serve analogous functions in the biosynthetic pathways to dTDP-L-daunosamine and dTDP-L-mycarose, respectively.	Erythromycin	14-28	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	165-169
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Erythromycin	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
11061575-4	2000	RESULTS: The percent of erythromycin metabolized per hour increased from 2.20% +/- 0.60% (mean +/- SD) at baseline to 2.67% +/- 0.55% on day 5 of dexamethasone (mean increase in hepatic CYP3A4 activity 25.7% +/- 24.6%; P = .004).	Erythromycin	24-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	186-192
11061575-7	2000	The extent of CYP3A4 induction was inversely correlated with baseline erythromycin breath test (r2 = 0.58).	Erythromycin	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Erythromycin	56-68	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-26
11144420-5	2000	The overall frequency of drug resistance traits among the 1,749 MRSA strains was high (over 70% and up to and over 90% of the strains) to ciprofloxacin, erythromycin, clindamycin, gentamicin, and tetracycline, and was somewhat less frequent to sulfamethoxazole-trimethoprim (45%), chloramphenicol (30%), and rifampin (38%).	Erythromycin	153-165	solute carrier family 9 member A6	Homo sapiens	64-68
11071469-11	2000	Erythromycin, a universally available motilin agonist, is a safe, effective, potent drug for the treatment of early gastric stasis after PPPD.	Erythromycin	0-12	motilin	Homo sapiens	38-45
10999959-1	2000	We determined whether the drug efflux protein P-glycoprotein (Pgp) could influence the extent of CYP3A-mediated metabolism of erythromycin, a widely used model substrate for CYP3A.	Erythromycin	126-138	phosphoglycolate phosphatase	Mus musculus	46-60
10999959-1	2000	We determined whether the drug efflux protein P-glycoprotein (Pgp) could influence the extent of CYP3A-mediated metabolism of erythromycin, a widely used model substrate for CYP3A.	Erythromycin	126-138	phosphoglycolate phosphatase	Mus musculus	62-65
10999959-1	2000	We determined whether the drug efflux protein P-glycoprotein (Pgp) could influence the extent of CYP3A-mediated metabolism of erythromycin, a widely used model substrate for CYP3A.	Erythromycin	126-138	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	97-102
10999959-1	2000	We determined whether the drug efflux protein P-glycoprotein (Pgp) could influence the extent of CYP3A-mediated metabolism of erythromycin, a widely used model substrate for CYP3A.	Erythromycin	126-138	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	174-179
10999959-2	2000	We compared CYP3A metabolism of erythromycin (a Pgp substrate) using the erythromycin breath test in mice proficient and deficient of mdr1 drug transporters.	Erythromycin	32-44	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	12-17
10999959-2	2000	We compared CYP3A metabolism of erythromycin (a Pgp substrate) using the erythromycin breath test in mice proficient and deficient of mdr1 drug transporters.	Erythromycin	32-44	phosphoglycolate phosphatase	Mus musculus	48-51
11062690-0	2000	Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats.	Erythromycin	21-33	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-51
11062690-1	2000	The macrolide antibiotic erythromycin has recently been shown to overcome the resistance to anticancer drugs that results from overexpression of P-glycoprotein.	Erythromycin	25-37	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	145-159
11062690-5	2000	These results suggest that erythromycin competitively inhibits P-glycoprotein-mediated biliary and renal excretion of doxorubicin.	Erythromycin	27-39	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	63-77
11062690-8	2000	The findings of these experiments suggest that the inhibitory effect of erythromycin on the P-glycoprotein-mediated biliary excretion of doxorubicin is competitive and that combination chemotherapy of doxorubicin with erythromycin may induce toxicity as a result of increased plasma concentrations of doxorubicin.	Erythromycin	72-84	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	92-106
11062690-8	2000	The findings of these experiments suggest that the inhibitory effect of erythromycin on the P-glycoprotein-mediated biliary excretion of doxorubicin is competitive and that combination chemotherapy of doxorubicin with erythromycin may induce toxicity as a result of increased plasma concentrations of doxorubicin.	Erythromycin	218-230	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	92-106
10999732-1	2000	The erythromycin breath test (EBT) is a putative in vivo probe for drug metabolism by cytochrome P450 3A4 (CYP3A4).	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	86-105
10999732-1	2000	The erythromycin breath test (EBT) is a putative in vivo probe for drug metabolism by cytochrome P450 3A4 (CYP3A4).	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	107-113
10960087-1	2000	The synthesis of macrolide 2"-phosphotransferase I [Mph(A)], which inactivates erythromycin, is inducible by erythromycin.	Erythromycin	79-91	macrolide 2'-phosphotransferase I	Escherichia coli	17-50
10960087-10	2000	These results indicate that transcription of the mph(A)-mrx-mphR(A) operon is negatively regulated by the binding of a repressor protein, MphR(A), to the promoter of the mph(A) gene and is activated upon inhibition of binding of MphR(A) to the promoter in the presence of erythromycin.	Erythromycin	272-284	macrolide 2-phosphotransferase	Escherichia coli	170-176
10960087-1	2000	The synthesis of macrolide 2"-phosphotransferase I [Mph(A)], which inactivates erythromycin, is inducible by erythromycin.	Erythromycin	79-91	macrolide 2'-phosphotransferase I	Escherichia coli	52-58
10960087-1	2000	The synthesis of macrolide 2"-phosphotransferase I [Mph(A)], which inactivates erythromycin, is inducible by erythromycin.	Erythromycin	109-121	macrolide 2'-phosphotransferase I	Escherichia coli	17-50
10960087-1	2000	The synthesis of macrolide 2"-phosphotransferase I [Mph(A)], which inactivates erythromycin, is inducible by erythromycin.	Erythromycin	109-121	macrolide 2'-phosphotransferase I	Escherichia coli	52-58
10960087-2	2000	The expression of high-level resistance to erythromycin requires the mph(A) and mrx genes, which encode Mph(A) and an unidentified protein, respectively.	Erythromycin	43-55	macrolide 2-phosphotransferase	Escherichia coli	69-75
10960087-2	2000	The expression of high-level resistance to erythromycin requires the mph(A) and mrx genes, which encode Mph(A) and an unidentified protein, respectively.	Erythromycin	43-55	Mrx	Escherichia coli	80-83
10960087-2	2000	The expression of high-level resistance to erythromycin requires the mph(A) and mrx genes, which encode Mph(A) and an unidentified protein, respectively.	Erythromycin	43-55	macrolide 2'-phosphotransferase I	Escherichia coli	104-110
10960087-8	2000	9 kb that corresponded to the transcript of mph(A) through mphR(A) was detected, and its level was elevated upon exposure of cells to erythromycin.	Erythromycin	134-146	macrolide 2-phosphotransferase	Escherichia coli	44-50
10960087-9	2000	Gel mobility shift assays and DNase I footprinting indicated that MphR(A) binds specifically to the promoter region of mph(A), and the amount of DNA shifted as a results of the binding of MphR(A) decreased as the concentration of erythromycin was increased.	Erythromycin	230-242	macrolide 2-phosphotransferase	Escherichia coli	119-125
10960087-10	2000	These results indicate that transcription of the mph(A)-mrx-mphR(A) operon is negatively regulated by the binding of a repressor protein, MphR(A), to the promoter of the mph(A) gene and is activated upon inhibition of binding of MphR(A) to the promoter in the presence of erythromycin.	Erythromycin	272-284	macrolide 2-phosphotransferase	Escherichia coli	49-55
10960087-10	2000	These results indicate that transcription of the mph(A)-mrx-mphR(A) operon is negatively regulated by the binding of a repressor protein, MphR(A), to the promoter of the mph(A) gene and is activated upon inhibition of binding of MphR(A) to the promoter in the presence of erythromycin.	Erythromycin	272-284	Mrx	Escherichia coli	56-59
10898107-9	2000	The rGC for hepatic CYP3A4 activity as measured by midazolam plasma clearance or the erythromycin breath test was 0.96 (0.92-0.98) (95% Cl) and 0.89 (0.65-0.98), respectively (P &lt; 0.05).	Erythromycin	85-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
10926350-7	2000	The macrolide antibacterials clarithromycin, erythromycin and troleandomycin are inhibitors of CYP3A4 and should not be used in conjunction with cisapride.	Erythromycin	45-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
10933646-6	2000	Ex vivo production of the CXC chemokines interleukin 8 (IL-8) and epithelial cell-derived neutrophil attractant 78 (ENA-78), in whole blood obtained after erythromycin infusion, was lower than that in blood drawn before erythromycin infusion (maximum inhibition post-infusion: 32.9 +/- 6.5% and 35.2 +/- 12.6% decrease in production, respectively, expressed as percentage change relative to production before infusion of erythromycin, both P &lt; 0.05).	Erythromycin	155-167	C-X-C motif chemokine ligand 5	Homo sapiens	66-114
10933646-6	2000	Ex vivo production of the CXC chemokines interleukin 8 (IL-8) and epithelial cell-derived neutrophil attractant 78 (ENA-78), in whole blood obtained after erythromycin infusion, was lower than that in blood drawn before erythromycin infusion (maximum inhibition post-infusion: 32.9 +/- 6.5% and 35.2 +/- 12.6% decrease in production, respectively, expressed as percentage change relative to production before infusion of erythromycin, both P &lt; 0.05).	Erythromycin	220-232	C-X-C motif chemokine ligand 5	Homo sapiens	116-122
10933646-6	2000	Ex vivo production of the CXC chemokines interleukin 8 (IL-8) and epithelial cell-derived neutrophil attractant 78 (ENA-78), in whole blood obtained after erythromycin infusion, was lower than that in blood drawn before erythromycin infusion (maximum inhibition post-infusion: 32.9 +/- 6.5% and 35.2 +/- 12.6% decrease in production, respectively, expressed as percentage change relative to production before infusion of erythromycin, both P &lt; 0.05).	Erythromycin	220-232	C-X-C motif chemokine ligand 5	Homo sapiens	116-122
10933646-7	2000	In contrast, infusion of erythromycin was associated with an enhanced capacity of whole blood to release the neutrophil degranulation products bactericidal/permeability increasing protein (BPI), human neutrophil elastase (HNE) and human lactoferrin (HLF) upon stimulation with S. pneumoniae.	Erythromycin	25-37	bactericidal permeability increasing protein	Homo sapiens	143-187
10933646-7	2000	In contrast, infusion of erythromycin was associated with an enhanced capacity of whole blood to release the neutrophil degranulation products bactericidal/permeability increasing protein (BPI), human neutrophil elastase (HNE) and human lactoferrin (HLF) upon stimulation with S. pneumoniae.	Erythromycin	25-37	bactericidal permeability increasing protein	Homo sapiens	189-192
10933646-7	2000	In contrast, infusion of erythromycin was associated with an enhanced capacity of whole blood to release the neutrophil degranulation products bactericidal/permeability increasing protein (BPI), human neutrophil elastase (HNE) and human lactoferrin (HLF) upon stimulation with S. pneumoniae.	Erythromycin	25-37	elastase, neutrophil expressed	Homo sapiens	201-220
10933646-7	2000	In contrast, infusion of erythromycin was associated with an enhanced capacity of whole blood to release the neutrophil degranulation products bactericidal/permeability increasing protein (BPI), human neutrophil elastase (HNE) and human lactoferrin (HLF) upon stimulation with S. pneumoniae.	Erythromycin	25-37	elastase, neutrophil expressed	Homo sapiens	222-225
10933646-7	2000	In contrast, infusion of erythromycin was associated with an enhanced capacity of whole blood to release the neutrophil degranulation products bactericidal/permeability increasing protein (BPI), human neutrophil elastase (HNE) and human lactoferrin (HLF) upon stimulation with S. pneumoniae.	Erythromycin	25-37	HLF transcription factor, PAR bZIP family member	Homo sapiens	250-253
10933646-8	2000	Effects of erythromycin were greatest 4 h after infusion was stopped, when BPI, HNE and HLF concentrations were increased by +107.6 +/- 33.5%, +134.7 +/- 34.8% and +205.9 +/- 55.9 %, respectively (expressed as percentage change relative to production before infusion of erythromycin) (all P &lt; 0.	Erythromycin	11-23	bactericidal permeability increasing protein	Homo sapiens	75-78
10933646-8	2000	Effects of erythromycin were greatest 4 h after infusion was stopped, when BPI, HNE and HLF concentrations were increased by +107.6 +/- 33.5%, +134.7 +/- 34.8% and +205.9 +/- 55.9 %, respectively (expressed as percentage change relative to production before infusion of erythromycin) (all P &lt; 0.	Erythromycin	11-23	elastase, neutrophil expressed	Homo sapiens	80-83
10933646-8	2000	Effects of erythromycin were greatest 4 h after infusion was stopped, when BPI, HNE and HLF concentrations were increased by +107.6 +/- 33.5%, +134.7 +/- 34.8% and +205.9 +/- 55.9 %, respectively (expressed as percentage change relative to production before infusion of erythromycin) (all P &lt; 0.	Erythromycin	11-23	HLF transcription factor, PAR bZIP family member	Homo sapiens	88-91
10939550-1	2000	STUDY OBJECTIVES: To evaluate hepatic cytochrome P450 (CYP) 3A4 activity in patients infected with the human immunodeficiency virus (HIV) using the erythromycin breath test (ERMBT), and to examine the relationship of the ERMBT to plasma concentrations of indinavir and nelfinavir.	Erythromycin	148-160	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-63
10936516-4	2000	CRL-1072 was taken up by MAI and enhanced the uptake of fluorescent-labeled streptomycin and erythromycin in broth culture.	Erythromycin	93-105	interleukin 31 receptor A	Homo sapiens	0-3
10926336-0	2000	Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils.	Erythromycin	0-12	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-27
10926336-0	2000	Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils.	Erythromycin	0-12	integrin subunit alpha M	Homo sapiens	39-44
10926336-0	2000	Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils.	Erythromycin	0-12	integrin subunit beta 2	Homo sapiens	45-49
10926336-0	2000	Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils.	Erythromycin	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	63-76
10866316-6	2000	In contrast, in vivo administration of the selective CYP3A inhibitor troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and the rate of CYP3A-catalyzed N-demethylation of erythromycin by isolated liver microsomes (55.5 and 49% reduction, respectively).	Erythromycin	188-200	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	53-58
10909450-8	2000	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that use of erythromycin to treat foals with pneumonia was associated with an increased risk of diarrhea, hyperthermia, and respiratory distress, compared with use of TMS or PGP.	Erythromycin	64-76	phosphoglycolate phosphatase	Homo sapiens	226-229
10866316-6	2000	In contrast, in vivo administration of the selective CYP3A inhibitor troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and the rate of CYP3A-catalyzed N-demethylation of erythromycin by isolated liver microsomes (55.5 and 49% reduction, respectively).	Erythromycin	188-200	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	153-158
10847234-5	2000	RESULTS: The mean transplacental transfers (TPT(SS)) for erythromycin, roxithromycin and azithromycin were 3.0%, 4.3% and 2.6%, respectively, calculated as the ratio between the steady state concentrations in fetal venous and maternal arterial sides.	Erythromycin	57-69	limb development membrane protein 1	Homo sapiens	44-47
10817686-8	2000	Two erythromycin-resistant strains of S. aureus that carried the ermC gene were as sensitive as wild-type cells to antibiotic inhibition.	Erythromycin	4-16	ErmC	Staphylococcus aureus	65-69
10817732-0	2000	Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.	Erythromycin	30-42	ATP binding cassette subfamily C member 1	Homo sapiens	52-80
10817732-0	2000	Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.	Erythromycin	30-42	ATP binding cassette subfamily C member 1	Homo sapiens	82-85
10817732-0	2000	Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.	Erythromycin	30-42	ATP binding cassette subfamily C member 1	Homo sapiens	90-93
10786743-4	2000	CYP3A4 is responsible for the metabolism of numerous other therapeutic agents, including those administered concurrently with fentanyl (e.g., nifedipine, lidocaine, erythromycin and cyclosporine).	Erythromycin	165-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
10837446-8	2000	In contrast to S. aureus, erythromycin resistance in E. faecium was almost exclusively due to the presence of the ermB gene (93%).	Erythromycin	26-38	erythromycin resistance methylase	Enterococcus faecium	114-118
10837198-0	2000	Gonorrhea among men who have sex with men: outbreak caused by a single genotype of erythromycin-resistant Neisseria gonorrhoeae with a single-base pair deletion in the mtrR promoter region.	Erythromycin	83-95	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	Homo sapiens	168-172
10783825-0	2000	P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.	Erythromycin	25-37	ATP binding cassette subfamily B member 1	Homo sapiens	0-14
10722498-2	2000	Positive PCR amplifications of ermB were obtained for 39 of 40 highly erythromycin-resistant Enterococcus isolates (MICs, &gt;128 microg/ml) of different species; the remaining highly resistant E. faecium isolate was positive for PCR amplification of ermA but was negative for PCR amplification of the ermB and ermC genes.	Erythromycin	70-82	erythromycin resistance protein	Enterococcus faecalis	31-35
10819233-9	2000	Erythromycin infusion significantly increased plasma insulin and decreased glucose concentrations in Type II diabetic and control subjects and greatly potentiated glucose-induced insulin secretion in the latter (third study).	Erythromycin	0-12	insulin	Homo sapiens	53-60
10783825-1	2000	OBJECTIVE: Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo.	Erythromycin	107-119	ATP binding cassette subfamily B member 1	Homo sapiens	44-58
10783825-1	2000	OBJECTIVE: Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo.	Erythromycin	107-119	ATP binding cassette subfamily B member 1	Homo sapiens	60-63
10783825-11	2000	CONCLUSION: We suggest that the increase in oral bioavailability of talinolol after concomitant erythromycin is caused by increased intestinal net absorption due to Pgp inhibition by erythromycin.	Erythromycin	96-108	ATP binding cassette subfamily B member 1	Homo sapiens	165-168
10783825-11	2000	CONCLUSION: We suggest that the increase in oral bioavailability of talinolol after concomitant erythromycin is caused by increased intestinal net absorption due to Pgp inhibition by erythromycin.	Erythromycin	183-195	ATP binding cassette subfamily B member 1	Homo sapiens	165-168
10668858-6	2000	Clinically important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice.	Erythromycin	91-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
10870985-0	2000	Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.	Erythromycin	56-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
10870985-1	2000	PURPOSE: To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).	Erythromycin	81-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	140-146
10870985-1	2000	PURPOSE: To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).	Erythromycin	81-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	227-233
10870985-1	2000	PURPOSE: To quantitatively predict the in vivo interaction between triazolam and erythromycin, which involves mechanism-based inhibition of CYP3A4, from in vitro studies using human liver microsomes (HLM) and recombinant human CYP3A4 (REC).	Erythromycin	81-93	zinc finger DHHC-type palmitoyltransferase 2	Homo sapiens	235-238
10870985-2	2000	METHODS: HLM or REC was preincubated with erythromycin in the presence of NADPH and then triazolam was added.	Erythromycin	42-54	zinc finger DHHC-type palmitoyltransferase 2	Homo sapiens	16-19
10870985-8	2000	Based on the kinetic parameters obtained using HLM and REC, the AUCpo of triazolam was predicted to increase 2.0- and 2.6-fold, respectively, following oral administration of erythromycin (333 mg t.i.d.	Erythromycin	175-187	zinc finger DHHC-type palmitoyltransferase 2	Homo sapiens	55-58
10870985-10	2000	CONCLUSIONS: In vivo interaction between triazolam and erythromycin was successfully predicted from in vitro data based on a PBPK model involving a mechanism-based inhibition of CYP3A4.	Erythromycin	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	178-184
10722081-5	2000	Studies to verify the separation of erythromycin and related substances on Hypersil BDS C18, Luna C18(2), Inertsil ODS-2 and Supelcosil ABZ+ have been performed and the results are presented.	Erythromycin	36-48	Bardet-Biedl syndrome 9	Homo sapiens	88-91
10722081-5	2000	Studies to verify the separation of erythromycin and related substances on Hypersil BDS C18, Luna C18(2), Inertsil ODS-2 and Supelcosil ABZ+ have been performed and the results are presented.	Erythromycin	36-48	Bardet-Biedl syndrome 9	Homo sapiens	98-101
10764957-6	2000	Motilin binding to these membranes was determined by the displacement of (125)I MOT by the native peptide MOT 1-22, or by peptide analogues MOT 1-12 [CH(2)NH](10-11) or GM-109 and by erythromycin derivative GM-611.	Erythromycin	183-195	promotilin	Oryctolagus cuniculus	0-7
10699320-2	2000	The maximum amount of recombinant LTB (rLTB) secreted into the modified 5PY medium containing erythromycin was about 350 mg l(-1) when cultivated at 30 degrees C for 8 days.	Erythromycin	94-106	lymphotoxin beta	Rattus norvegicus	34-37
10699320-2	2000	The maximum amount of recombinant LTB (rLTB) secreted into the modified 5PY medium containing erythromycin was about 350 mg l(-1) when cultivated at 30 degrees C for 8 days.	Erythromycin	94-106	lymphotoxin beta	Rattus norvegicus	39-43
10623585-0	2000	Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells.	Erythromycin	0-12	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	50-69
10796273-3	2000	Erythromycin (EM) is a motilin agonist with prokinetic effect at low doses (1-3mg/kg).	Erythromycin	0-12	motilin	Homo sapiens	23-30
10796273-3	2000	Erythromycin (EM) is a motilin agonist with prokinetic effect at low doses (1-3mg/kg).	Erythromycin	14-16	motilin	Homo sapiens	23-30
10867834-2	2000	We examined the in vivo and in vitro effects of 14-membered macrolide antibiotics erythromycin (EM) and clarithromycin (CAM) on interleukin (IL)-8 secretion from human nasal epithelial cells.	Erythromycin	82-94	C-X-C motif chemokine ligand 8	Homo sapiens	128-146
10867834-2	2000	We examined the in vivo and in vitro effects of 14-membered macrolide antibiotics erythromycin (EM) and clarithromycin (CAM) on interleukin (IL)-8 secretion from human nasal epithelial cells.	Erythromycin	96-98	C-X-C motif chemokine ligand 8	Homo sapiens	128-146
10756442-0	2000	[Suppressive action of erythromycin on cultured tracheal epithelial cell chloride channel activated by interferon-gamma].	Erythromycin	23-35	interferon gamma	Homo sapiens	103-119
10628970-6	2000	On the other hand, overproduction of Din7p from the DIN7 gene placed under control of the GAL1 promoter dramatically increases the frequency of petite formation and the frequency of mitochondrial mutations conferring resistance to erythromycin (E(r)).	Erythromycin	231-243	exodeoxyribonuclease DIN7	Saccharomyces cerevisiae S288C	37-42
10628970-6	2000	On the other hand, overproduction of Din7p from the DIN7 gene placed under control of the GAL1 promoter dramatically increases the frequency of petite formation and the frequency of mitochondrial mutations conferring resistance to erythromycin (E(r)).	Erythromycin	231-243	exodeoxyribonuclease DIN7	Saccharomyces cerevisiae S288C	52-56
10628970-6	2000	On the other hand, overproduction of Din7p from the DIN7 gene placed under control of the GAL1 promoter dramatically increases the frequency of petite formation and the frequency of mitochondrial mutations conferring resistance to erythromycin (E(r)).	Erythromycin	231-243	galactokinase	Saccharomyces cerevisiae S288C	90-94
10604943-9	2000	In J774 cells, the inhibition of 6-keto-PGF(1alpha) and NO(2)(-) production by roxithromycin and erythromycin was not dependent on direct inhibition of cyclooxygenase-2 and inducible nitric oxide synthase activity because it appears to be related to the inhibition of cyclooxygenase-2 and inducible nitric oxide synthase protein expression.	Erythromycin	97-109	nitric oxide synthase 2, inducible	Mus musculus	173-204
10609814-1	1999	BACKGROUND: In February, 1999, a local US health department identified a cluster of pertussis cases among neonates born at a community hospital and recommended oral erythromycin for post-exposure prophylaxis for about 200 neonates born at that hospital between Feb 1 and Feb 24, 1999.	Erythromycin	165-177	FEB1	Homo sapiens	261-266
10570031-7	1999	Studies using the CYP3A4 inhibitors ketoconazole, troleandomycin, and erythromycin suggested a role for CYP3A4 in the formation of 2-, 8-, and 12-hydroxyNVP.	Erythromycin	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
10570031-7	1999	Studies using the CYP3A4 inhibitors ketoconazole, troleandomycin, and erythromycin suggested a role for CYP3A4 in the formation of 2-, 8-, and 12-hydroxyNVP.	Erythromycin	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-110
10586386-0	1999	Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.	Erythromycin	33-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-110
11674780-6	1999	The ease of the equilibration between the erythro- and threo-aldolates is dictated by the electronic nature of the group at C-4 in substituted benzaldehydes, and the steric compression of the aldehyde group increases the rate of erythro/threo equilibration.	Erythromycin	42-49	complement C4A (Rodgers blood group)	Homo sapiens	124-127
10572152-5	1999	Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance - the erythromycin ribosomal methylase B (ermB) gene - found in C. perfringens and C. difficile.	Erythromycin	232-244	ermB	Clostridium perfringens	262-296
10572152-5	1999	Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance - the erythromycin ribosomal methylase B (ermB) gene - found in C. perfringens and C. difficile.	Erythromycin	232-244	ermB	Clostridium perfringens	298-302
10543746-0	1999	Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells.	Erythromycin	0-12	nuclear factor kappa B subunit 1	Homo sapiens	52-61
10543746-9	1999	These findings indicate that EM is capable of inhibiting expression of the IL-8 gene in T cells through transcriptional inhibition and that this inhibition is mediated through a non-calcineurin-dependent signaling event in T lymphocytes.	Erythromycin	29-31	C-X-C motif chemokine ligand 8	Homo sapiens	75-79
10460801-2	1999	The dealkylation of ethoxyresorufin, dextromethorphan, and erythromycin were all shown to be specific reactions for CYP1A2, CYP2D6, and CYP3A4 that allowed direct comparison with kinetic data for HLM.	Erythromycin	59-71	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	116-122
10473966-11	1999	However, the data suggest that the motilin-agonist erythromycin is superior with regard to the acceleration of gastric emptying, while both erythromycin and domperidone appear to be the most effective with regard to improvements in the symptom score.	Erythromycin	51-63	motilin	Homo sapiens	35-42
10539769-4	1999	Consumption of soy diets significantly increased monooxygenase activity toward the following: the CYP3A substrates erythromycin and ethylmorphine N-demethylase; corticosterone and testosterone 6beta-hydroxylase; and apoprotein and mRNA expression of CYP3A2 (P &lt; 0.05).	Erythromycin	115-127	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	98-103
10508560-0	1999	Simultaneous detection of erythromycin-resistant methylase genes ermA and ermC from Staphylococcus spp.	Erythromycin	26-38	rRNA methylase Erm(A)	Staphylococcus aureus	65-69
10508560-0	1999	Simultaneous detection of erythromycin-resistant methylase genes ermA and ermC from Staphylococcus spp.	Erythromycin	26-38	ErmC	Staphylococcus aureus	74-78
10508560-2	1999	A comparative analysis of the two most dominant erythromycin-resistance determinant genes in Staphylococcus sppnamely, the ermA and ermC genes, was carried out.	Erythromycin	48-60	rRNA methylase Erm(A)	Staphylococcus aureus	123-127
10508560-2	1999	A comparative analysis of the two most dominant erythromycin-resistance determinant genes in Staphylococcus sppnamely, the ermA and ermC genes, was carried out.	Erythromycin	48-60	ErmC	Staphylococcus aureus	132-136
10417041-3	1999	The proposed mechanism involves erythromycin inactivation of cytochrome P450 3A4 inhibition of sertraline metabolism, accumulation of the drug, and precipitation of the syndrome.	Erythromycin	32-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-80
10453038-6	1999	Incubation of cultured pulmonary alveolar macrophages caused up-regulation of NO production and expression of inducible NO synthase mRNA, an effect that was dose dependently inhibited by erythromycin, roxithromycin, or josamycin.	Erythromycin	187-199	nitric oxide synthase 2	Rattus norvegicus	110-131
10553724-7	1999	In a pharmacokinetic study, BP half-life was prolonged to 137% of the average control value by 7-day treatment with erythromycin, a CYP3A inhibitor, and shortened to 58% of the control by 2-day treatment with dexamethasone, a CYP3A inducer.	Erythromycin	116-128	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	132-137
10383920-8	1999	However, rokitamycin, LMA7, erythromycin, and clarithromycin inhibited the CYP3A4-catalyzed triazolam alpha-hydroxylation with IC50 (Ki) values of 5.8 (2.0), 40, 33 (20), and 56 (43) microM, respectively.	Erythromycin	28-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
10443540-10	1999	One QAC resistant strain harbouring the smr gene showed resistance to ampicillin, penicillin, tetracycline, erythromycin and trimethoprim.	Erythromycin	108-120	multidrug resistance efflux protein Smr	Staphylococcus epidermidis	40-43
10445377-9	1999	CNO in-vitro formation was significantly reduced by TAO and erythromycin by 44.5% and 45.0% (P&lt;0.01), respectively.	Erythromycin	60-72	biogenesis of lysosomal organelles complex 1 subunit 4	Homo sapiens	0-3
10381885-4	1999	The macrolide antibiotic erythromycin also interacted with the cloned motilin receptor, providing a molecular basis for its effects on the human GI tract.	Erythromycin	25-37	motilin	Homo sapiens	70-77
10348770-2	1999	Here it is shown that the Escherichia coli msbB mutant, which elaborates defective, penta-acylated lipid A, is practically as resistant to a representative set of hydrophobic solutes (rifampin, fusidic acid, erythromycin, clindamycin, and azithromycin) as the parent-type control strain.	Erythromycin	208-220	lipid A biosynthesis (KDO)2-(lauroyl)-lipid IVA acyltransferase	Escherichia coli	43-47
10234600-2	1999	The effect of erythromycin, a potent CYP3A4/5 inhibitor, on the pharmacokinetics and pharmacodynamics of argatroban was evaluated in 14 healthy male volunteers in an open-label, crossover study with a 5-day washout between regimens.	Erythromycin	14-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
10379638-1	1999	OBJECTIVE: To study the suggested pharmacokinetic interaction between erythromycin, a strong inhibitor of CYP3A4, and clozapine.	Erythromycin	70-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
10390974-5	1999	Discontinuation of erythromycin resulted in exacerbation of the patient"s asthmatic symptoms, with high fever, increased sputum volume and IgE levels, and worsening lung infiltrates.	Erythromycin	19-31	immunoglobulin heavy constant epsilon	Homo sapiens	139-142
10382903-0	1999	Erythromycin resistance amongst group A beta-haemolytic streptococci isolated in a paediatric hospital in Athens, Greece.	Erythromycin	0-12	amyloid beta precursor protein	Homo sapiens	38-44
10330474-2	1999	Lincomycin and erythromycin, inhibitors of plastid translation, decreased the accumulation of transcripts of nuclear photosynthesis genes in shoots of light-grown wild-type and lip1 seedlings, indicating that the plastid signal is required in the lip1 mutant.	Erythromycin	16-28	Ras-related small GTP-binding family protein	Arabidopsis thaliana	178-182
10330474-2	1999	Lincomycin and erythromycin, inhibitors of plastid translation, decreased the accumulation of transcripts of nuclear photosynthesis genes in shoots of light-grown wild-type and lip1 seedlings, indicating that the plastid signal is required in the lip1 mutant.	Erythromycin	16-28	Ras-related small GTP-binding family protein	Arabidopsis thaliana	248-252
10330474-3	1999	Treatment with lincomycin or erythromycin also reduced the accumulation of transcripts in shoots of dark-grown lip1 seedlings, indicating that light is not an obligate requirement for the synthesis or activity of the plastid signal.	Erythromycin	30-42	Ras-related small GTP-binding family protein	Arabidopsis thaliana	112-116
10103198-3	1999	We studied the effect of erythromycin, clarithromycin, josamycin, and other antibiotics on the release by eosinophils of interleukin-8 (IL-8), a potent chemokine for inflammatory cells, including eosinophils themselves.	Erythromycin	25-37	C-X-C motif chemokine ligand 8	Homo sapiens	121-134
10103198-3	1999	We studied the effect of erythromycin, clarithromycin, josamycin, and other antibiotics on the release by eosinophils of interleukin-8 (IL-8), a potent chemokine for inflammatory cells, including eosinophils themselves.	Erythromycin	25-37	C-X-C motif chemokine ligand 8	Homo sapiens	136-140
10103198-5	1999	Only 14-member macrolides (erythromycin and clarithromycin) showed a concentration-dependent suppressive effect on IL-8 release (control, 100%; erythromycin at 1 microgram/ml, 67.82% +/- 3.45% [P &lt; 0.01]; clarithromycin at 5 micrograms/ml, 56.81% +/- 9.61% [P &lt; 0.01]).	Erythromycin	27-39	C-X-C motif chemokine ligand 8	Homo sapiens	115-119
10103198-5	1999	Only 14-member macrolides (erythromycin and clarithromycin) showed a concentration-dependent suppressive effect on IL-8 release (control, 100%; erythromycin at 1 microgram/ml, 67.82% +/- 3.45% [P &lt; 0.01]; clarithromycin at 5 micrograms/ml, 56.81% +/- 9.61% [P &lt; 0.01]).	Erythromycin	144-156	C-X-C motif chemokine ligand 8	Homo sapiens	115-119
10213372-5	1999	RESULTS: Some (terfenadine, erythromycin and lovastatin) but not all (nifedipine and midazolam) CYP3A substrates were found to be P-gp substrates.	Erythromycin	28-40	phosphoglycolate phosphatase	Homo sapiens	130-134
11775917-9	1999	In the rats infected with MP but treated with erythromycin positive expression of bFGF mRNA was found to be scarcely distributed in alveolar walls.	Erythromycin	46-58	fibroblast growth factor 2	Rattus norvegicus	82-86
11775917-10	1999	Quantitative analysis showed that the optical densities of bFGF mRNA expression were 41.32 +/- 10.44 in the MP infected rats (n = 4), which were significantly higher than those in the control group (0.30 +/- 0.13, n = 4, P &lt; 0.01) and those in the MP infected and erythromycin treated rats (6.03 +/- 2.41, n = 4, P &lt; 0.01).	Erythromycin	267-279	fibroblast growth factor 2	Rattus norvegicus	59-63
10089966-0	1999	Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis.	Erythromycin	21-33	C-X-C motif chemokine ligand 8	Homo sapiens	37-50
10089966-2	1999	The authors studied the inhibitory effect of erythromycin on interleukin-8 (IL-8) secretion from exudative cells in the nasal discharge of patients with chronic sinusitis.	Erythromycin	45-57	C-X-C motif chemokine ligand 8	Homo sapiens	61-74
10089966-2	1999	The authors studied the inhibitory effect of erythromycin on interleukin-8 (IL-8) secretion from exudative cells in the nasal discharge of patients with chronic sinusitis.	Erythromycin	45-57	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
10089966-6	1999	RESULTS: The amount of secreted IL-8 in the absence of erythromycin was 682 +/- 226 pg/10(6) cells/24 h. The IL-8 secretion was significantly reduced to 66 +/- 15% and 46 +/- 13% of the control in the presence of 10(-6) and 10(-5) M of erythromycin, respectively.	Erythromycin	55-67	C-X-C motif chemokine ligand 8	Homo sapiens	32-36
10089966-6	1999	RESULTS: The amount of secreted IL-8 in the absence of erythromycin was 682 +/- 226 pg/10(6) cells/24 h. The IL-8 secretion was significantly reduced to 66 +/- 15% and 46 +/- 13% of the control in the presence of 10(-6) and 10(-5) M of erythromycin, respectively.	Erythromycin	236-248	C-X-C motif chemokine ligand 8	Homo sapiens	32-36
10089966-7	1999	CONCLUSION: Erythromycin may act as a biologic modulator that inhibits IL-8 secretion from exudative cells and thereby blocks the vicious circle of neutrophil recruitment and IL-8 generation in the inflammatory site in chronic sinusitis.	Erythromycin	12-24	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
10089966-7	1999	CONCLUSION: Erythromycin may act as a biologic modulator that inhibits IL-8 secretion from exudative cells and thereby blocks the vicious circle of neutrophil recruitment and IL-8 generation in the inflammatory site in chronic sinusitis.	Erythromycin	12-24	C-X-C motif chemokine ligand 8	Homo sapiens	175-179
10037757-4	1999	Erythromycin, a potent inhibitor of bacterial and mitochondrial protein synthesis, caused 8-12-fold higher accumulation of CYP1A1 mRNA, preferential accumulation of P450MT2, and 5-6-fold higher ERND activity in the mitochondrial compartment of rat C6 glioma cells.	Erythromycin	0-12	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	123-129
10037757-4	1999	Erythromycin, a potent inhibitor of bacterial and mitochondrial protein synthesis, caused 8-12-fold higher accumulation of CYP1A1 mRNA, preferential accumulation of P450MT2, and 5-6-fold higher ERND activity in the mitochondrial compartment of rat C6 glioma cells.	Erythromycin	0-12	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	165-172
10202210-13	1999	Erythromycin and related 14-member macrolide compounds inhibit the binding of motilin to its receptors on GI smooth muscle and, therefore, act as motilin agonists.	Erythromycin	0-12	motilin	Homo sapiens	78-85
10202210-13	1999	Erythromycin and related 14-member macrolide compounds inhibit the binding of motilin to its receptors on GI smooth muscle and, therefore, act as motilin agonists.	Erythromycin	0-12	motilin	Homo sapiens	146-153
10213372-7	1999	Studies in mdr1a disrupted mice confirmed that erythromycin was a P-gp substrate but the CYP3A-inhibitor ketoconazole was not.	Erythromycin	47-59	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	11-16
10213372-7	1999	Studies in mdr1a disrupted mice confirmed that erythromycin was a P-gp substrate but the CYP3A-inhibitor ketoconazole was not.	Erythromycin	47-59	phosphoglycolate phosphatase	Mus musculus	66-70
10051731-9	1999	Histopathological studies revealed that erythromycin markedly decreased neutrophils in the lung and skin lesions and myeloperoxidase in the lung, simultaneously with inhibiting ICAM-1 expression.	Erythromycin	40-52	myeloperoxidase	Homo sapiens	117-132
10051731-9	1999	Histopathological studies revealed that erythromycin markedly decreased neutrophils in the lung and skin lesions and myeloperoxidase in the lung, simultaneously with inhibiting ICAM-1 expression.	Erythromycin	40-52	intercellular adhesion molecule 1	Homo sapiens	177-183
10051731-12	1999	CONCLUSIONS: The therapeutic dosage of erythromycin significantly suppressed acute neutrophil influx into the lung, intradermal Arthus reaction and the expression of ICAM-1 in the lesions of experimental EAA.	Erythromycin	39-51	intercellular adhesion molecule 1	Homo sapiens	166-172
10597866-1	1999	Since 1990 it has repeatedly been reported that some histamine H1 receptor antagonists (e.g. terfenadine and astemizole) are able to produce ventricular arrhythmias (e.g. torsade de pointes) when they are given at dosages above the therapeutic range and/or administered together with cytochrome P-450 3A4 inhibitors, such as ketoconazole or erythromycin.	Erythromycin	341-353	histamine H1 receptor	Cavia porcellus	53-74
10092957-15	1999	Nevertheless, care should be taken with the use of known CYP3A4 inhibitors such as erythromycin, ketoconazole and cyclosporin.	Erythromycin	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	57-63
10092957-17	1999	Perliminary data suggest the erythromycin breath test, an indicator of CYP3A4 function, is a predictor of toxicity after treatment with docetaxel.	Erythromycin	29-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
9872752-3	1999	pVACMC1 plasmid DNA that had been exposed to degradation by fresh saliva was capable of transforming naturally competent Streptococcus gordonii DL1 to erythromycin resistance, although transforming activity decreased rapidly, with a half-life of approximately 50 s. S. gordonii DL1 transformants were obtained in the presence of filter-sterilized saliva and a 1-microg/ml final concentration of pVACMC1 DNA.	Erythromycin	151-163	Galactose-specific C-type lectin	Drosophila melanogaster	144-147
9987703-1	1999	The single-dose effects of the cytochrome P-450 inhibitors erythromycin and ketoconazole on the steady-state pharmacokinetics and electrocardiographic repolarization pharmacodynamics of intranasal levocabastine, a potent and selective H1-receptor antagonist, were evaluated in healthy young male subjects.	Erythromycin	59-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	31-47
10069109-0	1999	[Sensitivity of group A beta-hemolytic Streptococcus isolated from pediatric pharyngotonsillitis to erythromycin and clarithromycin: a primary care multicenter study].	Erythromycin	100-112	amyloid beta precursor protein	Homo sapiens	22-28
10092202-0	1999	Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells.	Erythromycin	11-23	C-X-C motif chemokine ligand 8	Homo sapiens	47-60
9797248-1	1998	We tested 16 erythromycin-resistant clinical isolates of S. aureus, recovered from patients hospitalized in the United States from 1958 to 1969, for the presence of ermA, ermB, and ermC by using PCR.	Erythromycin	13-25	rRNA methylase Erm(A)	Staphylococcus aureus	165-169
10803271-5	1999	The obtained results show that all tested cephalosporins (cephamandole, cefotaxime, cephradine) and aminogllycosides (gentamicin, streptomycin, amicacin) inhibit production of IFN-gamma by mouse lymphocytes T. The influence of penicillin G and ampicillin, as well as, erythromycin and lincomycin on the production IFN-gamma was not observed.	Erythromycin	268-280	interferon gamma	Mus musculus	176-185
9806981-5	1998	The growth of an ermC erythromycin-resistant strain of S. aureus was also significantly inhibited by nine ketolide compounds, suggesting that they were not inducers of methylase gene expression.	Erythromycin	22-34	ErmC	Staphylococcus aureus	17-21
11301566-4	1998	Similarly, after intramuscular progestin therapy, results from the erythromycin breath test showed a 23% mean increase in CYP3A4 activity.	Erythromycin	67-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-128
10097401-6	1999	Further experiments were performed in deuterated media (D2O/CD3OD 50%) which, along with the high-resolution MSn of erythromycin analogues, has enabled us to identify some of the steps in the ring fragmentation, particularly the loss of the polyketide starter acid.	Erythromycin	116-128	moesin	Homo sapiens	109-112
9832299-1	1998	OBJECTIVE: We have studied the possible interaction of erythromycin and itraconazole, both inhibitors of cytochrome P450 3A4 isoenzyme (CYP3A4), with intravenous lignocaine in nine healthy volunteers using a randomized cross-over study design.	Erythromycin	55-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	136-142
9863553-8	1998	Erythromycin metabolism and its P450 effects are used to illustrate the complexity and the consequences of metabolic transformation of a given drug.	Erythromycin	0-12	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	32-36
9849646-10	1998	Troleandomycin, erythromycin and M2 inhibited CYP3A-dependent testosterone 6beta-hydroxylation catalysed by liver microsomes from the dexamethasone-treated rat by 54, 33 and 23%, respectively, but roxithromycin, M3 and M1 were very weak by comparison.	Erythromycin	16-28	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	46-51
9755297-0	1998	Erythromycin resistance in group A beta hemolytic streptococcus.	Erythromycin	0-12	amyloid beta precursor protein	Homo sapiens	33-39
9806945-0	1998	Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.	Erythromycin	167-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-65
9806945-5	1998	Recombinant human CYP3A4 in a baculovirus system coexpressing NADPH-P450 reductase was very active in catalyzing the N-demethylation of roxithromycin, M1, and M2, as well as troleandomycin, erythromycin, and M3.	Erythromycin	190-202	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
9806945-6	1998	The order for inhibition of CYP3A4-dependent testosterone 6beta-hydroxylation activities by these macrolide antibiotics in the recombinant CYP3A4 system was estimated to be troleandomycin &gt; erythromycin &gt;/= M3 &gt;/= M2 &gt; M1 &gt;/= roxithromycin.	Erythromycin	193-205	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34
9806945-6	1998	The order for inhibition of CYP3A4-dependent testosterone 6beta-hydroxylation activities by these macrolide antibiotics in the recombinant CYP3A4 system was estimated to be troleandomycin &gt; erythromycin &gt;/= M3 &gt;/= M2 &gt; M1 &gt;/= roxithromycin.	Erythromycin	193-205	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-145
9822896-0	1998	Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.	Erythromycin	49-61	ATP binding cassette subfamily B member 1	Homo sapiens	17-31
9822896-1	1998	The effect of cytochrome P-450 3A (CYP3A) substrates (erythromycin, midazolam) and an inhibitor (ketoconazole) on P-glycoprotein-mediated transport was studied in Caco-2, the human colon adenocarcinoma cell line expressing various functions of differentiated intestinal epithelial cells.	Erythromycin	54-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-40
9822896-3	1998	The basal-to-apical transport of rhodamine 123, a P-glycoprotein substrate, was inhibited by erythromycin, midazolam and ketoconazole, as well as by P-glycoprotein inhibitors such as verapamil.	Erythromycin	93-105	ATP binding cassette subfamily B member 1	Homo sapiens	50-64
9822896-7	1998	In conclusion, erythromycin, midazolam and ketoconazole could interact with P-glycoprotein-mediated transport, and P-glycoprotein could be, at least in part, involved in the transport of erythromycin, but not of midazolam and ketoconazole, in the intestinal epithelia.	Erythromycin	15-27	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9822896-7	1998	In conclusion, erythromycin, midazolam and ketoconazole could interact with P-glycoprotein-mediated transport, and P-glycoprotein could be, at least in part, involved in the transport of erythromycin, but not of midazolam and ketoconazole, in the intestinal epithelia.	Erythromycin	187-199	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
9822896-7	1998	In conclusion, erythromycin, midazolam and ketoconazole could interact with P-glycoprotein-mediated transport, and P-glycoprotein could be, at least in part, involved in the transport of erythromycin, but not of midazolam and ketoconazole, in the intestinal epithelia.	Erythromycin	187-199	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
9789363-10	1998	MRSA-strains were more resistant to imipenem, ofloxacin, gentamicin, trimethoprim-sulfamethoxazole, tetracycline, erythromycin and clindamycin as oxacillin-sensitive Straphylococcus aureus strains.	Erythromycin	114-126	solute carrier family 9 member A6	Homo sapiens	0-4
9691922-2	1998	In humans, no effect has been shown, but erythromycin, a motilin receptor agonist, induces gall bladder emptying.	Erythromycin	41-53	motilin	Homo sapiens	57-64
10030456-4	1998	The specificity of the induction by 4-methylpyrazole and of the inhibition by diallyl sulfide for CYP2E1 was determined using the [14C]caffeine (CYP1A2), [14C]aminopyrine (CYP2C11), and [14C]erythromycin (CYP3A2) breath tests.	Erythromycin	191-203	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	98-104
9701415-0	1998	Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells.	Erythromycin	0-12	endothelin 1	Homo sapiens	59-71
9701415-6	1998	Erythromycin and clarithromycin uniquely suppressed mRNA levels as well as the release of ET- at therapeutic and non-cytotoxic concentrations (percentage inhibition of ET-1 protein release: 26.4+/-5.22% and 31.2+/-7.45%, respectively, at 10(-6) M).	Erythromycin	0-12	endothelin 1	Homo sapiens	168-172
9701415-7	1998	Furthermore, erythromycin and clarithromycin inhibited ET-1 expression in bronchoepithelial cells from patients with chronic, stable asthma.	Erythromycin	13-25	endothelin 1	Homo sapiens	55-59
9694927-12	1998	These potential dual actions on HERG currents suggest that precautions should be taken in long-term ketoconazole treatment, particularly for patients who have decreased liver function or are on a drug regimen requiring simultaneous medications that use cytochrome-P450 for breakdown, such as terfenadine or erythromycin, or Class III antiarrhythmic drugs.	Erythromycin	307-319	potassium voltage-gated channel subfamily H member 2	Homo sapiens	32-36
9661038-0	1998	Inhibitory effect of erythromycin on superoxide anion production by human neutrophils primed with granulocyte-colony stimulating factor.	Erythromycin	21-33	colony stimulating factor 3	Homo sapiens	98-135
9612923-0	1998	Erythromycin, a motilin agonist, increases postprandial gallbladder emptying during therapy with ursodeoxycholic acid.	Erythromycin	0-12	motilin	Homo sapiens	16-23
9650537-1	1998	The erythromycin breath test (EBT), which measures 14CO2 produced from [14C N-methyl] erythromycin, is one of the most frequently employed measures to examine drug interactions involving cytochrome P450 3A4 (CYP3A).	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	187-206
9650537-1	1998	The erythromycin breath test (EBT), which measures 14CO2 produced from [14C N-methyl] erythromycin, is one of the most frequently employed measures to examine drug interactions involving cytochrome P450 3A4 (CYP3A).	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	208-213
9630823-4	1998	CYP3A inhibition was verified with erythromycin breath test.	Erythromycin	35-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
9562252-7	1998	In addition, constitutive NO synthase (cNOS) protein expression of endothelial cells was dose-dependently enhanced by treatment with erythromycin, which might also contribute to the enhancement of NO release from endothelial cells by erythromycin.	Erythromycin	234-246	nitric oxide synthase 3	Homo sapiens	39-43
9562252-8	1998	The effect of erythromycin as an anti-inflammatory agent might be partially mediated through the enhancement of NO release from endothelial cells and the drug might be a useful tool for the investigation of cNOS of endothelial cells.	Erythromycin	14-26	nitric oxide synthase 3	Homo sapiens	207-211
9618413-4	1998	Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine.	Erythromycin	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
9618413-4	1998	Anti-CYP3A antibodies, as well as the specific CYP3A inhibitors troleandomycin and erythromycin, inhibited small intestinal metabolism of sirolimus, confirming that, as in the liver, CYP3A enzymes are responsible for sirolimus metabolism in the small intestine.	Erythromycin	83-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
9562252-7	1998	In addition, constitutive NO synthase (cNOS) protein expression of endothelial cells was dose-dependently enhanced by treatment with erythromycin, which might also contribute to the enhancement of NO release from endothelial cells by erythromycin.	Erythromycin	133-145	nitric oxide synthase 3	Homo sapiens	39-43
9612923-4	1998	In order to find out whether erythromycin, a motilin agonist, improves gallbladder emptying, we tested gallbladder motility after administration of ursodeoxycholic acid with and without oral application of erythromycin.	Erythromycin	29-41	motilin	Homo sapiens	45-52
9600717-13	1998	Co-administration of adinazolam with CYP 3A4 inhibitors such as ketoconazole or erythromycin might lead to reduced efficacy, since adinazolam by itself has relatively weak benzodiazepine agonist activity, with much of the pharmacological activity of adinazolam being attributable to its active metabolite NDMAD.	Erythromycin	80-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
9545160-4	1998	Erythromycin competitively inhibits hepatic metabolism of warfarin, specifically the R-warfarin enantiomer, by the cytochrome P450 3A3 and 3A4 pathways, resulting in increased prothrombin time and international normalized ratio (INR).	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-134
9563840-1	1998	The production of erythromycin A by Saccharopolyspora erythraea requires the synthesis of dTDP-D-desosamine and dTDP-L-mycarose, which serve as substrates for the transfer of the two sugar residues onto the macrolactone ring.	Erythromycin	18-32	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	90-94
9563840-1	1998	The production of erythromycin A by Saccharopolyspora erythraea requires the synthesis of dTDP-D-desosamine and dTDP-L-mycarose, which serve as substrates for the transfer of the two sugar residues onto the macrolactone ring.	Erythromycin	18-32	TAR DNA-binding protein-43 homolog	Drosophila melanogaster	112-116
9328287-13	1997	Recombinant P450 3A7 coexpressed in bacterial membranes with NADPH-cytochrome P450 reductase showed similar levels of activity toward erythromycin (N-demethylation) and ethylmorphine (N-demethylation) to P450 3A4 and 3A5 expressed in the same system, whereas 3A7 was less active toward midazolam (1"- and 4-hydroxylation) and nifedipine (oxidation).	Erythromycin	134-146	cytochrome p450 oxidoreductase	Homo sapiens	61-92
9551706-3	1998	The influence of concomitant administration of erythromycin, a potent CYP3A4 inhibitor, on cerivastatin bioavailability and pharmacokinetics was investigated.	Erythromycin	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
9597508-0	1998	[Inhibition of neutrophil-derived IL-8 production caused by EM (erythromycin) 201 derivative: modification of the activities by the 5-position desosamine side chain].	Erythromycin	60-62	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
9597508-0	1998	[Inhibition of neutrophil-derived IL-8 production caused by EM (erythromycin) 201 derivative: modification of the activities by the 5-position desosamine side chain].	Erythromycin	64-76	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
9391548-12	1997	The erythromycin breath test is a valuable tool for measuring instantaneous CYP3A activity in vivo.	Erythromycin	4-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-81
9420030-6	1997	Cross-resistance to clarithromycin and erythromycin, which was transferred by natural transformation from the Cla(r) Ery(r) donor strain H. pylori E to the Cla(s) Ery(s) recipient strain H. pylori UA802, was associated with an single A-to-G transition mutation at position 2142 of both copies of the 23S rRNA in UA802 Cla(r) Ery(r) mutants.	Erythromycin	39-51	selectin P ligand	Homo sapiens	110-113
9420030-6	1997	Cross-resistance to clarithromycin and erythromycin, which was transferred by natural transformation from the Cla(r) Ery(r) donor strain H. pylori E to the Cla(s) Ery(s) recipient strain H. pylori UA802, was associated with an single A-to-G transition mutation at position 2142 of both copies of the 23S rRNA in UA802 Cla(r) Ery(r) mutants.	Erythromycin	39-51	selectin P ligand	Homo sapiens	156-159
9420030-6	1997	Cross-resistance to clarithromycin and erythromycin, which was transferred by natural transformation from the Cla(r) Ery(r) donor strain H. pylori E to the Cla(s) Ery(s) recipient strain H. pylori UA802, was associated with an single A-to-G transition mutation at position 2142 of both copies of the 23S rRNA in UA802 Cla(r) Ery(r) mutants.	Erythromycin	39-51	selectin P ligand	Homo sapiens	156-159
9420030-7	1997	The transformation frequency for Cla(r) and Ery(r) was found to be approximately 2 x 10(-6) transformants per viable cell, and the MICs of both clarithromycin and erythromycin for the Cla(r) Ery(r) mutants were equal to those for the donor isolate.	Erythromycin	163-175	selectin P ligand	Homo sapiens	33-36
9420030-7	1997	The transformation frequency for Cla(r) and Ery(r) was found to be approximately 2 x 10(-6) transformants per viable cell, and the MICs of both clarithromycin and erythromycin for the Cla(r) Ery(r) mutants were equal to those for the donor isolate.	Erythromycin	163-175	selectin P ligand	Homo sapiens	184-187
9505999-0	1997	The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers.	Erythromycin	14-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-39
9505999-5	1997	The presence of erythromycin also significantly increased the dehydrosertindole Cmax and AUC means by 16% and 21%, respectively, possibly due to inhibition of the CYP3A metabolic isozyme responsible for the elimination of this metabolite.	Erythromycin	16-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-168
9378989-0	1997	Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway: L-cladinose is involved both in alterations of neutrophil functions and modulation of this transductional pathway.	Erythromycin	0-14	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	104-119
9378989-3	1997	Taking roxithromycin as an example of erythromycin A derivatives, we also found that these molecules interfered with the phospholipase D (PLD)-phosphatidate phosphohydrolase pathway in two ways.	Erythromycin	38-52	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	121-136
9378989-3	1997	Taking roxithromycin as an example of erythromycin A derivatives, we also found that these molecules interfered with the phospholipase D (PLD)-phosphatidate phosphohydrolase pathway in two ways.	Erythromycin	38-52	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	138-141
9473310-0	1998	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Erythromycin	90-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	6-10
9473310-0	1998	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Erythromycin	90-102	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	21-26
9473310-0	1998	Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.	Erythromycin	90-102	phosphoglycolate phosphatase	Mus musculus	27-41
9473310-5	1998	In combination these complementary approaches identified erythromycin as a drug whose intracellular retention is influenced by Pgp, while the intracellular accumulation and tissue distribution of retinoic acid and benzo(a)pyrene were unaffected by Pgp.	Erythromycin	57-69	phosphoglycolate phosphatase	Mus musculus	127-130
9337943-6	1997	Inhibitors of CYPIA2 (caffeine, erythromycin) have the opposite effect.	Erythromycin	32-44	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	14-20
9352310-2	1997	Erythromycin (2-100 micrograms ml-1) produced a concentration-related inhibition of superoxide generation and elastase release induced by in vitro exposure of human polymorphonuclear leukocytes (PMNs) to the chemotactic peptide N-formylmethionyl-leucyl-phenylalanine (FMLP; 30 nM).	Erythromycin	0-12	formyl peptide receptor 1	Homo sapiens	268-272
9296239-5	1997	DISCUSSION: Erythromycin frequently interacts with other drugs that are also metabolized by the CYP3A4 isoenzyme.	Erythromycin	12-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	96-102
9333111-2	1997	Erythromycin and itraconazole are potent inhibitors of CYP3A4, and they increase plasma concentrations and effects of certain drugs, for example, oral midazolam and triazolam.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
9333111-14	1997	CONCLUSIONS: Both erythromycin and itraconazole greatly increased plasma buspirone concentrations, obviously by inhibiting its CYP3A4-mediated first-pass metabolism.	Erythromycin	18-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-133
9284278-5	1997	In the second study we assessed whether erythromycin, a motilin receptor agonist, could induce migrating motor activity in preterm and term infants.	Erythromycin	40-52	motilin	Homo sapiens	56-63
9416990-5	1997	On the other hand, erythromycin derivatives showed only a weak contractile efficacy (about 20% of the maximum response of chicken motilin) even at high concentrations (10-100 microM).	Erythromycin	19-31	motilin	Gallus gallus	130-137
9416990-8	1997	In the rabbit duodenum, chicken motilin was a full agonist with the same intrinsic activity as Leu13 porcine motilin, canine motilin and the erythromycin derivatives.	Erythromycin	141-153	motilin	Gallus gallus	32-39
9416990-11	1997	The motilin receptor present in the ileum is different from that demonstrated in the rabbit intestine, because of a different rank order of motilin peptides in producing the contraction, low contracting activity of erythromycin derivatives and low antagonistic efficacy of GM109.	Erythromycin	215-227	promotilin	Oryctolagus cuniculus	4-11
9230759-0	1997	Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.	Erythromycin	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	23-27
9219693-1	1997	A genetic block was introduced in the first condensation step of the polyketide biosynthetic pathway that leads to the formation of 6-deoxyerythronolide B (6-dEB), the macrocyclic precursor of erythromycin.	Erythromycin	193-205	DebC	Drosophila melanogaster	158-161
9230759-4	1997	EM and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-8 at the therapeutic and noncytotoxic concentrations (% inhibition of IL-8 protein release: 25.0 +/- 5.67% and 37.5 +/- 8.99%, respectively, at 10(-6) M).	Erythromycin	0-2	C-X-C motif chemokine ligand 8	Homo sapiens	159-163
9834366-2	1997	This effect of erythromycin resembles that of motilin, a gastrointestinal hormone, in evoking contractions similar to phase 3 activity of the migrating motor complex.	Erythromycin	15-27	motilin	Homo sapiens	46-53
9203450-0	1997	Erythromycin derivative improves gastric emptying and insulin requirement in diabetic patients with gastroparesis.	Erythromycin	0-12	insulin	Homo sapiens	54-61
9203450-5	1997	CONCLUSIONS: Preliminary results obtained from a small number of patients suggest that EM523L or erythromycin analogs, which have agonistic activity to motilin receptors as well as no antibacterial effect, may be useful to accelerate gastric emptying and improve insulin requirement patterns, thereby establishing more stable glycemic control.	Erythromycin	97-109	insulin	Homo sapiens	263-270
9205959-0	1997	Blockade of the human cardiac K+ channel Kv1.5 by the antibiotic erythromycin.	Erythromycin	65-77	potassium voltage-gated channel subfamily A member 5	Homo sapiens	41-46
9205959-3	1997	For this reason we examined the effects of erythromycin on a rapidly activating delayed rectifier K+ channel (Kv1.5) cloned from human heart and stably expressed in human embryonic kidney cells.	Erythromycin	43-55	potassium voltage-gated channel subfamily A member 5	Homo sapiens	110-115
9205959-4	1997	When examined using the whole-cell patch clamp technique, erythromycin (100 microM) blocked Kv1.5 current in a time-dependent manner but required prolonged exposure to do so.	Erythromycin	58-70	potassium voltage-gated channel subfamily A member 5	Homo sapiens	92-97
9205959-5	1997	However, when we examined Kv1.5 current using inside-out macro-patches, erythromycin applied to the cytoplasmic surface rapidly (within 1-2 min) inhibited Kv1.5 current with an IC50 value of 2.6 x 10(-5)M (1.7 - 3.9 x 10(-5)M, 95% C.L.).	Erythromycin	72-84	potassium voltage-gated channel subfamily A member 5	Homo sapiens	26-31
9205959-5	1997	However, when we examined Kv1.5 current using inside-out macro-patches, erythromycin applied to the cytoplasmic surface rapidly (within 1-2 min) inhibited Kv1.5 current with an IC50 value of 2.6 x 10(-5)M (1.7 - 3.9 x 10(-5)M, 95% C.L.).	Erythromycin	72-84	potassium voltage-gated channel subfamily A member 5	Homo sapiens	155-160
9205959-6	1997	The main effect of erythromycin was to accelerate the rate of Kv1.5 current decay thereby reducing the current at the end of a prolonged voltage-clamp pulse.	Erythromycin	19-31	potassium voltage-gated channel subfamily A member 5	Homo sapiens	62-67
9205959-7	1997	Erythromycin also blocked Kv1.5 current in both a voltage- and frequency-dependent manner but had little effect on the activation kinetics, deactivation kinetics, or the steady-state inactivation properties of Kv1.5.	Erythromycin	0-12	potassium voltage-gated channel subfamily A member 5	Homo sapiens	26-31
9205959-8	1997	These data suggest that erythromycin acts as a blocker of an activated state of the Kv1.5 channel and that it may access its binding site from the intracellular face of the channel.	Erythromycin	24-36	potassium voltage-gated channel subfamily A member 5	Homo sapiens	84-89
9205959-10	1997	It is concluded that erythromycin blocks Kv1.5 at clinically relevant concentrations.	Erythromycin	21-33	potassium voltage-gated channel subfamily A member 5	Homo sapiens	41-46
9176206-6	1997	Erythromycin A and its derivative N-trimethyl erythromycin A cnol ether also bound to cerebellar motilin receptors (pKd,hi = 7.29 and 8.91, respectively).	Erythromycin	0-14	promotilin	Oryctolagus cuniculus	97-104
9441129-10	1997	In conclusion, EM can ameliorate bleomycin-induced pulmonary fibrosis possibly through suppression of TNF-alpha and PDGF as well as the inhibition on accumulation of inflammatory cells in the lung.	Erythromycin	15-17	tumor necrosis factor	Rattus norvegicus	102-111
9223231-9	1997	Interference with the MPO-H2O2-halide system was also observed with spiramycin, erythromycin and oxytetracycline, while the latter was also observed with penicillin.	Erythromycin	80-92	myeloperoxidase	Bos taurus	22-25
9164415-4	1997	Hepatic CYP3A activity was evaluated with the erythromycin breath test (ERMBT).	Erythromycin	46-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-13
9255055-2	1997	We investigated the effect of some macrolides, erythromycin (EM), rokitamycin (RKM), midecamycin (MDM) on the expression of neutrophil adhesion molecule Mac-1 using LPS-stimulated human whole blood as an experimental vivo model.	Erythromycin	47-59	integrin subunit alpha M	Homo sapiens	153-158
9107550-0	1997	Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation.	Erythromycin	74-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-25
9107550-2	1997	Cytochrome P450 3A4 is known to catalyze the metabolism of both endogenous substrates (such as the 6 beta-hydroxylation of testosterone) and many important therapeutic agents, including the N-demethylation of erythromycin.	Erythromycin	209-221	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
9107550-5	1997	In both human liver microsomal and recombinant CYP3A4 systems, erythromycin inhibited testosterone 6 beta-hydroxylation in a concentration dependent manner, and vice versa.	Erythromycin	63-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-53
9107550-11	1997	We conclude from these studies that testosterone and erythromycin mutually inhibit the metabolism of each other, consistent with the fact that CYP 3A4 catalyzes the metabolism of both substrates.	Erythromycin	53-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-150
9149974-8	1997	Erythromycin and pirlimycin demonstrated good activity against the S. aureus strains that were negative for beta-lactamase; 90% of the isolates had an MIC of &lt; or = 0.5 microgram/ml (MIC90).	Erythromycin	0-12	beta-lactamase	Staphylococcus aureus	108-122
9149974-9	1997	The MIC90 for erythromycin and pirlimycin for strains that were positive for beta-lactamase was &gt; 64.0 micrograms/ml.	Erythromycin	14-26	beta-lactamase	Staphylococcus aureus	77-91
9125127-2	1997	scavenging activity of erythromycin (EM) and of EM-iron complex by means of electron spin resonance spectroscopy, luminol-dependent chemiluminescence assay, and cytochrome c reduction assay.	Erythromycin	23-35	cytochrome c, somatic	Homo sapiens	161-173
9056243-5	1997	The mitochondrial-associated P450 forms are capable of metabolizing resorufin derivatives, erythromycin, and p-nitrophenol in an adrenodoxin- and adrenodoxin reductase-supported system.	Erythromycin	91-103	ferredoxin reductase	Rattus norvegicus	146-167
9597458-0	1997	[Effects and actions of EM (erythromycin), CAM (clarithromycin), and JM (josamycin) on IL-4 and IL-5 production by monocytes].	Erythromycin	24-26	interleukin 4	Homo sapiens	87-91
9597458-0	1997	[Effects and actions of EM (erythromycin), CAM (clarithromycin), and JM (josamycin) on IL-4 and IL-5 production by monocytes].	Erythromycin	24-26	interleukin 5	Homo sapiens	96-100
9088578-7	1997	Quinine 3-hydroxylation was inhibited by the specific CYP3A inhibitors, troleandomycin, midazolam and erythromycin.	Erythromycin	102-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-59
9143866-5	1997	The substrates of CYP2D6 such as thioridazine, amitriptyline and metoprolol inhibited the O-demethylation of codeine preferentially, while the substrates of CYP3A4 such as cyclosporine A, midazolam and erythromycin were all strong inhibitors of the N-demethylation of codeine.	Erythromycin	202-214	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	18-24
9143866-5	1997	The substrates of CYP2D6 such as thioridazine, amitriptyline and metoprolol inhibited the O-demethylation of codeine preferentially, while the substrates of CYP3A4 such as cyclosporine A, midazolam and erythromycin were all strong inhibitors of the N-demethylation of codeine.	Erythromycin	202-214	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	157-163
9255055-6	1997	These findings indicate that some macrolides such as EM suppress the surface expression of Mac-1 on neutrophil and may alleviate local alveolar injury in chronic pulmonary diseases.	Erythromycin	53-55	integrin subunit alpha M	Homo sapiens	91-96
9210180-4	1997	Clinical application of motilin as a prokinetic has become possible since erythromycin and its derivatives were proved to be nonpeptide motilin agonists.	Erythromycin	74-86	motilin	Gallus gallus	24-31
9210180-4	1997	Clinical application of motilin as a prokinetic has become possible since erythromycin and its derivatives were proved to be nonpeptide motilin agonists.	Erythromycin	74-86	motilin	Gallus gallus	136-143
11243219-1	1997	The possibility of involvement of cytochrome P4503A (CYP3A) in the monohydroxylation of the ring A of praziquantel (PZQ) was studied by using CYP3A specific inducer dexamethasone (DEX), specific inhibitor triacetyloeandomycin (TAO) and the activity of erythromycin (ERY) and ethylmorphine (EMP) N-demethylase which are known to be marker for CYP3A enzyme activity as probes.	Erythromycin	252-264	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	34-40
9200223-8	1997	The region responsible for erythromycin resistance was 98.2% identical to the erm gene of conjugative transposon Tn1545.	Erythromycin	27-39	erythromycin resistance protein	Lactobacillus fermentum	78-81
11243219-1	1997	The possibility of involvement of cytochrome P4503A (CYP3A) in the monohydroxylation of the ring A of praziquantel (PZQ) was studied by using CYP3A specific inducer dexamethasone (DEX), specific inhibitor triacetyloeandomycin (TAO) and the activity of erythromycin (ERY) and ethylmorphine (EMP) N-demethylase which are known to be marker for CYP3A enzyme activity as probes.	Erythromycin	252-264	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	53-58
11243219-1	1997	The possibility of involvement of cytochrome P4503A (CYP3A) in the monohydroxylation of the ring A of praziquantel (PZQ) was studied by using CYP3A specific inducer dexamethasone (DEX), specific inhibitor triacetyloeandomycin (TAO) and the activity of erythromycin (ERY) and ethylmorphine (EMP) N-demethylase which are known to be marker for CYP3A enzyme activity as probes.	Erythromycin	266-269	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	34-40
11243219-1	1997	The possibility of involvement of cytochrome P4503A (CYP3A) in the monohydroxylation of the ring A of praziquantel (PZQ) was studied by using CYP3A specific inducer dexamethasone (DEX), specific inhibitor triacetyloeandomycin (TAO) and the activity of erythromycin (ERY) and ethylmorphine (EMP) N-demethylase which are known to be marker for CYP3A enzyme activity as probes.	Erythromycin	266-269	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	53-58
8996099-0	1996	Minimal functional system required for expression of erythromycin resistance by msrA in Staphylococcus aureus RN4220.	Erythromycin	53-65	ABC transporter permease protein	Staphylococcus aureus	80-84
8996099-1	1996	Previous studies have suggested that inducible erythromycin (Er) resistance in staphylococci mediated by the plasmid-borne ABC-transporter msrA is dependent on additional unidentified chromosomally encoded transmembrane (TM) domains.	Erythromycin	47-59	ABC transporter permease protein	Staphylococcus aureus	139-143
8977529-6	1996	RESULTS: Aminophylline (AM), methylprednisolone (MP), erythromycin (EM), and clarithromycin (CAM) suppressed the IL-5 induced prolongation of eosinophil survival in a dose-dependent manner.	Erythromycin	54-66	interleukin 5	Homo sapiens	113-117
8977529-6	1996	RESULTS: Aminophylline (AM), methylprednisolone (MP), erythromycin (EM), and clarithromycin (CAM) suppressed the IL-5 induced prolongation of eosinophil survival in a dose-dependent manner.	Erythromycin	68-70	interleukin 5	Homo sapiens	113-117
8917691-2	1996	At the two highest doses, FB1 increased the renal and hepatic N-demethylation of erythromycin (CYP3A1) and the hepatic O-deethylation of ethoxyresorufin (CYP1A1).	Erythromycin	81-93	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	95-101
8968354-11	1996	Biotransformation of rifabutin in vivo and in vitro was markedly induced by dexamethasone and inhibited by erythromycin, suggesting that CYP3A is involved in the metabolism of rifabutin.	Erythromycin	107-119	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	137-142
8959645-0	1996	Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.	Erythromycin	11-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
8959645-2	1996	Roxithromycin and erythromycin were found to be relatively weak inhibitors of testosterone 6 beta-hydroxylation and nifedipine oxidation activities by rat and human liver microsomes or by reconstituted systems containing CYP3A4/5.	Erythromycin	18-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	221-227
8959645-4	1996	Erythromycin and roxithromycin were also activated slightly by rat liver microsomes to form P450.Fe(II)-metabolite complex, although these chemicals caused very little or undetectable levels, respectively, of spectral changes by human liver microsomes even when a human sample which contained relatively high levels of CYP3A4 was used.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	319-325
8959645-5	1996	These results suggested that roxithromycin and erythromycin were relatively less potent to inhibit CYP3A4-catalytic activities in human liver microsomes, because of their low capabilities to form P450.Fe(II)-metabolite complex.	Erythromycin	47-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
8894516-5	1996	Ciprofloxacin and norfloxacin significantly depressed the N-demethylation of erythromycin by CYP3A4 in human microsomes and by CYP3A2 in rat microsomes.	Erythromycin	77-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
8948090-13	1996	These data suggest that erythromycin and troleandomycin, but not roxithromycin, were able to induce CYP3A1 in rat liver microsomes, and that N-demethylation of roxithromycin, erythromycin and troleandomycin were catalysed mainly by 3A1 (and partly by 2B1) in rat and by 3A4 in man.	Erythromycin	24-36	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	100-106
8948090-13	1996	These data suggest that erythromycin and troleandomycin, but not roxithromycin, were able to induce CYP3A1 in rat liver microsomes, and that N-demethylation of roxithromycin, erythromycin and troleandomycin were catalysed mainly by 3A1 (and partly by 2B1) in rat and by 3A4 in man.	Erythromycin	24-36	UDP glucuronosyltransferase family 2 member B17	Rattus norvegicus	251-254
8948090-0	1996	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes.	Erythromycin	26-38	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	100-115
8948090-4	1996	Erythromycin and troleandomycin but not roxithromycin caused slight increases in CYP3A1 levels and the N-demethylation of roxithromycin, erythromycin and troleandomycin and oxidation of nifedipine in rat, but none of these chemicals induced significantly CYP2B1 levels or benzphetamine N-demethylation activities.	Erythromycin	0-12	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	81-87
8948090-4	1996	Erythromycin and troleandomycin but not roxithromycin caused slight increases in CYP3A1 levels and the N-demethylation of roxithromycin, erythromycin and troleandomycin and oxidation of nifedipine in rat, but none of these chemicals induced significantly CYP2B1 levels or benzphetamine N-demethylation activities.	Erythromycin	0-12	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	255-261
8886601-6	1996	Studies using chemical inhibitors of human P450 enzymes revealed that only agents known to inhibit CYP3A4 (e.g. ketoconazole and erythromycin) were capable of strongly inhibiting (&gt; or = 90%) microsomal fentanyl oxidation.	Erythromycin	129-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
8710862-1	1996	Here we show that protein synthesis inhibitors chloramphenicol and erythromycin, which bind to domain V of 23S rRNA of E. coli, can inhibit reactivation of denatured pig muscle lactate dehydrogenase and fungal glucose-6-phosphate dehydrogenase by 23S rRNA completely.	Erythromycin	67-79	glucose-6-phosphate dehydrogenase	Sus scrofa	210-243
8780573-0	1996	Erythromycin inhibits rabbit pyloric smooth muscle through neuronal motilin receptors.	Erythromycin	0-12	promotilin	Oryctolagus cuniculus	68-75
8780573-8	1996	Motilin tachyphylaxis both in the presence or absence of tetrodotoxin abolished the effects of erythromycin.	Erythromycin	95-107	promotilin	Oryctolagus cuniculus	0-7
8780573-10	1996	CONCLUSIONS: These studies suggest that motilin receptors are present on both pyloric muscle and inhibitory neurons to pyloric muscle, that the primary effect of erythromycin on the pylorus is mediated by activating motilin receptors on inhibitory motor neurons, and that both nitric oxide and vasoactive intestinal peptide may mediate the inhibitory effect of erythromycin.	Erythromycin	162-174	promotilin	Oryctolagus cuniculus	40-47
8780573-10	1996	CONCLUSIONS: These studies suggest that motilin receptors are present on both pyloric muscle and inhibitory neurons to pyloric muscle, that the primary effect of erythromycin on the pylorus is mediated by activating motilin receptors on inhibitory motor neurons, and that both nitric oxide and vasoactive intestinal peptide may mediate the inhibitory effect of erythromycin.	Erythromycin	162-174	promotilin	Oryctolagus cuniculus	216-223
8741708-7	1996	Erythromycin produced similar inhibitory effects on IL-8-induced goblet cell secretion and neutrophil accumulation, whereas amoxicillin and cefaclor had no effect.	Erythromycin	0-12	interleukin-8	Cavia porcellus	52-56
9231305-5	1996	It is postulated that the addition of erythromycin, a known inhibitor of CYP3A and CYP1A2, resulted in alterations in the metabolism of clomipramine and risperidone.	Erythromycin	38-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
9231305-5	1996	It is postulated that the addition of erythromycin, a known inhibitor of CYP3A and CYP1A2, resulted in alterations in the metabolism of clomipramine and risperidone.	Erythromycin	38-50	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	83-89
9231305-7	1996	Erythromycin would inhibit demethylation of clomipramine at the 1A2 isoenzyme and lead to a dual interaction between risperidone and clomipramine at the CYP2D6 isoenzyme.	Erythromycin	0-12	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	153-159
8726037-0	1996	Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells.	Erythromycin	21-33	C-X-C motif chemokine ligand 8	Homo sapiens	37-50
8726037-0	1996	Inhibitory effect of erythromycin on interleukin 8 production by 1 alpha,25-dihydroxyvitamin D3-stimulated THP-1 cells.	Erythromycin	21-33	GLI family zinc finger 2	Homo sapiens	107-112
8726037-1	1996	We have recently reported that long-term administration of erythromycin at a low dose reduced the number of neutrophils and concentrations of interleukin 8 (IL-8) in bronchoalveolar lavage fluid in patients with chronic lower respiratory tract disease.	Erythromycin	59-71	C-X-C motif chemokine ligand 8	Homo sapiens	142-155
8726037-1	1996	We have recently reported that long-term administration of erythromycin at a low dose reduced the number of neutrophils and concentrations of interleukin 8 (IL-8) in bronchoalveolar lavage fluid in patients with chronic lower respiratory tract disease.	Erythromycin	59-71	C-X-C motif chemokine ligand 8	Homo sapiens	157-161
8726037-2	1996	To investigate the mechanism of action of erythromycin, we evaluated its effect on IL-8 production in the 1 alpha,25-dihydroxyvitamin D3-stimulated human monocytic cell line THP-1.	Erythromycin	42-54	C-X-C motif chemokine ligand 8	Homo sapiens	83-87
8726037-2	1996	To investigate the mechanism of action of erythromycin, we evaluated its effect on IL-8 production in the 1 alpha,25-dihydroxyvitamin D3-stimulated human monocytic cell line THP-1.	Erythromycin	42-54	GLI family zinc finger 2	Homo sapiens	174-179
8726037-3	1996	Erythromycin at a concentration of 10 micrograms/ml significantly reduced IL-8 production by THP-1 cells stimulated with lipopolysaccharide (10 ng/ml) and 1% normal human serum compared with the amount produced by untreated cells (untreated cells, 2,448 pg/ml; erythromycin-treated cells, 872 pg/ml).	Erythromycin	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
8726037-3	1996	Erythromycin at a concentration of 10 micrograms/ml significantly reduced IL-8 production by THP-1 cells stimulated with lipopolysaccharide (10 ng/ml) and 1% normal human serum compared with the amount produced by untreated cells (untreated cells, 2,448 pg/ml; erythromycin-treated cells, 872 pg/ml).	Erythromycin	0-12	GLI family zinc finger 2	Homo sapiens	93-98
8726037-3	1996	Erythromycin at a concentration of 10 micrograms/ml significantly reduced IL-8 production by THP-1 cells stimulated with lipopolysaccharide (10 ng/ml) and 1% normal human serum compared with the amount produced by untreated cells (untreated cells, 2,448 pg/ml; erythromycin-treated cells, 872 pg/ml).	Erythromycin	261-273	GLI family zinc finger 2	Homo sapiens	93-98
8726037-4	1996	Our results suggest that erythromycin may impair IL-8 production by alveolar macrophages, ultimately reducing neutrophil accumulation in the airspace.	Erythromycin	25-37	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
8655571-2	1996	We now report the construction of a specific flgE mutant of T. denticola ATCC 35405 following electroporation utilizing an erythromycin resistance cassette inserted into an flgE DNA fragment.	Erythromycin	123-135	flagellar hook protein FlgE	Treponema denticola ATCC 35405	45-49
8807072-0	1996	Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas.	Erythromycin	29-41	interleukin-8	Cavia porcellus	45-58
8689812-13	1996	Inhibition of CYP3A4-mediated metabolism probably explains the increased toxicity of lovastatin caused not only by itraconazole but also by cyclosporine, erythromycin, and other inhibitors of CYP3A4.	Erythromycin	154-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
8646822-9	1996	CONCLUSION: This study suggests that erythromycin, an inhibitor of CYP3A4, inhibits the metabolism of alprazolam, providing an in vivo evidence for the involvement of CYP3A4 in its metabolism.	Erythromycin	37-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
8905799-1	1996	To clarify the involvement of cytochrome P4503A (CYP3A) and CYP2C19 in the metabolism of alprazolam, the effects of pretreatment with erythromycin, which is an inhibitor of CYP3A and S-mephenytoin 4-hydroxylation capacity on the single-oral dose kinetics of alprazolam were studied in 12 healthy male volunteers.	Erythromycin	134-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	173-178
8646822-9	1996	CONCLUSION: This study suggests that erythromycin, an inhibitor of CYP3A4, inhibits the metabolism of alprazolam, providing an in vivo evidence for the involvement of CYP3A4 in its metabolism.	Erythromycin	37-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	167-173
29681360-9	1996	Most PRSP were resistant to erythromycin and minocycline.	Erythromycin	28-40	HtrA serine peptidase 3	Homo sapiens	5-9
8608647-8	1996	Erythromycin therapy significantly reduced these cytokines to levels comparable to those of healthy volunteers, and produced a trend toward reduction in the level of IL-1Ra in BALF.	Erythromycin	0-12	interleukin 1 receptor antagonist	Homo sapiens	166-172
8608647-12	1996	Our results suggest that the relative amounts of IL-1beta and IL-1Ra or IL-8 may contribute, at least in part, to the neutrophil-mediated chronic airway inflammation in patients with chronic airway disease, and long-term erythromycin therapy may down-regulate the vigorous cycle between the cytokine network and neutrophil accumulation, with resultant reduction of neutrophil-mediated inflammatory response.	Erythromycin	221-233	interleukin 1 beta	Homo sapiens	49-57
8608647-12	1996	Our results suggest that the relative amounts of IL-1beta and IL-1Ra or IL-8 may contribute, at least in part, to the neutrophil-mediated chronic airway inflammation in patients with chronic airway disease, and long-term erythromycin therapy may down-regulate the vigorous cycle between the cytokine network and neutrophil accumulation, with resultant reduction of neutrophil-mediated inflammatory response.	Erythromycin	221-233	interleukin 1 receptor antagonist	Homo sapiens	62-68
8608647-12	1996	Our results suggest that the relative amounts of IL-1beta and IL-1Ra or IL-8 may contribute, at least in part, to the neutrophil-mediated chronic airway inflammation in patients with chronic airway disease, and long-term erythromycin therapy may down-regulate the vigorous cycle between the cytokine network and neutrophil accumulation, with resultant reduction of neutrophil-mediated inflammatory response.	Erythromycin	221-233	C-X-C motif chemokine ligand 8	Homo sapiens	72-76
8838458-4	1996	In heteromeric NR1A/NR2B receptors, (+) erythro- and (-) threo-ifenprodil (IC50 0.21 and 0.22 microM, respectively) were about 4 times more potent than (-) erythro- and (+) threo-ifenprodil (IC50 0.81 and 0.76, respectively).	Erythromycin	40-47	nodal homolog 1 L homeolog	Xenopus laevis	15-19
8838458-4	1996	In heteromeric NR1A/NR2B receptors, (+) erythro- and (-) threo-ifenprodil (IC50 0.21 and 0.22 microM, respectively) were about 4 times more potent than (-) erythro- and (+) threo-ifenprodil (IC50 0.81 and 0.76, respectively).	Erythromycin	40-47	glutamate receptor ionotropic, NMDA 2B	Xenopus laevis	20-24
8838458-4	1996	In heteromeric NR1A/NR2B receptors, (+) erythro- and (-) threo-ifenprodil (IC50 0.21 and 0.22 microM, respectively) were about 4 times more potent than (-) erythro- and (+) threo-ifenprodil (IC50 0.81 and 0.76, respectively).	Erythromycin	156-163	nodal homolog 1 L homeolog	Xenopus laevis	15-19
8838458-4	1996	In heteromeric NR1A/NR2B receptors, (+) erythro- and (-) threo-ifenprodil (IC50 0.21 and 0.22 microM, respectively) were about 4 times more potent than (-) erythro- and (+) threo-ifenprodil (IC50 0.81 and 0.76, respectively).	Erythromycin	156-163	glutamate receptor ionotropic, NMDA 2B	Xenopus laevis	20-24
8548776-5	1996	The formation of hydroxydocetaxel was strongly reduced by CYP3A inhibitors such as ketoconazole, midazolam, erythromycin, testosterone, orphenadrine, and troleandomycin, whereas quinidine (CYP2D6), hexobarbital, tolbutamide, and mephenytoin (CYP2C) had no or little effect.	Erythromycin	108-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-63
8548776-5	1996	The formation of hydroxydocetaxel was strongly reduced by CYP3A inhibitors such as ketoconazole, midazolam, erythromycin, testosterone, orphenadrine, and troleandomycin, whereas quinidine (CYP2D6), hexobarbital, tolbutamide, and mephenytoin (CYP2C) had no or little effect.	Erythromycin	108-120	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	189-195
8627536-7	1996	Cytochrome P-450 reactions attributed to P-450s other than CYP2D, such as aniline p-hydroxylation, the high Km system of MDMA demethylation and the N-demethylation of methamphetamine, benzphetamine, aminopyrine and erythromycin, all appeared to be minimally affected.	Erythromycin	215-227	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
8660328-6	1996	CYP3A9 cDNA was expressed in E. coli and the expressed P450 3A9 is active in the demethylation of erythromycin as well as benzphetamine.	Erythromycin	98-110	cytochrome P450, family 3, subfamily a, polypeptide 9	Rattus norvegicus	0-6
8861661-5	1996	The DM-3MM ratios were sensitive to the co-administration of selective CYP3A inhibitors grapefruit juice and erythromycin.	Erythromycin	109-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-76
8942140-8	1996	Furthermore, the levels of interleukin-8 and neutrophil chemotactic activity in the bronchoalveolar lavage fluid of cryptogenic organizing pneumonia patients with bronchoalveolar lavage fluid neutrophilia were significantly decreased following treatment with erythromycin.	Erythromycin	259-271	C-X-C motif chemokine ligand 8	Homo sapiens	27-40
8942140-10	1996	It is possible that cryptogenic organizing pneumonia is caused by neutrophil-mediated inflammation, and that the favorable clinical effect of erythromycin is due to inhibition of neutrophil accumulation in the peripheral airways through a biological activity other than bacteriostasis, e.g., local suppression of interleukin-8 production.	Erythromycin	142-154	C-X-C motif chemokine ligand 8	Homo sapiens	313-326
8959762-3	1996	The binding of [125I]motilin to BL membrane was competitively inhibited by both unlabeled motilin and erythromycin.	Erythromycin	102-114	promotilin	Oryctolagus cuniculus	21-28
8801522-10	1996	The motilin agonists erythromycin A and EM-523 were almost without effect.	Erythromycin	21-35	motilin	Gallus gallus	4-11
8577928-1	1995	Erythromycin, a motilin agonist, enhances gastrointestinal motility but also stimulates endogenous pancreatic polypeptide (PP) secretion.	Erythromycin	0-12	pancreatic polypeptide	Homo sapiens	99-121
8689938-9	1995	The metabolism of tacrolimus by human small intestine was inhibited by anti-CYP3A, troleandomycin, and erythromycin, indicating that, as in the liver, CYP3A enzymes are the major enzymes for tacrolimus metabolism in the human small intestine.	Erythromycin	103-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	151-156
8619599-0	1995	Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2"-phosphotransferase I in Escherichia coli.	Erythromycin	44-56	macrolide 2'-phosphotransferase I	Escherichia coli	93-126
8619599-2	1995	Deletion and complementation analyses indicated that the expression of high-level resistance to erythromycin requires two genes, mphA and mrx, which encode macrolide 2"-phosphotransferase I and an unidentified hydrophobic protein, respectively.	Erythromycin	96-108	macrolide 2-phosphotransferase	Escherichia coli	129-133
8619599-2	1995	Deletion and complementation analyses indicated that the expression of high-level resistance to erythromycin requires two genes, mphA and mrx, which encode macrolide 2"-phosphotransferase I and an unidentified hydrophobic protein, respectively.	Erythromycin	96-108	Mrx	Escherichia coli	138-141
8619599-2	1995	Deletion and complementation analyses indicated that the expression of high-level resistance to erythromycin requires two genes, mphA and mrx, which encode macrolide 2"-phosphotransferase I and an unidentified hydrophobic protein, respectively.	Erythromycin	96-108	macrolide 2'-phosphotransferase I	Escherichia coli	156-189
8575568-0	1995	Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells.	Erythromycin	10-22	interleukin 6	Homo sapiens	78-82
8575568-5	1995	Incubation of the epithelial cultures in the presence of 0.1-10 micrograms.mL-1 erythromycin significantly blocked the HIE-induced release of IL-6, IL-8, and sICAM-1, at all concentrations of erythromycin investigated.	Erythromycin	80-92	interleukin 6	Homo sapiens	142-146
8575568-5	1995	Incubation of the epithelial cultures in the presence of 0.1-10 micrograms.mL-1 erythromycin significantly blocked the HIE-induced release of IL-6, IL-8, and sICAM-1, at all concentrations of erythromycin investigated.	Erythromycin	80-92	C-X-C motif chemokine ligand 8	Homo sapiens	148-152
8959762-4	1996	The IC50s were (2.1 +/- 0.4) 10(-8) M and (1.3 +/- 0.1) 10(-6) M for motilin and erythromycin, respectively, and the Ki were (6.83 +/- 1.3) 10(-9) M for motilin and (4.32 +/- 0.33) 10(-7) M for erythromycin.	Erythromycin	81-93	promotilin	Oryctolagus cuniculus	153-160
8959762-4	1996	The IC50s were (2.1 +/- 0.4) 10(-8) M and (1.3 +/- 0.1) 10(-6) M for motilin and erythromycin, respectively, and the Ki were (6.83 +/- 1.3) 10(-9) M for motilin and (4.32 +/- 0.33) 10(-7) M for erythromycin.	Erythromycin	194-206	promotilin	Oryctolagus cuniculus	69-76
8833992-8	1996	In addition, the concentration of IL-8 in alveolar macrophages obtained from 2 volunteers before and after oral erythromycin administration also decreased ex vivo.	Erythromycin	112-124	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
8825372-3	1995	Recombination of an IS257-containing plasmid conferring erythromycin resistance, pOX7-IS, into either of the IS257s of pJ3356 has been observed.	Erythromycin	56-68	IS257 transposase	Staphylococcus aureus	20-25
8577928-1	1995	Erythromycin, a motilin agonist, enhances gastrointestinal motility but also stimulates endogenous pancreatic polypeptide (PP) secretion.	Erythromycin	0-12	pancreatic polypeptide	Homo sapiens	123-125
8577928-2	1995	We investigated whether the effect of erythromycin on PP release is dependent on (1) prokinetic activity of erythromycin generated from the antrum and (2) the long vagus nerve since erythromycin acts via cholinergic neurons.	Erythromycin	38-50	pancreatic polypeptide	Homo sapiens	54-56
8577928-3	1995	Erythromycin induced PP secretion was determined in 14 patients with antrectomy (6 patients with Billroth I type anastomosis, 8 patients with Billroth II type anastomosis), in 6 patients with truncal vagotomy and pyloroplasty but without gastric resection and in 8 healthy controls.	Erythromycin	0-12	pancreatic polypeptide	Homo sapiens	21-23
8577928-4	1995	Plasma PP levels in response to erythromycin (3 mg/kg i.v.)	Erythromycin	32-44	pancreatic polypeptide	Homo sapiens	7-9
8577928-6	1995	Erythromycin induced a significant increase in plasma PP in the control subjects from 22 +/- 4 pmol/l (basal) to 49 +/- 4 pmol/l at 10 min.	Erythromycin	0-12	pancreatic polypeptide	Homo sapiens	54-56
8577928-7	1995	In the patients with truncal vagotomy plasma PP secretion after erythromycin was significantly (P &lt; 0.05) increased (peak increment vs. basal: 98 +/- 10 pmol/l vs. 27 +/- 2 pmol/l) and prolonged compared to controls.	Erythromycin	64-76	pancreatic polypeptide	Homo sapiens	45-47
8577928-9	1995	It is concluded that erythromycin stimulates PP secretion in healthy controls.	Erythromycin	21-33	pancreatic polypeptide	Homo sapiens	45-47
8577928-10	1995	The PP response to erythromycin is exaggerated after truncal vagotomy but absent after antrectomy indicating that the antrum is essential for erythromycin induced PP secretion.	Erythromycin	19-31	pancreatic polypeptide	Homo sapiens	4-6
8577928-10	1995	The PP response to erythromycin is exaggerated after truncal vagotomy but absent after antrectomy indicating that the antrum is essential for erythromycin induced PP secretion.	Erythromycin	19-31	pancreatic polypeptide	Homo sapiens	163-165
8577928-10	1995	The PP response to erythromycin is exaggerated after truncal vagotomy but absent after antrectomy indicating that the antrum is essential for erythromycin induced PP secretion.	Erythromycin	142-154	pancreatic polypeptide	Homo sapiens	4-6
8577928-10	1995	The PP response to erythromycin is exaggerated after truncal vagotomy but absent after antrectomy indicating that the antrum is essential for erythromycin induced PP secretion.	Erythromycin	142-154	pancreatic polypeptide	Homo sapiens	163-165
7668024-1	1995	The motilin agonist erythromycin affects gastrointestinal motility.	Erythromycin	20-32	motilin	Homo sapiens	4-11
7628702-2	1995	Five mutations causing a 100-400-fold increase in the frequency of erythromycin-resistant (ErR) mt mutants in yeast mapped to the 3"-5" exonuclease (Exo) domain, and mainly to the three conserved motifs Exo1, Exo2 and Exo3 of this domain, highlighting the importance of proofreading in accurate mt DNA replication.	Erythromycin	67-79	Rad2 family nuclease EXO1	Saccharomyces cerevisiae S288C	203-207
7890608-5	1995	The rate of CO binding to the total mixture of P450 3A4 conformers was increased in the presence of nifedipine and erythromycin, decreased by quinidine, testosterone, and warfarin, and unaffected by cimetidine and 17 alpha-ethynylestradiol.	Erythromycin	115-127	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	47-51
7763252-0	1995	Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action.	Erythromycin	0-12	interleukin 6	Homo sapiens	24-37
7763252-2	1995	Among those tested, erythromycin (EM) and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-6 at the therapeutic and non-cytotoxic concentration (10(-6)M).	Erythromycin	20-32	interleukin 6	Homo sapiens	121-125
7763252-2	1995	Among those tested, erythromycin (EM) and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-6 at the therapeutic and non-cytotoxic concentration (10(-6)M).	Erythromycin	34-36	interleukin 6	Homo sapiens	121-125
7785987-7	1995	Erythromycin increased intracellular levels of cyclic AMP (cAMP) to 150% of control levels in neutrophils.	Erythromycin	0-12	cathelicidin antimicrobial peptide	Homo sapiens	59-63
7785987-9	1995	H-89, an inhibitor of cAMP-dependent protein kinase A, partially blocked the survival-shortening effect of erythromycin.	Erythromycin	107-119	cathelicidin antimicrobial peptide	Homo sapiens	22-26
7785987-10	1995	Our findings suggest that erythromycin shortens neutrophil survival at least in part through elevation of intracellular cAMP levels.	Erythromycin	26-38	cathelicidin antimicrobial peptide	Homo sapiens	120-124
7617555-1	1995	Interaction between erythromycin, a strong inhibitor of CYP3A4, and nitrazepam, a long-acting benzodiazepine, was investigated in a double-blind and randomized cross-over study of two phases.	Erythromycin	20-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
7604665-6	1995	We used the motilin agonistic properties of erythromycin to resolve this issue in man.	Erythromycin	44-56	motilin	Homo sapiens	12-19
7726500-1	1995	The epidemiology of the two common erythromycin resistance methylase (erm) genes ermA and ermC was analyzed by Southern blotting in 428 erythromycin-resistant Staphylococcus aureus strains isolated from blood between 1959 and 1988 in Denmark.	Erythromycin	35-47	ErmC	Staphylococcus aureus	90-94
7726500-2	1995	ermA and/or ermC was present in 98% of the erythromycin-resistant strains tested.	Erythromycin	43-55	ErmC	Staphylococcus aureus	12-16
7726500-7	1995	ermC was first seen in 1971 and spread rapidly in the S. aureus population, with a 5- to 10-fold increase every 5 years, and in 1984 to 1988, it was responsible for erythromycin resistance in 72% of the strains.	Erythromycin	165-177	ErmC	Staphylococcus aureus	0-4
7897148-0	1995	In vitro detection of specific IgE antibodies to erythromycin.	Erythromycin	49-61	immunoglobulin heavy constant epsilon	Homo sapiens	31-34
7897148-2	1995	OBJECTIVE: We attempted to verify that IgE-mediated reactions to erythromycin occur and to identify IgE antibodies specific for erythromycin in serum from a patient who had urticaria immediately after administration of the drug.	Erythromycin	65-77	immunoglobulin heavy constant epsilon	Homo sapiens	39-42
7897148-2	1995	OBJECTIVE: We attempted to verify that IgE-mediated reactions to erythromycin occur and to identify IgE antibodies specific for erythromycin in serum from a patient who had urticaria immediately after administration of the drug.	Erythromycin	128-140	immunoglobulin heavy constant epsilon	Homo sapiens	100-103
7897148-4	1995	Serum from the patient, pooled sera from nonatopic subjects allergic to common aeroallergens, and cord blood controls were analyzed for erythromycin-specific IgE by radioimmunoassay.	Erythromycin	136-148	immunoglobulin heavy constant epsilon	Homo sapiens	158-161
7897148-6	1995	RESULTS: We were able to detect erythromycin-specific IgE antibodies in serum from the patient who had an allergic reaction to this antibiotic, but specific IgE could not be detected in control sera.	Erythromycin	32-44	immunoglobulin heavy constant epsilon	Homo sapiens	54-57
7897148-7	1995	CONCLUSION: Immunologic IgE-mediated reactions to erythromycin do occur, and in vitro diagnosis of such reactions can be made by using Sepharose as a solid phase covalently linked to this drug.	Erythromycin	50-62	immunoglobulin heavy constant epsilon	Homo sapiens	24-27
7883194-0	1995	Identification of a chromosomally encoded ABC-transport system with which the staphylococcal erythromycin exporter MsrA may interact.	Erythromycin	93-105	ABC transporter permease protein	Staphylococcus aureus	115-119
7604665-7	1995	Administration of a low dose of erythromycin induced a MMC which started from the gastric antrum, unaccompanied by a motilin peak.	Erythromycin	32-44	motilin	Homo sapiens	117-124
7604665-17	1995	Finally, we hypothesized that the actions of erythromycin on motilin receptors on enteric neurons and intestinal smooth muscle offer a potential for therapeutic applications in gastrointestinal motility disorders.	Erythromycin	45-57	motilin	Homo sapiens	61-68
8560094-4	1995	25 microM erythromycin inhibited fMLP-induced O2- production by about 50%, but not PMA-induced O2- production.	Erythromycin	10-22	formyl peptide receptor 1	Homo sapiens	33-37
7875024-4	1995	Furthermore, treatment of mice with anti-IL-4 monoclonal antibody abolished the antitumor resistance conferred by erythromycin.	Erythromycin	114-126	interleukin 4	Mus musculus	41-45
7875024-5	1995	These results indicate that erythromycin exhibits an indirect antineoplastic activity by enhancing the production of IL-4 which augments the tumoricidal activity of macrophages.	Erythromycin	28-40	interleukin 4	Mus musculus	117-121
7571853-18	1995	EM and Roxythromycin, suppressed IL-8 production in Pseudomonas-stimulated neutrophils in a dose-dependent manner.	Erythromycin	0-2	C-X-C motif chemokine ligand 8	Homo sapiens	33-37
8571260-8	1995	Correlation between frequency of high levels of antibodies to SAP and bicillin 5 or erythromycin administration, duration of RHD was not established.	Erythromycin	84-96	SH2 domain containing 1A	Homo sapiens	62-65
7995002-4	1994	To overcome the variable of route of administration, the aim of this study was to determine whether the elimination of two intravenously administered CYP3A4 substrates (alfentanil and erythromycin) correlate.	Erythromycin	184-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
7995222-2	1994	A recently developed motilin antagonist confirms that motility effects of erythromycin are mediated by motilin receptors.	Erythromycin	74-86	promotilin	Oryctolagus cuniculus	21-28
7995222-2	1994	A recently developed motilin antagonist confirms that motility effects of erythromycin are mediated by motilin receptors.	Erythromycin	74-86	promotilin	Oryctolagus cuniculus	103-110
7730236-5	1994	The analysis of outer membrane proteins showed that erythromycin treatment resulted in a reduction in the amount of the 38 kDa protein (OprF) and in a prominent increase of 41 kDa protein band in the strain S-6, but not in the strain PAO-1.	Erythromycin	52-64	outer membrane porin F	Pseudomonas aeruginosa PAO1	136-140
7840576-0	1994	Effects of localized Pasteurella haemolytica infection on erythromycin-binding properties of bovine alpha-1-acid glycoprotein, albumin, serum, and tissue chamber fluids.	Erythromycin	58-70	alpha-1-acid glycoprotein	Bos taurus	100-125
7956594-6	1994	Intravenous erythromycin markedly accelerated the gastric emptying (all three parameters studied) of solids (P &lt; 0.01) in seven of nine patients with postsurgical gastroparesis [baseline T1/2 154 +/- 15 min; after intravenous erythromycin, T1/2 56 +/- 17 min (mean +/- SEM)].	Erythromycin	12-24	CD5 molecule	Homo sapiens	190-205
7956594-6	1994	Intravenous erythromycin markedly accelerated the gastric emptying (all three parameters studied) of solids (P &lt; 0.01) in seven of nine patients with postsurgical gastroparesis [baseline T1/2 154 +/- 15 min; after intravenous erythromycin, T1/2 56 +/- 17 min (mean +/- SEM)].	Erythromycin	12-24	CD2 molecule	Homo sapiens	243-261
7956594-7	1994	Oral erythromycin enhanced (P &lt; 0.05) the gastric emptying rate (T1/2, area under the curve) in five of seven patients (baseline T1/2 146 +/- 16 min; after oral erythromycin, T1/2 87 +/- 20 min).	Erythromycin	5-17	CD5 molecule	Homo sapiens	132-147
7956594-7	1994	Oral erythromycin enhanced (P &lt; 0.05) the gastric emptying rate (T1/2, area under the curve) in five of seven patients (baseline T1/2 146 +/- 16 min; after oral erythromycin, T1/2 87 +/- 20 min).	Erythromycin	5-17	CD2 molecule	Homo sapiens	178-192
7878692-1	1994	Erythromycin is a strong inhibitor of cytochrome P450 [CYP3A4] and has a potentially dangerous interaction with midazolam and triazolam.	Erythromycin	0-12	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
7942728-1	1994	OBJECTIVES: Erythromycin, a macrolide antibiotic, has been shown to mimic the effects of the polypeptide motilin in the gastrointestinal tract.	Erythromycin	12-24	motilin	Homo sapiens	105-112
7895614-4	1994	Hepatic levels of CYP3A4 can be estimated by the erythromycin breath test and vary at least 10-fold among patients.	Erythromycin	49-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
7840576-1	1994	The in vitro erythromycin-binding properties of bovine alpha-1-acid glycoprotein (AAG) and albumin were studied by using equilibrium dialysis.	Erythromycin	13-25	alpha-1-acid glycoprotein	Bos taurus	55-80
7840576-1	1994	The in vitro erythromycin-binding properties of bovine alpha-1-acid glycoprotein (AAG) and albumin were studied by using equilibrium dialysis.	Erythromycin	13-25	alpha-1-acid glycoprotein	Bos taurus	82-85
7840576-3	1994	At a concentration of 5 micrograms/ml, erythromycin was moderately bound to AAG (39% +/- 4% free) and was only slightly bound to albumin (86% +/- 2% free).	Erythromycin	39-51	alpha-1-acid glycoprotein	Bos taurus	76-79
7840576-4	1994	Scatchard analysis of the data describing binding to pure bovine AAG indicated that erythromycin was bound to a single high-affinity (6.45 x 10(4) M-1) site on the protein.	Erythromycin	84-96	alpha-1-acid glycoprotein	Bos taurus	65-68
7927669-0	1994	Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases.	Erythromycin	57-69	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
7927669-7	1994	Treatment with erythromycin caused significant reductions of neutrophil numbers, IL-8/albumin ratios, and NE/albumin ratios in BAL fluids from these patients.	Erythromycin	15-27	C-X-C motif chemokine ligand 8	Homo sapiens	81-85
7927669-8	1994	To elucidate the mechanism of erythromycin therapy, we also examined whether erythromycin suppressed IL-8 production by human alveolar macrophages and neutrophils in vitro.	Erythromycin	77-89	C-X-C motif chemokine ligand 8	Homo sapiens	101-105
7927669-9	1994	We demonstrated a moderate inhibitory effect of erythromycin on IL-8 production in Pseudomonas-stimulated neutrophils but not in alveolar macrophages.	Erythromycin	48-60	C-X-C motif chemokine ligand 8	Homo sapiens	64-68
7927669-11	1994	The clinical efficacy of erythromycin therapy for CAD patients might be partly mediated through a reduced IL-8 production, diminishing neutrophil accumulation and NE release in the airways.	Erythromycin	25-37	C-X-C motif chemokine ligand 8	Homo sapiens	106-110
7851087-3	1994	CP-99,219 was 32-fold and fourfold more potent than ciprofloxacin and sparfloxacin, respectively, against Streptococcus pneumoniae, including strains resistant to penicillin G and erythromycin (MIC90 &lt; or = 0.25 microgram/ml).	Erythromycin	180-192	fusion protein	Pseudomonas aeruginosa	0-9
7979468-1	1994	The motilin agonist erythromycin was used successfully in four infants receiving prolonged parenteral nutrition for severe intestinal dysmotility after gastrointestinal surgery.	Erythromycin	20-32	motilin	Homo sapiens	4-11
8034584-4	1994	Specific CYP3A1 substrates or ligands, such as erythromycin, triacetyloleandomycin, and clotrimazole (CTZ) protected the enzyme from degradation in hepatocytes and inhibited in a concomitant manner (r = 0.99) glucagon-induced phosphorylation of the enzyme.	Erythromycin	47-59	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	9-15
8313822-0	1994	Motilin agonist erythromycin increases human lower esophageal sphincter pressure by stimulation of cholinergic nerves.	Erythromycin	16-28	motilin	Homo sapiens	0-7
7937537-0	1994	Inhibition of human CYP3A catalyzed 1"-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.	Erythromycin	96-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-25
8204093-8	1994	Effects of alpha-naphthoflavone, erythromycin, troleandomycin and nifedipine on microsomal CA 8-hydroxylation were generally consistent with CYP3A involvement.	Erythromycin	33-45	carbonic anhydrase 8	Homo sapiens	91-95
7979287-1	1994	Dirithromycin and, to a lesser extent, erythromycylamine and erythromycin directly induced the release of three intragranular enzymes (lysozyme, lactoferrin, and beta-glucuronidase) from unstimulated human neutrophils.	Erythromycin	61-73	glucuronidase beta	Homo sapiens	162-180
8313822-3	1994	Recently, it has been shown that erythromycin was a motilin agonist.	Erythromycin	33-45	motilin	Homo sapiens	52-59
8114683-3	1994	Using a panel of prototypical substrates and inhibitors for specific cytochromes P450, we identified substrates for CYP3A4 (midazolam, erythromycin, cyclosporin, and dexamethasone) as inhibitors of catechol formation from both etoposide and teniposide.	Erythromycin	135-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122
8311129-2	1994	Erythromycin has a motilin-like effect on the stomach and significantly increases the lower esophageal sphincter (LES) pressure in normal volunteers.	Erythromycin	0-12	motilin	Homo sapiens	19-26
8297350-1	1994	Studies on the physiological role of motilin, and more recently, on the relationship between motilin and erythromycin A, have been hampered by the lack of antagonists.	Erythromycin	105-119	promotilin	Oryctolagus cuniculus	93-100
7903909-7	1994	The formation of metabolite M4 was substantially reduced both by antibody directed against CYP3A and by the addition of CYP3A substrates such as orphenadrine, erythromycin, troleandomycin, and testosterone.	Erythromycin	159-171	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-125
8140975-12	1994	Pharmacologic therapy of chronic gastric stasis with the benzamide prokinetic agents (metoclopramide, cisapride, renzapride), domperidone, and the motilin agonist erythromycin, may be effective initially, but long-term results are still undefined, and postvagotomy and postgastrectomy patients have not been studied adequately.	Erythromycin	163-175	motilin	Homo sapiens	147-154
8311129-9	1994	Serum motilin decreased slightly after the administration of erythromycin.	Erythromycin	61-73	motilin	Homo sapiens	6-13
8309727-7	1993	Among the same family of antibiotics such as macrolides, differences on cytokine modulation were observed: spiramycin and erythromycin increased IL-6 production while roxithromycin did not exert any significant effect.	Erythromycin	122-134	interleukin 6	Homo sapiens	145-149
8119865-5	1994	Culture with EM induced the expression of a surface antigen CD71, one of the activation markers of macrophages as compared with control cultures.	Erythromycin	13-15	transferrin receptor	Homo sapiens	60-64
8265621-1	1993	Human cytochrome P450 3A4 is recognized as the catalyst for the oxygen-dependent metabolism of a diverse group of medically important chemicals, including the immunosuppressive agent cyclosporin; macrolide antibiotics, such as erythromycin; drugs such as benzphetamine, nifedipine, and cocaine; and steroids; such as cortisol and testosterone to name but a few.	Erythromycin	227-239	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-25
8367809-2	1993	Erythromycin, a motilin agonist, has recently been studied as a gastrointestinal and biliary prokinetic agent.	Erythromycin	0-12	motilin	Canis lupus familiaris	16-23
8240450-1	1993	Erythromycin acistrate (Erasis, CAS 96128-89-1) is a 2"-acetyl ester prodrug of erythromycin.	Erythromycin	80-92	BCAR1 scaffold protein, Cas family member	Homo sapiens	32-35
8379926-7	1993	Phosphorylation of a p18 substrate required higher concentrations of sphingosine (20-100 microM) and showed a significant preference for the erythro isomers of sphingosine and dihydrosphingosine over the threo isomers.	Erythromycin	141-148	H3 histone pseudogene 12	Homo sapiens	21-24
8335350-7	1993	The sspA gene in S. gordonii DL1 was insertionally inactivated by homologous recombination of the erythromycin resistance (Emr) determinant ermAM onto the streptococcal chromosome.	Erythromycin	98-110	Galactose-specific C-type lectin	Drosophila melanogaster	29-32
8432466-0	1993	Erythromycin effects on gastric emptying, antral motility and plasma motilin and pancreatic polypeptide concentrations in anorexia nervosa.	Erythromycin	0-12	motilin	Homo sapiens	69-76
8348856-5	1993	Erythromycin exerts its prokinetic effect by acting as a motilin agonist; it has been used in the treatment of diabetic gastroparesis and appears to improve symptoms of colonic pseudo-obstruction and postoperative ileus.	Erythromycin	0-12	motilin	Homo sapiens	57-64
8470625-0	1993	Erythromycin: a motilin agonist and gastrointestinal prokinetic agent.	Erythromycin	0-12	motilin	Homo sapiens	16-23
8470625-3	1993	Early investigations demonstrated that erythromycin increased gastrointestinal motility, and more recent studies suggest that it fortuitously binds to and stimulates the receptor for the gastrointestinal peptide motilin.	Erythromycin	39-51	motilin	Homo sapiens	212-219
8501007-3	1993	Although erythromycin A contains five hydroxyl groups, regioselective methylation at the C-6 hydroxyl group was achieved to the extent of 90% when a 9-O-substituted erythromycin A 9-oxime was employed as substrate.	Erythromycin	9-23	complement C6	Homo sapiens	89-92
8342132-2	1993	Erythromycin has a motilin-like effect on the stomach, but possible esophageal effects have not been evaluated and are the focus of our investigation.	Erythromycin	0-12	motilin	Homo sapiens	19-26
8342132-7	1993	Serum motilin levels decreased from 96.4 +/- 10.9 pmol/L to 81.8 +/- 10.9 pmol/L (p &lt; 0.01) after erythromycin administration.	Erythromycin	101-113	motilin	Homo sapiens	6-13
8482186-8	1993	The plasma motilin concentration increased significantly during EM-induced IMCs, and this suggested a close relationship between this hormone and induction of the IMC.	Erythromycin	64-66	motilin	Homo sapiens	11-18
8483799-5	1993	Bombesin, morphine, and erythromycin, recognized stimulants for motilin release in vivo, failed to influence the secretion of motilin in vitro.	Erythromycin	24-36	motilin	Canis lupus familiaris	64-71
7679086-4	1993	After administration of rat interferon-gamma, erythromycin metabolism was impaired (53% of control; p &lt; 0.01).	Erythromycin	46-58	interferon gamma	Rattus norvegicus	28-44
8432466-10	1993	Motilin concentrations decreased slightly more and pancreatic polypeptide concentrations increased markedly more with erythromycin than with placebo, possibly because the meal reached the intestine earlier.	Erythromycin	118-130	motilin	Homo sapiens	0-7
7679086-7	1993	In rats, rat interferon-gamma decreased erythromycin metabolism to 57% of control (p &lt; 0.005).	Erythromycin	40-52	interferon gamma	Rattus norvegicus	13-29
1358562-0	1992	Erythromycin stimulates gallbladder emptying and motilin release by atropine-sensitive pathways.	Erythromycin	0-12	motilin	Homo sapiens	49-56
8450276-2	1993	In this study we investigated the effect of EM on peripheral neutrophil adhesion molecules such as LFA-1 and Mac-1 obtained from six healthy subjects.	Erythromycin	44-46	integrin subunit alpha L	Homo sapiens	99-104
1493610-0	1992	pH effects on the N-demethylation and formation of the cytochrome P-450 iron II nitrosoalkane complex for erythromycin derivatives.	Erythromycin	106-118	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	55-71
1493610-1	1992	The effects of pH on access to the cytochrome P-450 active site, N-demethylation and formation of the cytochrome P-450 Fe(II)-RNO metabolite complex for a series of erythromycin derivatives were examined.	Erythromycin	165-177	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	35-51
1493610-1	1992	The effects of pH on access to the cytochrome P-450 active site, N-demethylation and formation of the cytochrome P-450 Fe(II)-RNO metabolite complex for a series of erythromycin derivatives were examined.	Erythromycin	165-177	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	102-118
1358562-1	1992	The effect of administering different doses of erythromycin on gallbladder emptying and plasma concentrations of immunoreactive motilin was investigated in healthy volunteers.	Erythromycin	47-59	motilin	Homo sapiens	128-135
1425065-4	1992	However, in a previous study we demonstrated that erythromycin, a macrolide antibiotic, stimulates gallbladder emptying and motilin release in healthy human subjects by an atropine-sensitive pathway.	Erythromycin	50-62	motilin	Homo sapiens	124-131
1425065-13	1992	Erythromycin administration caused an approximately twofold increase in plasma motilin concentrations in healthy subject and patients without AN, but did not stimulate motilin release in neuropathic patients.	Erythromycin	0-12	motilin	Homo sapiens	79-86
1358562-7	1992	At 100 mg/hr, erythromycin caused a 2.5-fold increase in plasma motilin concentration, which reached a peak after 30 min infusion.	Erythromycin	14-26	motilin	Homo sapiens	64-71
1420750-1	1992	Erythromycin is a prokinetic agent for the lower oesophageal sphincter, the stomach, the gallbladder and the small bowel, acting directly on motilin receptors.	Erythromycin	0-12	motilin	Homo sapiens	141-148
1643634-12	1992	Complete inhibition of the potentiation of MRA by human liver microsomes was found when the CYP3A substrates cyclosporin A and erythromycin were used in the reaction system.	Erythromycin	127-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
1281070-9	1992	Erythromycin, mimicking the potent gastrokinetic effect of motilin, may hold considerable promise for the future.	Erythromycin	0-12	motilin	Homo sapiens	59-66
1416647-0	1992	Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro.	Erythromycin	0-12	tumor necrosis factor	Homo sapiens	57-84
1416647-1	1992	The mechanism of clinical effectiveness of low-dose and long-term erythromycin (EM) treatment for diffuse panbronchiolitis, sinobronchial syndrome, and associated otitis media with effusion was investigated by studying the effects of EM on tumor necrosis factor alpha (TNF-alpha) production by cultured human monocytes stimulated with lipopolysaccharide.	Erythromycin	66-78	tumor necrosis factor	Homo sapiens	269-278
1642641-2	1992	The clearance of quinidine, midazolam, triazolam, erythromycin, and lidocaine declines with age; these drugs are metabolized by the isoform, CYP3A.	Erythromycin	50-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-146
1642641-4	1992	The activity of the human hepatic cytochrome P450, CYP3A, was quantified in vitro as erythromycin N-demethylation in microsomes prepared from forty-three resected human liver specimens obtained from patients, age 27 to 83, with normal liver function.	Erythromycin	85-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-56
1319843-2	1992	We demonstrate that disruption of PDR5 causes marked hypersensitivity not only to cycloheximide but also to sulphometuron methyl and the mitochondrial inhibitors chloramphenicol, lincomycin, erythromycin and antimycin.	Erythromycin	191-203	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	34-38
1630156-4	1992	In human liver microsomes, the glucocorticoid-inducible cytochrome P-450IIIA, CYP3A, catalyzes the N-demethylation of erythromycin.	Erythromycin	118-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-83
1402080-3	1992	In this study, we investigated the effect of EM on intrapulmonary influx of neutrophils by intratracheal injection of lipopolysaccharide (LPS), and the following results were obtained.	Erythromycin	45-47	toll-like receptor 4	Mus musculus	138-141
1402080-4	1992	1) The intrapulmonary influx of neutrophils was significantly suppressed (p less than 0.001) in mice intraperitoneally injected with EM at 5 mg per animal 2 hr before intratracheal injection of LPS (control group: 6.5 +/- 0.8 x 10(5) vs EM-treated group: 1.7 +/- 0.3 x 10(5)), but not 10 hr before lung challenge.	Erythromycin	133-135	toll-like receptor 4	Mus musculus	194-197
1733270-8	1992	Motilin receptor protection from alkylation by N-ethylmaleimide preserved contraction to motilin and erythromycin but not acetylcholine or cholecystokinin, whereas protection with erythromycin preserved contraction to motilin but not other agonists.	Erythromycin	101-113	motilin receptor	Oryctolagus cuniculus	0-16
1561839-1	1992	The IMP2 gene of Saccharomyces cerevisiae is involved in the nucleo-mitochondrial control of maltose, galactose and raffinose utilization as shown by the inability of imp2 mutants to grow on these carbon sources in respiratory-deficient conditions or in the presence of ethidium bromide and erythromycin.	Erythromycin	291-303	endopeptidase catalytic subunit	Saccharomyces cerevisiae S288C	4-8
1732074-0	1992	Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol.	Erythromycin	45-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-22
1732074-1	1992	The N-demethylation of erythromycin and 6 beta-hydroxylation of cortisol are both functions of the glucocorticoid-inducible CYP3A in human liver microsomes.	Erythromycin	23-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-129
1727784-1	1992	Erythromycin markedly accelerates gastric emptying, possibly because it acts as a motilin agonist.	Erythromycin	0-12	motilin	Homo sapiens	82-89
1727784-10	1992	Our data show that motilin accelerates gastric emptying in diabetic gastroparesis and support the hypothesis that erythromycin"s effect is mediated through motilin receptors.	Erythromycin	114-126	motilin	Homo sapiens	19-26
1727784-10	1992	Our data show that motilin accelerates gastric emptying in diabetic gastroparesis and support the hypothesis that erythromycin"s effect is mediated through motilin receptors.	Erythromycin	114-126	motilin	Homo sapiens	156-163
1759822-5	1991	Spiramycin and, to a lesser extent, erythromycin increased total IL-6 production without affecting IL-1 alpha, IL-1 beta, or tumor necrosis factor alpha production, whereas roxithromycin had no effect.	Erythromycin	36-48	interleukin 6	Homo sapiens	65-69
1759822-0	1991	Differential modulation of cytokine production by macrolides: interleukin-6 production is increased by spiramycin and erythromycin.	Erythromycin	118-130	interleukin 6	Homo sapiens	62-75
1759822-3	1991	We compared the in vitro effects of three macrolides (roxithromycin, spiramycin, and erythromycin) actively concentrated by leukocytes on interleukin-1 alpha, (IL-1 alpha), IL-1 beta, IL-6, and tumor necrosis factor alpha production by human monocytes stimulated with lipopolysaccharide.	Erythromycin	85-97	interleukin 1 alpha	Homo sapiens	138-157
1759822-3	1991	We compared the in vitro effects of three macrolides (roxithromycin, spiramycin, and erythromycin) actively concentrated by leukocytes on interleukin-1 alpha, (IL-1 alpha), IL-1 beta, IL-6, and tumor necrosis factor alpha production by human monocytes stimulated with lipopolysaccharide.	Erythromycin	85-97	interleukin 1 alpha	Homo sapiens	160-170
1759822-3	1991	We compared the in vitro effects of three macrolides (roxithromycin, spiramycin, and erythromycin) actively concentrated by leukocytes on interleukin-1 alpha, (IL-1 alpha), IL-1 beta, IL-6, and tumor necrosis factor alpha production by human monocytes stimulated with lipopolysaccharide.	Erythromycin	85-97	interleukin 1 beta	Homo sapiens	173-182
1759822-3	1991	We compared the in vitro effects of three macrolides (roxithromycin, spiramycin, and erythromycin) actively concentrated by leukocytes on interleukin-1 alpha, (IL-1 alpha), IL-1 beta, IL-6, and tumor necrosis factor alpha production by human monocytes stimulated with lipopolysaccharide.	Erythromycin	85-97	interleukin 6	Homo sapiens	184-188
1759822-3	1991	We compared the in vitro effects of three macrolides (roxithromycin, spiramycin, and erythromycin) actively concentrated by leukocytes on interleukin-1 alpha, (IL-1 alpha), IL-1 beta, IL-6, and tumor necrosis factor alpha production by human monocytes stimulated with lipopolysaccharide.	Erythromycin	85-97	tumor necrosis factor	Homo sapiens	194-221